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There has been a dramatic increase in web-based systems developed to support patients to 
report/manage cancer treatment side effects (ePROM systems). However, little is known 
about processes underpinning patient engagement and impact on experience. 
Aims 
To explore the patient perspective on using ePROM systems during chemotherapy. 
Mixed methods 
Preliminary work 
Interviews (n=27) and questionnaires (n=40) explored patient experience of chemotherapy and 
indicated that difficulty deciding when to seek medical support during treatment was 
common. Field usability testing of eRAPID (n=12) indicated potential to support patients but 
variable engagement. A systematic review of ePROM systems (n=41) indicated a scarcity of 
robust evidence with few RCTs, with patient engagement and psychosocial outcomes such as 
self-efficacy not routinely explored or assessed. 
Main studies 
Qualitative and quantitative evaluation of patient engagement/experience was integrated into 
an RCT to evaluate eRAPID (n=354). Engagement was evaluated by weekly symptom reports 
and use of website. Validated measures assessed impact of eRAPID on self-efficacy to manage 
side effects (CSES) and cope with cancer (CBI-B), and patient activation (PAM). Relationships 
between outcomes and engagement were explored. A subset of patients were interviewed 
(n=23) to explore patient engagement/experience. Triangulation techniques were used to 





Engagement was generally high with few barriers to use reported. One of the main motivators 
for sustained patient engagement was providing information to clinicians for use in 
consultations. Patients reported eRAPID provided psychological benefits and improved care. 
There was a positive impact of eRAPID on CSES (p=.015) but not CBI-B or PAM. Engagement 
was a significant predictor of improvement in CSES (p<.001) and CBI-B (p<.01) but not PAM. 
Conclusion 
ePROM systems have potential to improve patient’s experience of chemotherapy. Further 
exploration using qualitative and quantitative assessments is needed to provide insights into 
motivators and barriers. Clinician engagement is intertwined with patient engagement and 
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Chapter 1 Introduction 
1.1 Background 
A growing and aging population coupled with increasingly successful cancer treatments has led 
to a dramatic increase in the number of people living with and beyond cancer. Approximately 2 
million people in the United Kingdom have had a cancer diagnosis at some point in their lives 
and this is expected to rise to 4 million by 2030 [1]. The number of new diagnoses of cancer 
continues to rise. 303,135 people were registered with new cases of cancer in England in 2016, 
the equivalent of 828 new cases per day. This is comparison to 268,758 cases registered in 
2010 [2]. However, cancer mortality rates continue to decrease each year, reflecting 
improvements in cancer treatment cancer care [3]. 
The common treatments available for cancer include chemotherapy, surgery, radiotherapy, 
hormone therapies and immunotherapies. The type of treatment used is dependent on the 
type and stage of cancer with many patients receiving multiple treatments or a combination of 
therapies. Treatment can be delivered with curative intent, where the goal is to eradicate 
disease altogether, or with non-curative intent, where the goal is to control symptoms, 
improve quality of life (QoL) and slow disease progression. 
1.1.1 The costs and benefits of chemotherapy 
An increasing number of cancer patients are treated with chemotherapy in the United 
Kingdom [4]. Chemotherapy can slow disease progression, ease symptoms of the disease and 
in some cases cure disease altogether. However, the treatment is not without costs and many 
patients experience a vast array of side effects such as nausea, pain, fatigue, constipation and 




system [5-8]. These side effects can have a detrimental impact on QoL for patients both during 
and after chemotherapy [9-12], and can have a huge impact on patients emotionally, 
psychologically and socially [10, 13, 14]. 
Although some side effects are unavoidable with chemotherapy, many can be treated 
effectively with early intervention through supportive medication or self-management 
techniques [14]. However where side effects are poorly controlled, patients can require 
emergency assessment and admissions [15, 16]. Furthermore, untreated side effects such as 
febrile neutropenia can escalate and become life-threatening in a relatively short amount of 
time [17]. 
1.1.2 Challenges of managing chemotherapy side effects 
It has become increasingly common for chemotherapy to be delivered in an ambulatory 
setting. Patients typically receive chemotherapy as a day case and are discharged home on the 
same day, with information and advice on expected and possible side effects and are advised 
to seek help if symptoms become a cause for concern. The next scheduled contact with their 
healthcare team will be arranged for a couple of days before their next treatment is due (often 
three weeks later). These pre-assessment appointments with a clinician (usually an oncologist 
or specially trained nurse) assess whether the patient is fit and well enough for their next cycle 
of treatment. 
This method of treatment delivery places a demand on patients to play a significant role in the 
management of their own care [18]. However, evidence suggests that patients do not always 
feel equipped for this role. The beginning of cancer treatment can be a very distressing time 
and patients may not always be able to absorb the information they are given [19]. They often 
report being feeling overwhelmed by the amount of written information they receive, which 
impacts on confidence in making decisions about when to access support, and when self-




several days before contacting the hospital about problematic symptoms arising from 
chemotherapy which may result in symptoms escalating [23]. These decisions can be 
influenced by a number of psychosocial factors, including their perception of the accessibility 
of hospital advice and support, and their expectations and beliefs about being able to control 
symptoms [24]. Patients have also expressed a reluctance to ‘bother’ healthcare staff, 
particularly if they are uncertain about the relevance of certain symptoms and believe that 
they are a normal part of cancer and cancer treatment [24-27]. Patients also may delay 
contacting the hospital if they have an upcoming hospital appointment or even to purposively 
try to avoid a hospital admission [21, 25, 28]. Patients are also much less likely to seek out 
advice or follow self-management advice given by clinicians (e.g. taking prescribed or over the 
counter supportive medications, or making lifestyle changes) if they have low expectations 
about the influence that these behaviours can have on symptoms [29]. Escalation of symptoms 
and side effects can impact on patient’s confidence to manage during chemotherapy and 
subsequently they may be less likely to engage in self-management behaviours or contact the 
hospital in the future [30]. Conversely, patients may contact the hospital frequently about mild 
side effects because they are worried, and simply need reassurance that their side effects are a 
normal part of the treatment trajectory. Unnecessary contacts place a burden on already 
stretched services in busy oncology units, and there is a need to develop more sustainable 
ways to support patients to manage at home and aid decision-making about contacting the 
hospital. 
When patients attend for pre-assessment appointments prior to each cycle of chemotherapy, 
clinicians are required to make treatment decisions based on the level of side effects and 
toxicity experienced. For example, they may need to reduce or delay chemotherapy while the 
patient recovers, in addition to providing supportive medication to manage side effects [31]. 
While some objective measures such as blood tests can assess how well patients are tolerating 




experiencing between treatments. The level of side effects experienced by patients is typically 
cyclic in nature, sometimes referred to as the ‘rollercoaster effect’ [24, 32]. Patients usually 
experience the greatest burden in the week immediately following chemotherapy and feel 
most well just before their next treatment, which is generally when a clinic appointment takes 
place. Although their health and well-being at this point is most relevant for clinicians 
prescribing the next cycle of chemotherapy, it may not always provide the most accurate 
picture of symptom experience during the preceding weeks. Patients may have difficulty 
remembering symptoms when reporting retrospectively and may be unsure of the relevance 
of side effects, or the acceptable level of severity [20, 33, 34]. Clinicians often underestimate 
the prevalence and impact of side effects, resulting in poor documentation and ineffective 
management, despite the availability of supportive medications [14, 35, 36]. 
1.1.3 Use of Patient Reported Outcome Measures (PROMs) in clinical practice 
PROMs are defined as ‘any report of the status of a patient’s health condition that comes 
directly from the patient, without interpretation of the patient’s response by a clinician or 
anyone else’ [37]. As the focus on effective cancer treatments shifts from survival alone to 
improved health related quality of life (HRQoL), PROMs have become an increasingly 
important tool for understanding outcomes in cancer populations and assisting in patient 
monitoring during cancer care and treatment. PROMs can have a direct impact on care during 
cancer treatment by facilitating the identification of issues to clinicians, theoretically leading to 
better intervention and care. For example, if a patient completes a PROMs assessment prior to 
a consultation, this may highlight to the clinician that the patient is experiencing particular 
problems with nausea, which might result in the clinician prescribing a stronger antiemetic. 
The evidence for the benefits of integrating PROMs data into clinical practice to assess HRQoL 
and support clinical assessments during cancer treatment is growing [38-40]. Provision of 




identification, discussion and documentation of symptoms and HRQoL. There is some evidence 
for improved HRQoL, symptom control and even survival but this evidence is mixed [41-52]. It 
has been suggested that differences in efficacy may be in part due to methodological issues 
related to the many challenges associated with implementing PROMs into clinical practice, 
which have been well documented [49, 53-55]. Considerations include what measures to 
choose, method of collection, frequency of completion, presentation to clinicians and training 
of clinicians [56-59]. 
Engaging clinicians to use PROMs data in consultations has proven to be challenging. Clinicians 
generally report finding PROMs data useful but are often concerned that reviewing data during 
consultations may increase their workload and make consultations longer, despite evidence to 
suggest that this is not the case [42-44, 60]. Other barriers to effective clinician use of PROMs 
data include concerns about a negative impact on communication and a belief that patients do 
not require PROMs to raise issues they are concerned about [61-65]. However, research 
suggests that patients often do not raise issues without probing, even when they are 
experiencing substantial difficulties [36, 66, 67]. In addition, some clinicians express concerns 
that PROMs create an expectation of intervention for patients, when there is not always a 
clear management strategy, particularly for difficult to manage symptoms such as fatigue [62, 
63, 68, 69]. Engaging clinicians in the selection of measures and training in the interpretation 
and use of PROMs in consultations has shown good promise in overcoming some of these 
barriers [70]. 
Early research has relied on patients completing PROMs in clinic waiting rooms prior to 
consultations, initially using pen and paper methods, and later using touch screen devices [42-
45, 49]. However, completion of PROMs data immediately prior to clinic appointments has 
some limitations. In this scenario, patients are still required to provide accounts of symptoms 
retrospectively, at a time point when they generally feel most well, which may impact on the 




developments to support patients to complete PROMs data from home, and integrate this 
data into clinical practice in real-time. 
1.1.4 Web-based reporting of PROMs data (ePROM systems) 
Technological developments have made it possible for patients to report PROMs data from 
home in real-time in the interim period between hospital appointments. Web-based or 
electronic ePROM systems can be accessed from patients own devices such as laptops or 
smartphones, or specially developed devices can be provided. Feasibility studies indicate that 
web-based reporting is generally acceptable to patients, although patient use of systems is 
often variable [71-75]. Patients report higher frequency and severity of symptoms using real-
time reporting in comparison to retrospective reporting before clinic appointments. As 
patients commonly report difficulty remembering symptoms, this would suggest that real-time 
reporting provides a more accurate picture of patient symptoms and side effects [33, 76]. 
Although this wave of research is still in it’s infancy, evidence for the benefits of this approach 
are encouraging. Use of ePROM systems can improve symptom control and HRQoL, reduce 
healthcare utilisation, improve safe delivery of cancer treatment and even impact on survival 
[51, 77-83]. However, different approaches to design, implementation and evaluation make 
comparison difficult [79, 84-86]. While some ePROM systems focus on collection of PROMs 
data for clinical review [51, 87, 88], some have argued that there is an ethical responsibility to 
develop strategies to guide patients to deal with severe symptoms and side effects and alert 
clinicians in real-time [89]. A number of ePROM systems are now utilising PROMs data to 
support patients to self-manage in the interim period between hospital appointments by 
utilising algorithms to provide automated tailored advice on how to manage side effects [90-
94]. There is evidence to suggest that incorporating these self-management and real-time 
monitoring elements into ePROM systems has benefits over and above simply providing 




This new era of research reflects a general shift towards supported self-management in 
healthcare [97]. There are many different factors contributing towards this shift such as a 
growing and aging population, a rise in the incidence of chronic illness and a lack of 
sustainability of traditional models of healthcare [98-100]. The fast-paced advance of the 
internet and technology has led to a changing environment in which self-management 
interventions can be integrated into routine care [101, 102]. Research in other chronic illnesses 
such as diabetes, asthma and hypertension has made advances in developing more 
sophisticated telehealth and telecare interventions (interventions which allow patients to 
measure and report physical markers such as bloods from home) to support self-management 
for people living with a chronic illness by integrating objective physical markers into ePROM 
systems [103]. Systems have demonstrated promising benefits both on an individual patient 
level, and at a wider social level, such as improved HRQoL, reduced healthcare utilisation, and 
even a significant reduction in mortality [97, 104]. 
1.1.5 The patient perspective 
It is important to recognise that ePROM systems are complex interventions which usually 
require behaviour change from both patients and clinicians [105]. However, the complexities 
underpinning how patients interact with them are still largely unknown. Until recently, PROMs 
data was collected from patients in clinic waiting rooms prior to routine appointments, 
meaning that patient engagement was relatively straightforward [42-45, 49]. Little is known 
about the processes of how patients interact and engage with ePROM systems in their own 
home environments. 
The term patient engagement is sometimes used in healthcare research to describe patient’s 
autonomous engagement in their own health and care [106], in addition to describing 
engagement with specific services or care. For the purposes of this thesis, I refer to patient 




‘engagement’ is often used interchangeably in this context with terms like ‘adherence’ and 
‘usage’. However, adherence suggests an evidence-based optimal way to use a technology and 
this is something that is rarely easy to define [107]. Studies vary in the frequency they ask 
patients to complete ePROMs, and there is little evidence to indicate what the most beneficial 
frequency of completion, if any, may be. While the term ‘usage’ is broader, it doesn’t take into 
account the nuances of how and why patients interact with systems. Studies evaluating 
adherence or usage have tended to focus on ‘if’ patients use systems, and much less is known 
about ‘how’ or ‘why’ they use them, or conversely why they may not use them. 
Better understanding about how patients engage with ePROM systems, and the impact that 
this has on individuals’ experience of self-management, is essential to inform implementation 
and continuing development. This field of research is still in it’s infancy, and there is not yet 
enough of an evidence base to build theories to try and conceptualise patient engagement. 
There is a range of literature and evidence based theory on adherence to medications in 
healthcare research, and there may be something to be learned from these. This literature 
suggests that there are broadly two categories of non-adherence behaviours: intentional and 
non-intentional [108, 109]. Non-intentional non-adherence in the context of ePROM systems 
may occur simply because a patient forgets to complete symptom assessments, or may be due 
to technical issues accessing the system. Intentional non-adherence on the other hand, can be 
much more complex. The Necessity-Concerns Framework (NCF) postulates that intentional 
non-adherence to medication regimes is influenced by patients’ perception of their personal 
need for treatment, and of their concerns about potential adverse consequences of treatment 
and there is strong evidence to support this theory by assessment of these perceptions using 
the validated Beliefs about Medicines questionnaire [110, 111]. Similarly, illness perceptions, a 
central component of Leventhal’s self-regulatory model [112] have been demonstrated to be 




using the Illness Perception Questionnaire (IPQ)) [113] have been shown to have better 
predictive value than clinical or demographic variables [114]. 
Broadly, we can apply some of this theory to patient engagement with ePROM systems in that 
patient engagement is likely to be highly related to their perceived motivations and perceived 
barriers to using the system. For example, do they perceive ePROM systems are easy to use? Is 
it something they think would be useful for them? However, there are some very important 
differences which limit the application of these theories. Most importantly, ePROM systems 
are not a treatment for cancer. Studies on adherence to medication are usually in reference to 
treatments which have a strong evidence base for their efficacy, and where evidence on 
potential consequences such as side effects are relatively well established. ePROM systems on 
the other hand are generally complex interventions which aim to improve patient care in some 
way. However, the evidence for their efficacy to actually do this is still limited, as many 
systems are still in early phases, and much less the processes by the which they might improve 
care are complex and still somewhat unknown. 
In addition, little is known about what specific motivations and barriers to patient engagement 
with systems might be. Although systems appear to be well received by patients, engagement 
is often variable [74, 75, 115, 116]. There is evidence to suggest that engagement may be 
related to socio-demographic factors such as age or socioeconomic status, with many 
criticising ePROM and other eHealth systems for creating a ‘digital divide’ in healthcare [117, 
118]. However, others have contested the current magnitude of the divide with use of the 
internet becoming increasingly widespread [119]. 
Patients’ beliefs about how important their role is in their care during chemotherapy may also 
impact on how they engage with ePROM systems [30, 120]. While some patients view their 
role as equally important to that of the clinician, and feel confident in their ability to learn 




[34, 121-124]. These beliefs are likely to impact on how patients perceive the use of ePROMs 
in clinical care and about self-management more generally. 
However, there is also some evidence to suggest that ePROM systems may have the potential 
to actually influence patients’ confidence and beliefs about taking a more active role in 
managing their health [81, 91, 92, 96]. Although heterogeneity in system designs and 
evaluation methods makes comparison difficult [78-80, 84-86], it seems logical that equipping 
patients with the knowledge, skills and confidence to successfully self-manage during 
chemotherapy may foster a sense of empowerment and control over their own care [125, 
126]. 
1.2 Context of thesis  
Since 2010, I have worked as a research assistant in the section of Patient Centred Outcomes 
Research (PCOR) led by Professor Galina Velikova based at St. James University Hospital in 
Leeds. This section specialises in the use of PROMs in oncology clinical practice, and more 
recently, the development and evaluation of ePROM systems. In 2011, the group were 
awarded an 18 month grant to develop eRAPID (electronic patient self-Reporting of Adverse-
events: Patient Information and aDvice) funded by an NIHR PDG scheme RP-DG-1209-10031. 
eRAPID is an online system for patients to report and manage symptoms and side effects 
during and after cancer treatments. Following the successful development of eRAPID, a further 
5 year NIHR programme grant was awarded, which commenced in July 2013 (Grant Reference 
Number RP-PG-0611-20,008). The programme grant aimed to evaluate eRAPID in a large scale 
Randomised Controlled Trial (RCT) in systemic therapy, and to develop eRAPID for use in 
radiotherapy and surgical practice. 
I was employed as a research assistant both on the eRAPID development grant, and the 
subsequent programme grant. This experience provided me with a good understanding and 




Patients’ experiences of cancer and cancer treatment vary dramatically. The actual treatment 
pathway is largely variable dependent on disease, however, even patients receiving exactly the 
same treatment may have completely different experiences. Patients have different physical 
reactions to treatments, but in addition individual differences mean they vary hugely in their 
approaches to managing and coping with cancer and treatment, and in the support that they 
have available to them. The processes involved in patient decision-making about managing 
and reporting side effects during treatment are complex and I was interested in exploring how 
eRAPID would impact on this. 
In January 2014, I began a part-time PhD, undertaken alongside my work as a research 
assistant to explore the patient perspective of using ePROM systems to report and manage 
side effects of cancer treatment. Specifically, I was interested in how patients engage with 
systems, and also the impact that systems have on patients’ experience of cancer treatment. I 
felt that this was work which could make a valuable contribution to the field. This is an area of 
research which is rapidly growing. In recent years, there have been many exciting new 
developments which illustrate that ePROMs and telehealth if implemented and used well, can 
not only dramatically decrease hospital usage but even reduce mortality rates [97]. However, 
there is an acknowledged need to develop evidence-based theory to inform implementation 
[127] and understanding patient engagement and experience is a vital part of this [128]. 
1.3 Aims 
The overall aim of this thesis is to explore the patient perspective of using ePROM systems to 
report and manage symptoms and side effects during chemotherapy. Specifically to explore: 
1) The main challenges that patients face managing symptoms and side effects of 




2) The potential for ePROM systems to support patients to overcome some of these 
challenges. 
3) How patients engage with eRAPID over the course of chemotherapy treatment. 
4) How eRAPID impacts on patient experience of chemotherapy. 
1.4 Structure of the thesis 
Chapter 2 gives an overview of the methodology of the thesis. The eRAPID intervention is 
described in detail in this chapter, in addition to the main work undertaken for development 
and evaluation. Information on the specific methodology used is provided in addition to a 
summary of how this was integrated into the eRAPID programme. 
Chapter 3 summarises qualitative and quantitative data from two strands of work to explore 
factors that influence how patients manage and report symptoms and side effects during 
chemotherapy in routine care, and the impact that this can have on their chemotherapy 
experience (Aim 1). 
Chapter 4 describes the clinical field usability testing of eRAPID in a breast cancer clinic, 
focusing on patient experiences of eRAPID, both in terms of how patients engaged with the 
system and the impact that it had on their experience of chemotherapy (Aims 3 and 4). 
Chapter 5 describes a systematic review of online systems to support patients to report and 
manage side effects of chemotherapy. An inclusive approach is taken to identify and 
characterise existing systems and evidence for engagement and outcomes is synthesised (Aim 
2). 
Chapter 6 describes quantitative work to explore patient engagement with eRAPID, and the 
impact of eRAPID on colorectal, gynae and breast patients’ experiences of chemotherapy over 




Chapter 7 describes qualitative work undertaken with participants following their 
participation in the eRAPID RCT to further explore motivations and barriers for engagement 
with the system, and their perception of its impact on their care (Aims 3 and 4). 
Chapter 8 summarises and discusses the work in the preceding chapters. Strengths and 




Chapter 2 Methodology and overview of eRAPID 
2.1 Overview 
The purpose of this Chapter is to give an overview of the methodology of this thesis (more 
detailed descriptions of methodology are provided in individual Chapters). Much of the work 
undertaken for this thesis was integrated into the main eRAPID development and evaluation 
work. The Principal Investigator (Professor Galina Velikova) and the Senior Research Fellow (Dr 
Kate Absolom) for the eRAPID programme grant were also supervisors for this thesis. As such, I 
was able to work with them, and my other supervisors to develop my own original ideas and 
integrate these into the eRAPID study design. The first three sections of this chapter describe 
the eRAPID intervention, and the main work undertaken for its development and evaluation. 
The final section focuses on the methodology for this thesis and how this was integrated into 
the planned RCT to evaluate eRAPID. 
The Chapter is comprised of four sections outlined below: 
 Section 2.2 Description of eRAPID. This section describes the eRAPID system on a 
functional level and describes how it works in practice from both patient and staff 
points of view. 
 Section 2.3 eRAPID development work overview provides a brief overview of the work 
undertaken to develop eRAPID. In addition, a small field usability study of eRAPID is 
described, which was undertaken prior to the commencement of the RCT with an 
internal pilot. Some of the findings from this work were integral in forming some of 
the initial ideas for this PhD, and are described in greater detail in Chapters 3 and 4. 
 Section 2.4 eRAPID RCT with internal pilot. The eRAPID programme grant aimed to 




eRAPID in radiotherapy and surgery. This section focuses only on the evaluation of 
eRAPID in systemic therapy. The protocol for this study has been published [94]. 
 Section 2.5 The role of this thesis. This final section briefly gives an overview of the 
methodology used in this thesis and describes how it was integrated into the main 




2.2 eRAPID intervention 
eRAPID is an online system for patients to report and manage symptoms and side effects 
during and after cancer treatments. Patients can log onto the eRAPID website from any web-
enabled device from their own homes and access information and self-management advice on 
treatment side effects. At any time, patients can click a button on the website to complete a 
short symptom assessment which takes approximately 5-10 minutes to complete. The patient 
then receives advice on how to manage reported symptoms and side effects. The advice 
patients receive is targeted to the severity of the symptoms reported. For example, if patients 
report mild symptoms, and self-management is appropriate, they will receive brief automated 
advice on how to self-manage their reported symptoms (e.g. over the counter medications or 
diet tips). If the symptoms they report are more serious, and medical intervention is required, 
the patient will receive a standard alert to contact the hospital immediately and a number for 
the local acute oncology service is provided. 
In addition to this, an email notification is also sent to the key clinical staff in the patient’s 
medical team to inform them. However clinicians are not required to take any action in 
response to the notification, and patients are not informed of the notifications, to ensure that 
there is no expectation that they will be contacted by clinicians and that the focus remains on 
self-management. 
All patient reported data is transferred in real-time into patients’ individual electronic medical 
records in the hospital, and is available for clinical staff to view at any time. Figure 2.1 




Figure 2.1 Overview of eRAPID system 
 
2.2.1 eRAPID from the patient’s point of view 
On the day of their first chemotherapy appointment, patients are given a brief demonstration 
of the system and are provided with a A5 postcard with their unique logon details and a 
detailed user manual with instructions on how to access the eRAPID website and complete the 
symptom reports. 
2.2.1.1 The eRAPID website 
Patients can log on to the eRAPID website (see Figure 2.2) from any web-enabled device using 
the unique username provided. They can then access self-management advice and information 
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on common treatment side effects. The website also comprises of helpful information on 
emotional coping with cancer and treatment, in addition to practical information on local 
services that are available. All information has been collated from standard medical 
information provided to patients and from reputable websites. 
 
2.2.1.2 The eRAPID symptom report 
Patients are asked to complete the eRAPID symptom report at least once a week and receive a 
weekly reminder by text, email or both. However, the symptom report is accessible at any 
time, and patients are advised to complete it any time they feel unwell. To access the 
symptom report, patients click the orange button in the top left of the page (see Figure 2.2) 
and are taken to QTool, a questionnaire management system, where they are asked to enter 
their eRAPID password. Patients complete a symptom assessment comprising of 10-14 
questions (dependent on cancer type). The questions are multiple choice and are based on 




specific grading criteria commonly used by oncology clinicians [129] (see section 1.3.2). An 
example of a symptom report question is illustrated in Figure 2.3. 
Figure 2.3 Example of eRAPID symptom report question 
 
Patients can also choose to report less common symptoms from a drop down list at the end, or 
add free text to describe a symptom they are experiencing that they have not been asked 
about (see Figure 2.4). 
Figure 2.4 Example 2 of eRAPID symptom report question 
 




Figure 2.5 Example 3 of eRAPID symptom report 
 
2.2.1.3 Symptom advice 
Algorithms are used to provide severity dependent tailored automated advice based on 
patients’ symptom reports. The algorithms are complex and some symptoms are considered 
more clinically important than others. Each question response is allocated a level of 1, 2 or 3, 
with 3 being the most severe, see example below. However, not all questions have a level 3 
response. For example, although difficulty sleeping is a disruptive symptom for many patients, 
it is less clinically important in terms of safely delivering chemotherapy, and as such does not 
have a level 3 response (see Table 2.1). 
Table 2.1 Example of eRAPID symptom question and corresponding severity level 










I have had diarrhoea and opened my bowels 2-3 times more in a 24 
hour period than is normal for me 
1 
I have had diarrhoea and opened my bowels 4-6 times more in a 24 
hour period than is normal for me 
2 
I have had diarrhoea and opened my bowels over 7 times more in a 
24 hour period than is normal for me or I have been incontinent 















I often have difficulty falling asleep, staying asleep or I wake too 
early 
1 




Each combination of symptoms and levels falls into one of 5 algorithm advice categories. 
2.2.1.3.1 Algorithm D 
Algorithm D is triggered if a patient does not report experiencing any symptoms at all. The 
patient is thanked for their completion, and asked to complete again next week. 
2.2.1.3.2 Algorithm C 
Algorithm C is slightly more complex. As a general rule, it is triggered if the severity of all 
symptoms patients report are at levels 1 and 2, as long as they have less than three level 2 
severity symptoms. Self-management advice is provided for up to six symptoms and is listed in 
order of clinical importance. 
2.2.1.3.3 Algorithm B 
Algorithm B is triggered when a patient reports three or more symptoms with level ‘2’ severity. 
Patients are shown an alert in red text at the end of the questionnaire which reads ‘If your 
symptoms are new or have changed recently, please either contact the hospital when 
convenient to discuss your symptoms with the medical team or mention them at your next 
clinic appointment (if in the next 1-2 weeks).’ Patients are provided with self-management 
advice for all symptoms with Level 2 severity. 
2.2.1.3.4 Algorithm A2 
If a patient reports a Level 3 severity for any symptom, a branching question pops up to ask if 
this is a current problem, or a problem they have experienced previously which has now 
improved. If the patient reports that they are no longer experiencing the symptom, then 




questionnaire that says ‘You have reported that you have been experiencing some serious 
problems which have now improved. If you have not already been in contact with your medical 
team, we recommend that you contact them to discuss your symptoms when convenient, or 
mention them at your next clinic appointment (if in the next 1-2 weeks). If you have already 
been in touch with your medical team regarding your symptoms, please follow the advice they 
have given you.’ Self-management advice is provided for Level 3 and Level 2 symptoms. 
2.2.1.3.5 Algorithm A1 
If a patient reports a Level 3 severity for any symptom, and subsequently indicates that the 
symptom is a current problem when answering the branching question, Algorithm A1 is 
triggered. The patient is shown an immediate alert in red text which reads ‘You have indicated 
a serious problem in this area. We recommend that you contact the hospital now to discuss 
your symptoms with the medical team (St James's University Hospital 0113 243 3144 and ask 
for the Oncology Patient Enquiries Bleep Holder). Before you contact the hospital and if you 
feel able, please complete the remaining questions.’ If the patient continues to complete the 
symptom report, they will again receive an alert in red text at the end which will read ‘We 
recommend that you contact the hospital now to discuss your symptoms with the medical 
team (St James's University Hospital 0113 243 3144 and ask for the Oncology Patient Enquiries 




Figure 2.6 Example of symptom advice (Algorithm C) 
 
Patients then have the option to email the advice to themselves, or alternatively they can print 
it out. 
2.2.1.4 Symptom graphs 
Following completion of the symptom report and provision of the severity related symptom 
advice, patients are shown a graph for each symptom, representing severity changes over 




Figure 2.7 eRAPID symptom graphs 
 
Patients can then view the graphs of their responses at any time, or view individual 
completions in tabular form. 
2.2.2 eRAPID from the clinician point of view 
2.2.2.1 Documentation in the Electronic patient record (EPR) 
Once a patient completes a symptom report, this is immediately documented in their 
individual EPR, on the local system Patient Pathway Manager (PPM) (within a four minute 
period). Clinicians use PPM to manage patient care during chemotherapy by accessing blood 
results and other clinical information. The eRAPID symptom report data is easily accessible on 
a tab within PPM, and is accessed in a similar way to blood results. Clinicians are prompted to 
review patient data in routine and pre-assessment consultations prior to each cycle of 
chemotherapy. 
Clinicians have the option to view patient data in graphical form (see Figure 2.8 for example) or 




completed symptom reports, but clinicians can easily configure this to view all symptom 
reports, or individual reports. 
Figure 2.8 Example of clinician view of eRAPID symptom report data 
 
2.2.2.2 Notifications for severe symptoms 
When Algorithm A1 is triggered for any patient, an email notification is sent to key members of 
the patients clinical team to inform them. For data protection purposes, the email does not 
contain any identifiable information about the patient. The email provides the patient’s unique 
username, and information about the severe symptom, or symptoms, that they have reported. 
The clinician can then log onto PPM and view a report for eRAPID which shows a list of any 
severe symptoms reported by patients on study in the last 2 weeks, with corresponding unique 
usernames. The clinicians can simply click on the relevant username, and will be brought to 
that patient’s individual health record. They can then view more information on the patient’s 
symptom report if they wish, or more importantly, they can check if that patient has contacted 
the hospital. Clinicians can also make annotations to record if they have contacted a patient or 





2.3 eRAPID development work overview 
eRAPID is a complex intervention and the development work consisted of three separate but 
related work packages, described below. 
2.3.1 Work stream 1: Development and evaluation of the eRAPID electronic 
platform. 
The main aim of this work stream was to develop and evaluate a working electronic platform 
from which patients could securely complete the symptom assessments from home and 
receive automated, tailored advice, in addition to the display of symptom reports in patients’ 
individual EPR in the hospital to be viewed by clinicians. The development and user testing of 
the online systems is described in a published paper [130]. 
To facilitate symptom reports, an existing web-based questionnaire tool (QTool) previously 
commissioned by the PCOR group by a private software company (X-Lab) was further 
developed to meet the needs of eRAPID. QTool had previously been successfully used in a 
large scale study to collect patient reported data from cancer survivors and link it with cancer 
registries [131]. The main development needed for eRAPID was the facility to provide 
automated, tailored advice based on scoring algorithms in response to patient symptom 
reports, in addition to general improvement of usability and functionality. The PCOR team 
worked closely with X-Lab to incorporate new functionality using scoring and dependencies to 
facilitate the use of scoring algorithms, which could then be used to display automated advice 
based on questionnaire responses. 
In order to facilitate the display of patient symptom reports in individual EPRs, a link was 
created between QTool and the existing electronic health record system PPM used in the 
Leeds Teaching Hospitals Trust. This link was created via a service called QStore. The main 
challenge of this task was to maintain security of patient data within the EPR and work within 




interface was developed for clinicians to view data within individual records via QStore, with a 
similar interface available for administrators to customise the display of patient reported data 
in graph and tabulated form. 
Usability testing was carried out by members of a patient advisory group (n=2) and a small 
sample of patients receiving chemotherapy on the day unit (n=14). This usability testing was 
carried out in conjunction with patient review of the items and advice described in the next 
section. 
2.3.2 Work stream 2: Selection, adaption and evaluation of patient symptom 
report items, self-management advice and guidelines 
The main aim of work stream 2 was to develop the individual items or questions for patient 
report of treatment side effects, and to develop associated guidelines and self-management 
advice. To identify the most common symptoms and side effects experienced by patients with 
breast, gynaecological, colorectal, lung and renal cancer which would be suitable for self-
report, an extensive literature review was undertaken, in addition to analysis of a databank of 
800 cancer patients’ consultations. 16 common side effects were identified and a further three 
item areas were added after consultation with clinical and patient representatives. Self-report 
items were developed by the POCR group for each side effect, using criteria which mapped 
directly on the Common Terminology Criteria for Adverse Events (CTCAE). The CTCAE is 
commonly used by clinicians to grade patients’ chemotherapy toxicities. It was essential that 
patient self-report could map onto the CTCAE, in order for them to be clinically relevant to 
staff, and so that clear guidelines for necessary medical intervention could be established 
based on existing practice. 
In order to evaluate the items for comprehensibility and relevance to patients, cognitive 
interviews were undertaken. 60 patients purposively sampled by age, gender and tumour 
group (median age 61.5, range 35–84, 12 breast, 12 gynaecological, 13 colorectal, 12 lung and 




prior to taking part in an audio-recorded cognitive interview to explore understanding of each 
item. Following interviews, 33 amendments were made. 29% of changes related to question 
comprehension, 68% to response options and 3% to order effects. These amendments to 
phrasing and language improved patient understanding but maintained CTCAE grading and key 
medical information. Changes were endorsed by a patient advisory group and clinical staff 
[132]. The cognitive interviews are described in detail in a published paper [133]. Secondary 
analysis of these interviews is described in Chapter 3. 
Self-management advice for each of the symptoms was collated from local and national 
guidelines and reputable websites. Advice was iteratively reviewed by patients (N=14) and 
clinical staff (N=22) during usability testing to ensure comprehensibility and clinical relevance. 
This advice evolved into two forms – brief, immediate advice to be displayed at the end of the 
self-report questionnaire for reported symptoms, and more detailed advice (lifestyle advice 
etc.) for each symptom to be displayed on a separate website for patients to browse at their 
leisure. 
In addition to self-management advice where appropriate, guidelines were developed to 
identify thresholds for advising patients to contact the hospital. These were developed with 
expert clinicians from each of the relevant disease groups (breast, colorectal and 
gynaecological) in keeping with local and national guidelines. These were further developed 
into a set of algorithms to allow for automated tailored advice on the online system. 
2.3.3 Work stream 3: Integration of eRAPID into clinical pathways 
The main aim of this work stream was to understand existing care patient care pathways for 
the management of treatment side effects at St. James University Hospital and to identify how 
eRAPID could be most effectively integrated. In addition, methods of collecting patient 




additional costs patients endured as a result of their chemotherapy (e.g. non-prescription 
medications, travelling costs etc.) were piloted. 
In order to map clinical pathways, patients (n=26), carers (n=6) and staff (n=15) at varying 
stages of the treatment trajectory were interviewed. An audit of the newly introduced local 
acute oncology service was undertaken, focusing on the telephone triage system. Patients who 
had unplanned admissions were asked to complete a survey about their experiences (n=40), 
and a subset (n=26) completed interviews to further explore their experiences. This audit is 
described in detail in a published paper [21], but some of the most relevant findings from the 
patient survey and interviews, which were integral in forming the ideas for this PhD are 
described in Chapter 3. 
2.3.4 Field usability testing of eRAPID in a breast cancer clinic 
Prior to commencement of the RCT to formally evaluate eRAPID, field usability testing of the 
system was carried out. The aim was to have end users (staff and patients) use eRAPID in a real 
life clinical setting to troubleshoot practical issues not identified by standard usability testing 
[134, 135], in addition to streamlining the processes of integration into clinical practice for 




2.4 eRAPID RCT with internal pilot 
Following the successful development of eRAPID, the PCOR team were awarded a further 5 
year NIHR programme grant which commenced in July 2013 (Grant Reference Number RP-PG-
0611-20,008). The programme grant aimed to evaluate eRAPID in a large scale RCT in systemic 
therapy, and to develop eRAPID in radiotherapy and surgery. This section focuses only on the 
evaluation of eRAPID in systemic therapy. The protocol for this study has been published [94]. 
eRAPID is currently being evaluated in a large scale RCT with patients receiving systemic cancer 
treatment for breast, gynaecological and colorectal cancers, which is scheduled to finish in 
October 2018. For the purposes of this thesis, quantitative analysis described in chapter 7 was 
undertaken part way through the main RCT once a sufficient sample was reached. Details of 
sample sizes for this thesis are given in individual chapters. 
2.4.1 Study design 
2.4.1.1 Overview of study design  
This study was a single centre; 1:1 allocation prospective randomised two-arm parallel group 
design with repeated measures and mixed methods with an internal pilot phase. 
The internal pilot phase (n=87) assessed the feasibility and acceptability of the intervention 
and allowed for minor modifications before further large scale recruitment was conducted. As 
only minor changes were required, the study successfully progressed to the main trial and 
patients recruited during this pilot phase could be included in the main analysis. The full trial 
aims to recruit 504 patients using methods established during the internal pilot. Figure 2.9 





Figure 2.9 Overview of eRAPID RCT design 
 
2.4.1.2 Usual care arm 
Patients are provided with verbal and written information specific to their treatment and 
expected side effects, and information on what to do and who to contact if they experience 
problems. During their treatment (which could be weekly, 2-weekly or 3-weekly) patients have 
Key 
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Endpoints and analysis 
 Patient recruitment rates, attrition over time; proportion of missing data 
 Use of resources- including hospital contacts, community health care contacts, medication and 
additional expenses incurred 
 Patient reported outcomes- QOL: FACT-G, EORTC QLQ-C30, EQ-5D 
 Clinical process measures- hospital contacts, alerts and hospital admissions, readmissions (with 
reasons), changes to supportive medications and chemotherapy dose changes, contacts with 
GP/community services will be extracted from hospital records 
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routine consultations with either an oncologist, Clinical Nurse Specialist (CNS) or staff grade 
doctor to assess and manage treatment side effects and determine if they are well enough to 
go ahead with their next cycle of treatment. Depending on the severity of side effects being 
experienced by the patient, treatment doses can be reduced, and/or supportive medications 
changed (e.g. anti-sickness drugs, anti-diarrhoea drugs). If a patient experiences serious 
problems during their treatment, they are asked to contact the acute oncology ward and the 
nurse dealing with the patient phone call uses an Acute Triage Form to record reasons for the 
call and advice given. 
2.4.1.3 eRAPID intervention 
In addition to usual care, participants randomised to the eRAPID intervention arm receive 
training on using the system and are given a user manual and unique login details. Patients are 
asked to complete the eRAPID symptom report at least once a week and are sent a reminder 
by text or email. Patients are also encouraged to complete more frequently if they are 
experiencing problems and require support or advice. The symptom report consists of 12-15 
items depending on the disease group assessing the severity of the common side effects such 
as: nausea, vomiting, pain, fatigue, diarrhoea, constipation, mucositis (sore mouth/tongue), 
temperature, chills, performance status (general activity level), fatigue, sleep, and appetite. In 
addition there is a free text option for participants to provide details about any additional 
problems they are experiencing at the end of the standard questions. 
At the end of each symptom report, patients receive automated tailored advice on how to 
manage their symptoms and a graph is displayed for each symptom showing their responses 
over time. Patients also have access to the eRAPID website which consists of information on 
symptoms and side effects, advice about keeping healthy during cancer treatment and 




Patient-reported information is immediately available in the EPR for clinicians to view. 
Clinicians are prompted to review this data at routine pre-assessment appointments. In 
addition, email alerts are sent to specified clinicians when a patient reports a severe issue. 
Patients are not informed of this, in order to ensure that patients will contact the hospital 
when prompted, rather than waiting for a clinician to get in touch with them. 
2.4.2 Ethical considerations 
The study was approved by the National Research Ethics Service (now part of the Health 
Research Authority) Yorkshire & The Humber Leeds East Committee in September 2014 
(Reference 14/YH/1066). Local approvals from the Leeds Teaching Hospitals NHS Trust 
Research and Innovation Department were also obtained. 
2.4.3 Patient sample and eligibility 
Inclusion criteria were adult patients (aged 18 years or over) attending St James University 
Hospital Bexley wing with gynaecological or colorectal cancer requiring chemotherapy and 
breast cancer patients receiving adjuvant or neo-adjuvant chemotherapy and metastatic 
patients receiving their 1st-3rd line of chemotherapy. Patients needed to have been prescribed 
at least three months of planned chemotherapy cycles at the time of study consent and 
needed to be able and willing to give informed consent, to read and understand English and 
have access to the internet at home. Exclusion criteria were taking part in other clinical trials 
involving the completion of extensive patient reported outcome or QoL measures, exhibiting 
overt psychopathology/cognitive dysfunction or previous participation in any eRAPID studies. 
2.4.3.1 Sample size 
The sample size for the full trial is based on the primary outcome (FACT-G Physical Wellbeing 
scale, see 2.4.6.1). Allowing for 30% attrition, a minimum of 252 patients per arm (504 total) is 




necessary to detect a 2-point change in scale with 80% power and 5% significance. This change 
corresponds to a small to moderate effect size (0.3) [136]. 
2.4.4 Recruitment processes 
2.4.4.1 Identification and approach of patients 
Patients were recruited from breast, gynaecological and colorectal clinics at St. James 
University Hospital, Leeds. Eligible patients were identified by clinical staff by screening lists 
prior to relevant clinics. Clinicians introduced the study to patients at their initial consultation 
or subsequent pre-assessment appointment prior to starting chemotherapy. Patients were 
given a patient information sheet (Appendix 1) and permission was sought for a researcher to 
speak to them about the study at that time, or at a subsequent appointment. 
2.4.4.2 Consent and randomisation 
A researcher met with the patient at a convenient time (usually after their pre-assessment 
appointment prior to starting chemotherapy). The researcher ensured that the patient had 
read the information sheet provided and had an adequate understanding of the study to 
provide informed consent. Patients were given the opportunity to ask questions and if they 
were willing to participate, they were asked to sign a consent form. 
The researcher then randomised the patient to a study arm. Randomisation was performed 
centrally at the University of Leeds Clinical Trials Research Unit (CTRU) using the automated 24 
hour telephone randomisation system. Patients were stratified by cancer site, gender and 
previous chemotherapy. 
2.4.4.3 Patient training 
Patients randomised to the eRAPID intervention arm of the study were given a brief training 




access the website and complete the symptom reports. Patients were advised to complete 
weekly even if they did not experience symptoms. 
At their first chemotherapy treatment, patients were provided with a user manual to take 
home, along with a ‘postcard’ with relevant contact details, the eRAPID URL, and their unique 
username and password to access the system. 
Patients were encouraged to contact the team if they experienced any problems accessing or 
using the system, and a phone number and/or email address was taken to send weekly 
reminders. 
2.4.4.4 Completion of baseline outcome measures 
Patients were required to complete all baseline measures before their first cycle of 
chemotherapy. These included a one-off socio-demographic questionnaire which included 
questions about patients’ computer usage, in addition to the baseline completions of the 
outcome measures specified in section 2.4.5.1. 
2.4.4.5 Study follow-up procedures 
2.4.4.5.1 eRAPID intervention 
Following completion of outcome measures at baseline, patients were required to complete 
outcome measures again at 6 weeks, 12 weeks and 18 weeks after the date of their first 
chemotherapy. In addition they were asked to complete health economics data on contacts 
with healthcare outside of the hospital, list prescription and non-prescription medications and 
list any additional costs incurred during the previous 6 weeks as a result of their treatment 
such as travel, parking, food and drink or clothes. Most of the patients in the sample were 
receiving chemotherapy every 3 weeks which usually coincided with when outcome measures 
were due. In this case, the researcher would visit the patient on the chemotherapy ward to ask 
them to complete the questionnaire. If the patient chemo cycle did not coincide with the due 




the questionnaire was posted out to them and a stamped addressed envelope was provided 
for its return. 
Patients were also asked to complete the eRAPID symptom reports at least once a week and 
were sent a reminder by text or email. When patients were attending pre-assessment 
appointments, or clinic appointments, the clinician seeing the patient was prompted to check 
their eRAPID data and asked to complete a brief feedback form indicating whether they used 
the data, whether it was useful, and if so, in what way it was useful. 
Clinicians were also asked to complete a symptom assessment for each patient at six weeks. 
This symptom assessment asked clinicians to grade patient symptoms using CTCAE criteria, 
and the symptoms they were asked to grade mapped directly onto the eRAPID symptom 
report for that clinical group. 
Intervention patients were also asked to complete a system usability questionnaire at 18 
weeks. 
2.4.4.5.2 Usual care 
Patients on the usual care arm of the study were asked to complete the same paper-based 
outcome measures and health economics data at 6, 12 and 18 weeks, and similarly to the 
intervention arm patients, these were given to patients to complete on the chemotherapy 
ward where possible. 
Clinicians were also asked to complete a symptom assessment for usual care patients at the six 
week time point. 
2.4.4.6 Withdrawal procedures 
All patients had the right to withdraw from the study at any time without giving a reason. 
Patients could let the researcher know they wished to withdraw from the study via email, 




on their reasons for withdrawal. The researcher completed a withdrawal form which 
annotated the date of withdrawal and the reasons for it. 
Withdrawals were also sometimes necessary for other reasons such as cessation of 
chemotherapy, or occasionally if a member of the clinical team advised that it was no longer 
appropriate. For example, some patients’ health deteriorated while they were on study and 
they had to be taken off chemotherapy and referred into palliative care. It was no longer 
appropriate for these patients to be kept on the study and so they were withdrawn by the 
researcher. 
Initially, all patients who wished to withdraw from the eRAPID intervention were withdrawn 
fully from the study. However, shortly after the commencement of the main phase of the RCT 
the eRAPID DMEC (Data monitoring and Ethics Committee) recommended some changes to 
the withdrawal procedures for the study. The committee discussed the difference between 
patients withdrawing from the intervention and withdrawing from the trial and raised 
concerns that the final analysis may be biased. 
Following this, some changes were made to withdrawal procedures in Oct 2016. Patient 
randomised to the eRAPID intervention arm of the study who wished to withdraw from the 
intervention were given the options to a) Withdraw from the intervention but continue to 
complete outcome measures and allow their medical information to be collected for the 
remaining 18 week study period or b) Withdraw from the intervention and completion of 
outcome measures but allow their medical information to be collected for the remaining 18 
week study period or c) Withdraw from the intervention and completion of outcome measures 
and withdraw consent for collection of their medical information from that point. Similarly 
patients in the usual care arm had two options a) Withdraw from completion of outcome 
measures but allow their medical information to be collected for the remaining 18 week study 
period or b) Withdraw from completion of outcome measures and withdraw consent for 




Where patients were withdrawn for other reasons (e.g. cessation of treatment and referral to 
palliative care due to progression), a complete withdrawal from the study was undertaken. 
2.4.5 Data collection 
2.4.5.1 Outcome measures 
Outcome measures were collected from all patients at baseline, six weeks, twelve weeks and 
eighteen weeks unless otherwise indicated. 
2.4.5.1.1 Socio-demographics and computer usage (baseline only) 
After consenting to participation in the study, patients were asked to complete a questionnaire 
to collect socio-demographic information in addition to information on current computer 
usage. 
2.4.5.1.2 Functional Assessment in Cancer Therapy Scale (FACT-G) 
The FACT-G [137] is a cancer specific measure widely used in clinical trials. It has four 
subscales: physical wellbeing, social or family wellbeing, emotional wellbeing, and functional 
wellbeing. Question responses range from 0-4. Higher scores on the questionnaire indicate 
better HRQL (score range, 0 to 108). 
2.4.5.1.3 EORTC-QLQ-C30 
The EORTC QLQ-C30 [138] is a 30-item questionnaire consisting of five functional scales 
(physical, emotional, cognitive, social, role), three symptom scales (fatigue, pain, 
nausea/vomiting), a global HRQoL scale, and six single items (anorexia, insomnia, dyspnoea, 
diarrhoea, constipation, financial difficulties). Questions are rated on a 4 response scale and 






The EQ-5D [139] is a standardised instrument for use as a measure of health outcome 
developed by the EuroQol Group. The measure has been used with a range of health 
conditions and treatments and provides a simple descriptive profile and a single index value 
for health status that can be used as part of a health-economic evaluation. The instrument 
assesses five dimensions: mobility; self-care; usual activities; pain/discomfort and 
anxiety/depression. Each dimension has five response levels (ranging from no problems to 
extreme problems). The instrument also includes a scale to rate health from 0 (worst health 
you can imagine) to 100 (best health you can imagine). 
2.4.5.1.5 Use of resources form 
The use of resources form was included to assess patient use of health resources and the 
financial impact of cancer treatment. Patients were asked about non-hospital contacts (e.g. 
appointments with GPs (general practitioners)/community services, counsellors, local support 
services), as well as medication use and costs incurred as a consequence of cancer 
diagnosis/treatment. This form is based on those developed by Hulme for a recently 
completed trial assessing treatment for chemotherapy-related nausea/vomiting 
(http://www.hta.ac.uk/1723). The forms were evaluated in the eRAPID Programme 
Development Grant in 15 patients for clarity of concept (missing data), validity, acceptability, 
feasibility, and revised with user input. 
2.4.5.1.6 System Usability Scale and end of study questionnaire (18 weeks only) 
Patients on the intervention arm of the study were asked to complete the System Usability 
Scale (SUS) and an end of study questionnaire at their end of study time-point (18 weeks after 
baseline). The SUS is a 10 item instrument to assess subjective views of usability of different 
systems including hardware, software, mobile devices, websites and applications [140]. The 10 
items cover the ease of using the system, its complexity and user confidence. Each item is 




The end of study questionnaire (Appendix 2) was developed by the research team to assess 
patient experiences of using the eRAPID system. 
2.4.5.2 Clinical process measures 
Research staff collected clinical process information on all patients (intervention and usual 
care) from patient medical records. This was collected retrospectively at the end of the 18 
week study period and included any changes to the treatment plan during the study period 
(e.g. dose reduction, delay, drug changed), the number of unplanned hospital admissions, 
number of days spent in hospital and the number of triage events. Triage events included 
patient phone calls to the acute oncology unit, for which the nurse would complete a triage 
assessment to determine the course of action, in addition to physical assessments on the unit, 
where patients would be assessed to determine if there was a need for admission. 
2.4.5.3 Patient Interviews 
2.4.5.3.1 Pilot phase 
At the end of the internal pilot phase, a subset of participants per disease group in the 
intervention arm were purposively sampled by gender and age and invited for interview. The 
interview procedures and findings are detailed in full in Chapter 7. 
2.4.5.3.2 Full trial 
During the course of the trial, between 5-10 participants per disease group and study arm are 
being invited to interview. These interviews will build on those included in the pilot study by 
exploring in more depth with both intervention and usual care patients, their treatment 
experience, how they managed and monitored their symptoms and perceptions of reporting 
and discussing their symptoms with hospital staff. 
2.4.5.4 Staff interviews 




After the pilot phase a number of health care staff (n=10) were interviewed to determine their 
views of eRAPID, the perceived value and use of the patient data in clinical practice (e.g. 
improving the detection, documentation and management of side effects, supporting 
treatment decision-making in routine care). Perceptions of staff training needs and 
recommendations for improving the system were also explored. 
2.4.5.4.2 Full trial 
A further 5 health professionals from each disease group will be interviewed at the end of the 
full trial. 
2.4.6 Study Outcomes 
2.4.6.1 Primary outcomes 
The primary outcome for the RCT to evaluate eRAPID is the FACT-G [137]. Changes in score 
over time and differences between treatment arms will be explored using a multilevel 
repeated measures model. The model for each post-randomisation point will be adjusted for 
baseline score and stratification factors. 
2.4.6.2 Secondary outcomes 
Secondary outcomes for the trial are: 
1. Cost effectiveness assessed via use of health care services (including telephone 
contacts and consultations from EPR), medication and personal expenses (from Use of 
Resources Form). In addition participant records from PPM will be linked to costs held 
within the local pilot database of the National Patient-Level Information and Costing 
System (PLICS) scheme. This provides a cost for hospital based accident and 
emergency department visits, outpatient attendances and inpatient stays. In addition 
resource use and outcome data (EQ-5D, EORTC QLQ- C30) for a subgroup of 




2. Number of alerts generated by the eRAPID severe symptom reports 
3. Number of acute admissions 
4. Number of weekly and additional eRAPID symptom reports completed 
5. Comparison of clinician-recorded CTCAE and patient-reported symptom reports 
6. Clinicians use of eRAPID symptom information during the consultation 
7. Changes to supportive medication 
8. Percentage of planned chemotherapy received 
9. Changes to chemotherapy dose (dose reductions, delays) 
10. Changes to treatment plans 
11. Number of contacts with GP/community services from patients with mild/moderate 
side effects 
12. Missing clinical data collected by researchers and the hospital database 
13. Number of deaths 




2.5  Methodology of thesis 
A detailed description of methods is provided within the individual chapters of this thesis. 
However, this section aims to give an overall description of the methods used, and a 
description of how methods were integrated into the eRAPID trial. 
2.5.1 Mixed methods approach 
Mixed methods is increasingly recognised as a valuable approach in health research, 
particularly when the area of study or research topic is multi-faceted or complex. The 
deductive nature of quantitative research allows researchers to control confounding variables 
and make some generalisations from results. However, quantitative research alone cannot 
explain the how and why of what is happening, which can be particularly important, not just in 
the early development stages of research, but throughout the whole process. Qualitative 
research is more inductive, and research questions may be broad, rather than having a defined 
hypothesis. While qualitative analysis can provide insight into complex processes, findings are 
not usually generalizable due to small sample sizes, and as a result, it rarely impacts on policy 
and practice when used alone. Mixed methods can harness the strengths and balance the 
weaknesses of both approaches, and is particularly useful for the complex research questions 
often posed in health research [141]. 
There are five common approaches used. The complementary approach uses findings from 
one method to illustrate results from another. The developmental approach uses results from 
one method to develop or inform the use of the other method. The initiation approach uses 
results from different methods to specifically look for areas of incongruence in order to 
generate new insights. The expansion approach uses different methods to examine different 
aspects of a research question. Finally, the triangulation approach uses data obtained by both 




This thesis uses a combination of developmental and complementary approaches. The initial 
qualitative work described in Chapters 3 and 4, in combination with the results of the 
systematic review described in Chapter 5 informed the design and development of the later 
work. The qualitative work in Chapter 7 complements and informs the quantitative work 
described in Chapter 6. Data analysis for both methods of work were undertaken separately. 
Findings are compared, contrasted and combined in Chapter 8 using triangulation techniques 
[143, 144]. 
2.5.2 Integration with eRAPID 
An overview of the source of data for each Chapter in relation to the main eRAPID 
development and evaluation work is outlined in Figure 2.10. Data for Chapters 3 and 4 was 
collected as part of the eRAPID development. Chapter 5 describes a standalone systematic 
review which was not integrated into the eRAPID trial. Data for Chapters 6 and 7 was collected 




Figure 2.10 Data from main eRAPID development and evaluation used in each chapter 
 
 
The design of the thesis was closely integrated into the design of the main eRAPID studies and 
as such there is some overlap between work undertaken to develop and evaluate eRAPID and 
work undertaken for the thesis. Table 2.2 aims to summarise my specific role in each study, 
and subsequently where I have made original contribution. 
Table 2.2 Role and contribution for each Chapter 
Chapter Design Role in main eRAPID 
studies  











study to explore 
patient 
understanding of 
self-report items for 
side effects of 
treatment (n=60) 
Completed about half the 
interviews and half the 
transcribing. 
Completed the majority of 
the analysis 
Contributed to the main 
published manuscript 
(second author) 
Planned and completed 
secondary analysis of 
interviews focusing on 
patient experiences of 
side effects of 
chemotherapy.  
Planned data check with 
a second researcher. 
Chapter 3: Patient experiences of 
reporting and managing side 
effects during cancer treatment 
Chapter 7: Qualitative exploration 
of the patient perspective of using 














Work stream 1: Development and evaluation of 
the eRAPID electronic platform. 
 
Work stream 2: Selection, adaption and 
evaluation of patient symptom report items, self-
management advice and guidelines 
 
Work stream 3: Integration of eRAPID into clinical 
pathways 
 
Field usability testing of eRAPID in a breast 
cancer clinic 
 
Internal pilot phase 
(n=87) 
 
RCT to evaluate eRAPID in systemic therapy. 
 
Main study phase 
(planned n=417) 
 
End-of-study interviews with patients 
 
Internal pilot phase 
(n=23) 
 














Chapter 4: Field usability study of 
eRAPID in a breast cancer clinic 
 
Chapter 5: Systematic review of 
online systems to support patients 
to manage and report side effects 
of treatment 
 
Chapter 6: Quantitative 
exploration of the patient 














interviewed a subset 
of these patients to 
explore experiences 
further (n=26).  
Administered the majority 
of surveys and interviews  
Completed all data 
analysis and arranged data 
check with a second 
researcher.  
Prepared the manuscript 
for publication (first 
author) 
Reformatted existing 
analysis to focus on 
patient experiences 









Field usability study 
with 12 patients 
receiving adjuvant 
treatment for early 
breast cancer. 
Patients used eRAPID 
for 4 cycles of chemo 
(approx. 12 weeks). 
Feedback collected 
from staff and 
patients throughout 
and patients 
interviewed at the 
end of study period. 
Assisted in the planning, 
development and 
preparation of protocol  




recruitment, follow up and 
interviewing of patients 
Developed end-of-study 
interview schedule 
Analysed all of data from 
the study 
Prepared the manuscript 
for publication (joint first 
author, currently under 
review) 
Developed the 
interview schedule to 
explore patient 
experiences of using 
eRAPID for the purpose 
of the thesis.  
Worked with PI and 
senior researcher to 
ensure the schedule 
also covered the 




analysis to focus on the 
impact of eRAPID on 














Systematic review of 
online systems to 
support patients to 
report and manage 
side effects of 
treatment. A 
taxonomy of features 





n/a Responsible for all 
elements of planning, 
development and 
implementation of the 
review 
Planned data checks 




publication (first author, 
accepted for publication 












RCT with internal 
pilot (Total n=508). 
1:1 randomisation to 
eRAPID intervention 
or usual care. Breast, 
gynae and colorectal 
patients over 18 
week study period. 
Outcome measures 
collected throughout 
the study.  
Assisted in the planning, 
development and 
preparation of protocol  
Contributed towards 
published protocol (third 
author) 
Assisted in the planning 
and preparation of ethics 
application and completed 
the online Integrated 
Research Application 
System (IRAS) form. 
Worked as part of the core 
eRAPID team, responsible 
Developed the 
evaluation of patient 
engagement with 
eRAPID. Worked with 
technical support to set 
up website analytics 
and develop reports to 
assess engagement and 
adherence. 
Developed the 
evaluation of the impact 
of eRAPID on patient 
self-efficacy for 




for recruitment and 
follow-up of eRAPID 
patients, data collection 
and the day-to-day 
management of the study.  
Lead recruitment and 
follow up in the breast 
clinic. 
self-efficacy for coping 
with cancer, and patient 
activation. Selected the 
appropriate measures 
and worked with 
eRAPID team to 
incorporate these into 
the trial design.  
Planned and 











End of study 
interviews with a 
subset of patients at 
the end of the 
internal pilot phase 
of the RCT (n=23) to 
explore motivators 
and barriers for 
patient engagement 
and patient 




Developed framework for 
analysis  
Worked as part of the core 
team completing 
interviews 
Worked as part of the core 
team completing analysis 
 
Developed the 
interview schedule to 
explore patient 
engagement and 
patient experiences of 
using eRAPID for the 
purpose of the thesis.  
Worked with PI and 
senior researcher to 
ensure the schedule 
also covered the 
necessary topics for the 
main trial. 
Reformatted existing 





Chapter 3 Patient experiences of reporting and managing side effects 
during cancer treatment 
3.1 Background 
3.1.1 Overview 
Chapter 1 described some of the literature outlining the challenges associated with managing 
the many side effects patients experience during chemotherapy. This Chapter further explores 
these challenges, describing findings from two separate but complementary strands of work 
undertaken as part of the eRAPID development grant described in Chapter 2. This work builds 
on previous research by exploring patient experience of treatment with a large number of 
patients purposively sampled by age, gender and disease group. In addition, the experiences of 
patients admitted for severe side effects during treatment are explored. This work was hugely 
influential in developing the initial ideas for the project and highlighted the potential for 
eRAPID to positively impact on patient experience of chemotherapy in addition to the variation 
in how patients manage and engage with their health during cancer treatment. 
3.1.2 Role and original contribution 
As the sole research assistant on the eRAPID development grant, I had a key role on both 
strands of work described in this chapter. The first strand focuses on findings from cognitive 
interviews undertaken to evaluate newly developed self-report items for eRAPID (see section 
2.3.2). The main aim of the interviews was to explore the understanding, acceptability and 
clinical meaningfulness of the items to ensure their accuracy and suitability for remote 
monitoring in routine oncology practice. I worked closely together with the research fellow on 
the grant to develop, conduct and analyse the cognitive interviews. I also contributed to the 
writing up of the main results, which were published in 2016 [133]. As part of the interviews, 




their expectations. The work described in this Chapter is secondary analysis of the interviews, 
focusing on these themes. I was responsible for the planning and completion of this secondary 
analysis. This work has not previously been published as a full manuscript but has been 
published as a conference abstract [145]. 
The second strand of work focuses on an audit of the then newly established acute oncology 
service at St. James University Hospital (see section 2.3.3). The overall aim of the audit was to 
evaluate the acute oncology service in terms of patient experiences during the admission 
process and staff utilisation of the telephone triage system. I had a lead role in data collection, 
analysis and preparation of the results for publication. The main manuscript was published in 
2016 [21]. The work described in this Chapter was undertaken as part of the main audit, but 
the results outlined here focus on patient experiences prior to their admission. 
3.2 Aims 
The aim of this Chapter is to summarise data from two strands of work to explore factors that 
influence how patients manage and report symptoms during chemotherapy, and the impact 





3.3.1 Strand 1 - Secondary analysis of cognitive interviews 
3.3.1.1 Eligibility and patient sample 
Patients were eligible if they were over 18 years of age, had breast, gynaecological, lung, renal 
or colorectal cancer, were undergoing or had recently completed chemotherapy or biological 
treatment with curative or palliative intent, could read and understand English and did not 
exhibit overt psychopathology or serious cognitive dysfunction. Interviews were completed in 
rounds of 20 so that changes could be made to items before recommencing with the next 
round. We aimed to complete interviews until data saturation was reached, or until 60 
interviews were completed. Patients were purposively sampled by age (overall sample 50% 
over 60 years, 50% under 60 years), gender (overall sample 50% male, 50% female) and 
tumour group (20% per disease group, Breast, Gynae, Colorectal, Lung and Renal) to ensure 
representation. 
3.3.1.2 Recruitment and study processes 
Ethical approval was granted from Leeds East Ethics Committee, on 07/06/2011: REC ref: 
11/YH/0159. The cognitive interviews ran from 26th July 2011 to the 27th January 2012. 
Patients were recruited from the outpatient, day case and acute oncology admissions units at 
the Institute of Oncology at St James University Hospital Leeds UK. 
Patients were introduced to the research team by clinical staff and written informed consent 
was obtained. The interview could be carried out at this point, or arranged for a later date, 
dependent on the patient’s preferences. 
3.3.1.3 Patient interviews 
Semi-structured cognitive interviews were conducted, the main purpose of which was to 




development work for eRAPID [94]. Patients were asked to complete 2 self-report 
questionnaires [133] on side effects of treatment on a touch-screen computer on a single 
occasion in a private area in the oncology outpatient clinic at St James University Hospital, 
Leeds. Alternatively patients attending for treatment completed the questionnaires on the 
chemotherapy day unit, or in their hospital room on the acute oncology assessment unit. 
Immediately after completion, patients took part in cognitive interviews to explore their 
understanding of the items. As part of this interview, patients were also asked to elaborate on 
their experiences of treatment and any side effects which they had reported, and to describe 
how this compared to their expectations prior to commencement. Interviews were, on 
average, approximately 45 minutes long and were all audio-recorded. 
3.3.1.4 Analysis 
Interviews were transcribed verbatim and managed in NVivo version 9 software. The 
interviews were analysed using thematic analysis. Thematic analysis was selected as it is a 
flexible method which can be useful to summarise key features of large qualitative datasets, 
generate unanticipated insights and highlight similarities and differences [146]. An inductive 
approach was undertaken to identify, analyse and report patterns within the data. Interviews 
were analysed as they were completed throughout the data collection period and themes 
were coded as they emerged to create an initial framework. An iterative approach was 
adopted where interview extracts were reread and recoded by two researchers (LW & TH) 
several times to ensure all relevant extracts were included, to clarify themes and identify 
relationships between themes. Any disagreements were resolved by consensus after 
discussion. 
3.3.2 Strand 2 – Patient experiences of acute admissions 




The Trust Research and Development department approved the audit as service evaluation 
and approval from the local research ethics committee was not required. However procedures 
were undertaken in line with the DPA (Data Protection Act) [147] and GCP (Good Clinical 
Practice) guidelines [148]. 
Eligible patients were those admitted to the acute admissions ward, 18 years or over with a 
diagnosis of solid tumour or haematological cancer with sufficient English to complete the 
questionnaire and interview. 
3.3.2.2 Recruitment and study processes 
During March 2011, we aimed to survey and interview consequtively admitted patients on the 
Acute Oncology Service (AOS). However, as the majority of admitted patients were acutely 
unwell and many were undergoing medical procedures, it was inappropriate to approach all 
patients. Instead, the researcher liaised daily with clinical staff on the ward to identify suitable 
patients well enough to be approached on that day. 
Clinical staff approached patients and introduced them to the researcher. Patients were asked 
to complete a questionnaire about their experiences of the admission process and following 
this, those who were well enough and willing were asked to take part in the semi-structured 
interview to explore their experiences further. 
3.3.2.3 Royal College of Physicians (RCP) survey 
The questionnaire was developed by the RCP along with local and national cancer research 
network patient representatives, for the purpose of conducting a national audit of acute 
oncology services. The 29-item questionnaire asked about diagnosis, treatment regime, 
symptoms, experience of and satisfaction with the admission process and care within the 
service. It comprised of 27 closed questions with categorical responses, plus two open-ended 




with ‘Cancer Nurse Specialist’, and ‘ward 95 or 96’ for ‘Medical Asessment Unit’ to ensure 
relevance to the local services. The full questionnaire is available online in the RCP working 
party report [23]. 
3.3.2.4 Patient interviews 
Patients who completed the questionnaire were also invited to take part in a semi-structured 
interview about their experiences of admission. The interview schedule is outlined in Table 3.1. 
Interviews were conducted on the admissions unit. Although it was initially planned to audio-
record interviews, this proved impractical with patients receiving acute care. Therefore 
detailed notes were taken which allowed the flexibility to sometimes suspend interviews until 
a more convenient time, ensuring medical procedures and tests were prioritised. 
Table 3.1 Semi-structured interview schedule for admitted patients on the acute oncology 
ward 
Question 
Please could you tell me a bit about the problem that led to your admission? 
How long did the problem exist before you sought help? 
Did you know who to contact for help/advice? 
When did you receive information about who to contact? 
Who provided the information? 
How was the information about who to contact provided? (Written/verbally/both) 
Did the information distinguish between what you should do if you had a problem during the night? 
What happened when you contacted (insert relevant contact from q3) 
What advice were you given? 
Did you contact your GP (Did you consider contacting your GP at any time? 
What if anything might have improved the process of admission to hospital? 
3.3.2.5 Analysis 
Questionnaire responses were analysed using cross tabular descriptive statistics (IBM SPSS 
version 19) and interview data was managed using Microsoft Excel. Thematic analysis was 
chosen as the most appropriate method for data analysis (see section 3.3.1.4). However, as the 
purpose of collecting the qualitative data was to provide more in-depth insight into the 
questionnaire data, a deductive approach was employed. the interview data was assigned to 




themes included decision to seek help, information provision, patient knowledge and 
understanding, routes to admission and experience of care. Two researchers (LZ and LW) 






3.4.1 Strand 1 - Secondary analysis of cognitive interviews 
3.4.1.1 Recruitment 
A total of 107 patients were approached to take part in the interviews. 60 (56%) patients 
completed the interviews, 19 (18%) declined to take part, 20 (19%) became ineligible before 
they were interviewed (e.g. finished treatment) and 8 (7%) were missed (e.g. patients 
recruited from the acute oncology ward who were discharged before interview). 
3.4.1.2 Demographic and clinical data 
Table 3.2 displays the demographic and clinic data for patients. As patients were purposely 
sampled by age, gender and tumour group and there was fairly even distribution on these 
variables. The majority of patients were receiving chemotherapy (n=49, 81.7%) and only 33.3% 
(n=20) had chemotherapy previously. Of those 33% (n=20) who had chemotherapy previously, 
21.7% (n=13) were on second line treatment, 8.3% (n=5) were on third line treatment and 
3.3% (n=2) were on fourth line treatment. 
Table 3.2 Demographic and clinical data for patients who took part in the cognitive 
interviews 
 Mean Standard deviation 
Age (years) 
Age 59.6 12.2 
 N % 
Age group 
Up to 34 years 0 0.0% 
35-49 years 14 23.3% 
50-59years 14 23.3% 
60-69 years 18 30.0% 
70+years 14 23.3% 
Total 60  
Gender 
Male 27 45.% 
Female 33 55.0% 
Total 60  
Education 
Up to school leaving age 20 33.3% 




Degree or equivalent 23 38.3% 
Total 60  
Diagnosis 
Breast 12 20.0% 
Gynae 12 20.0% 
Colorectal 13 21.7% 
Renal 11 18.3% 
Lung 12 20.0% 
Total 60  
Treatment 
Chemotherapy 49 81.7% 
Biological therapy 11 18.3% 
Total 60  
Curative intent? 
Yes 24 40.0% 
No 36 60.0% 
Total 60  
Previous chemo? 
Yes 20 33.3% 
No 40 66.7% 
Total 60  
Treatment line 
1st line treatment (no previous chemo) 40 66.7% 
2nd line treatment  13 21.7% 
3rd line treatment 5 8.3% 
4th line treatment 2 3.3% 
3.4.1.3 Thematic analysis of interviews 
Three main themes were identified from the data: 1) Perceptions of chemotherapy, 2) 
Managing and reporting the side effects of chemotherapy and 3) Coping with chemotherapy. 
An overview of the content of these themes is outlined in Table 3.3. 
Table 3.3 Overview of themes identified in interviews 
Theme Description 
Perceptions of chemotherapy This theme described how patients perceived their experiences of 
chemotherapy, particularly in relation to their prior expectations 
or experiences with chemotherapy.  
Managing and reporting the 
side effects of chemotherapy 
This theme describes some of the challenges patients experienced 
in making decisions about when to contact the hospital and when 
self-management was appropriate.  
Coping with chemotherapy This theme describes some of the methods patients reported using 
to cope with the physical and emotional burden of chemotherapy. 
3.4.1.3.1 Perceptions of chemotherapy 
Most of the patients that were interviewed reported that they had generally found the 




recurrent theme and for many patients was synonymous with their perception of cancer and 
cancer treatment, and most patients had suffered it to some degree. However, in relation to 
other common symptoms such as pain, nausea and vomiting, patients often felt that their 
experiences of chemotherapy were not as severe as they had expected prior to commencing 
treatment. 
“I thought it might be a bit painful, I don't know what I thought the pain 
would be, because you don’t know actually do you, and I mean obviously people 
lose their hair and I don’t know whether you think there’s any pain associated with 
that” 
(Female, 64 years, Gynae) 
“I thought I'd be more sick and I thought I'd lose weight, which I didn't. I 
didn't know what else to expect. I knew I was gonna lose my hair, that was 
probably the worst thing really... I think I coped alright with it really. Some people, 
doctors have said oh you sailed through it. Apart from losing all my hair, I feel 
alright now.” 
(Female, 42 years, Breast) 
The majority of patients in this sample were having chemotherapy for the first time, but many 
had close friends or family who had gone through chemotherapy before. Patients commonly 
compared their own experiences to those of their friends and family, and generally seemed to 
feel that they had an easier time in comparison. However, not all patients felt this way, and 
one patient felt that his friend’s warning of the difficulty of chemotherapy was entirely 
accurate. 
“He said it will knock the hell out of you. He said just beware. That was 
spot on… you feel tired, you just want to give in, just want to give up. Just die 
basically” 
(Male, 63 years, Lung) 
Some patients who were having chemotherapy for the first time didn’t have any close friends 




treatment prior to their diagnosis. For these patients, their perceptions of chemotherapy were 
heavily influenced by representations in the media, such as newspapers and television. 
Patients generally felt that the media portrayal of cancer and cancer treatment was much 
worse than their experiences had been, and caused unnecessary distress. 
 “I anticipated it being a lot worse because it’s like I said to my 
friend, you saw Jade Goody on the TV and it was plastered over the news. I 
didn't even watch it to be honest, I only just saw clips of it and that was all 
you needed to see was how ill she was.” 
(Female, 45 years, Lung) 
“What makes it worse is that you never, ever read in the paper 
about chemotherapy without it seeing it prefixed with the word ‘gruelling’ 
and everybody thinks that chemotherapy is gruelling and it is shit but I 
didn’t even give up work, I have half days.” 
(Female, 51 years, Breast) 
3.4.1.3.2 Managing and reporting the side effects of treatment 
Patients reported that they were given information about potential side effects and that they 
were advised by the medical team to contact the hospital if they were concerned. However, 
patients were also told that side effects were part of chemotherapy and would be expected to 
some degree. Many patients described struggling to decide at what point their symptoms were 
severe enough to warrant medical attention. 
 “They send a card out saying if you get any of these headings, 
well I got the heading and then I was having to decide in my own mind is it 
really of sufficient severity to warrant following me up. Well is the patient 
the best person to be making that judgement?” 
(Male, 66 years, Colorectal) 
“You have absolutely no idea. And they don't really give you any 
guidelines, all they say usually is if there's any problems at all, give us a 
ring. But that's a flipping generalisation is that...” 




One patient described how he had suffered from severe constipation for several days before 
he contacted anyone. The patient was liquidising all his food as his stomach was too painful to 
eat properly. However as he had been told that constipation was a common side effect of his 
treatment, he thought that this was normal. 
“I got told off, ‘you are not being soft you must ring us’. Then I got and 
read my notes properly, oh yes, I should have rung and told them but I just 
thought it was part of the chemo and something that happens” 
(Male, 59 years, Colorectal) 
Patients often expressed a reluctance to contact the hospital as they didn’t want to ‘bother’ 
people and ‘waste’ staff time, particularly in the knowledge of how stretched hospital 
resources were. 
“I would always think a) I'm bothering them and b) the symptoms aren't 
all that bad. You know, I would really need to be bedbound before I would get in 
touch with the hospital.” 
(Female, 76 years, Breast) 
“Well you do think 'Oh they told me I could have this, I don't know if I 
should ring and bother them.” 
(Female, 49 years, Gynae) 
Patients generally described their healthcare teams as very supportive and helpful, particularly 
the oncology nurses. However, one patient did describe how an unfortunate experience of a 
junior doctor being quite dismissive of her pain following surgery subsequently influenced her 
perception of contacting the hospital about any chemotherapy symptoms she might 
experience. 
 “The Doctor came round and he made me feel about 3 feet tall. When I 
couldn’t sit up, this little boy, he told me that I must remember I’ve had a very 
minor procedure and that I clearly had a low pain threshold. Now, I was absolutely 
gutted. I felt so bad I couldn't even swear. I couldn't give him anything back at all 




But I am conscious now… I didn’t think I had a low pain threshold but it 
has made me think, would I actually ring the ward if I had pain? I would 
think if I'm a wuss, do I want to take staff away from someone who is 
really poorly…?” 
(Female, 51 years, Breast) 
3.4.1.3.3 Coping with chemotherapy 
Many patients wanted to be as informed as possible about their treatment and any potential 
side effects they might experience. Some patients reported spending a lot of time researching 
information about potential side effects online, and found it reassuring when they could find 
out that their experiences were normal and nothing to worry about. 
“Sometimes you don't always know if it’s relevant or you just 
being silly because we all have our ups and downs. So if you can just 
check, I think it’s useful to know. Like this thing I had there, it’s just a bit 
swollen. I looked it up online and it said it was a side effect of 
chemotherapy but I didn't know that. It was reassuring.. because you think 
well it’s something that other people get as well, not just me.” 
(Female, 64 years, Gynae) 
Many patients found that keeping a diary was a useful way to cope with symptoms and side 
effects, as tracking patterns of fluctuation in their side effects throughout their chemotherapy 
cycle allowed them to predict the times when they would feel fairly well, and the times when 
they would feel really poorly. Subsequently they knew what to expect each month and could 
even arrange social events to correspond with the times when they expected to feel better. In 
addition, the diarising allowed them to record strategies that had been effective in managing 
side effects such as nausea, so that they could try these again in the future. 
“Someone would say to me ‘do you fancy doing coffee next 
Monday?’ and I'd go 'Hang on a minute, no last time Monday wasn't so 




to arrange something for the Monday and then be thinking oh I actually don't 
know if I'm going to be well enough.” 
(Female, Breast, 48 years) 
“I started keeping a journal and I found that really useful because I could 
look back to where I was the previous month and think 'Oh yeah, that happened, 
or this is to come...' I found it really helpful. I even used to write down things I had 
eaten that were alright and then you forget, you go back and think, 'Oh yeah, that 
was alright, I'll try that again'. 
(Breast, 48, Female) 
Conversely, other patients reported that their approach to coping with the side effects of 
chemotherapy was to try not to think about it too much. Some patients reported that they 
hadn’t read any of the information given to them by the healthcare team, tried to put it out of 
their minds as much as possible and just tried to deal with side effects as and when they 
experienced them. 
“I personally never read the side effects of anything I am taking until I 
have something. Obviously I know about tiredness, I’ve been on the job so long 
and sickness… and things like that but I don’t read anything else till it happens, 
just to clarify it is the drug and nothing else. So I’m not one who delves into 
it....You have enough to worry about” 
(Female, 67 years, Breast) 
“Like I said, I put my head in the sand; the problems are the problems that 
you will face. What’s the point in my knowing? It only makes you worry…and then 
you start looking for things.” 
(Female, Colorectal, 67) 
3.4.2 Strand 2 – Patient experiences of acute admissions 
Some key results from the audit are presented below. Demographic and clinical data are 
presented, followed by some key results from the RCP survey, and finally some key findings 
which map onto the survey results. 




40 patients completed the RCP questionnaire. Table 3.4 displays demographic and clinical 
information for the sample. The mean age of the sample was 61.1 years old with a standard 
deviation of 10.6 years. The majority of participants were female (n= 27, 67.5%) and a large 
proportion were breast patients (n=11, 32.4%). The majority of patients (n=24, 61.5%) were on 
chemotherapy at the time of their admission. 
Of the subset of patients (n=26) who took part in the semi-structured interviews, the mean age 
was 59.0 years old with a standard deviation of 11.6 years. Again the majority were female 
(n=18, 69.2%) and on chemotherapy (n=18, 69.2%). 
Table 3.4 Demographic and clinical data for patients who completed the RCP questionnaire 
 Mean SD 
Age (years) 
Mean and standard deviation 61.1 10.6 
 N (Total n=40) % 
Age group 
Up to 34 years 0 0.0% 
35-49 years 6 15.0% 
50-59years 10 25.0% 
60-69 years 15 37.5% 
70+years 9 22.5% 
Total 40  
Gender 
Male 13 32.5% 
Female 27 67.5% 
Total 40  
Diagnosis (missing n=6) 
Breast 11 32.4% 
Colorectal 7 20.6% 
Upper Gastrointestinal 4 11.8% 
Lung 3 8.8% 
Urology 3 8.8% 
Haematology 3 8.8% 
Gynae 2 5.9% 
Sarcoma 1 2.9% 
Total 34  
Treatment (missing n=1) 
No anti-cancer treatment at present 8 20.0% 
Chemotherapy 24 61.5% 
Radiotherapy 4 10.3% 
Biological therapy 3 7.5% 
Total 39  




A summary of the responses for the questionnaire are summarised in Table 3.5. The majority 
of patients felt informed about potential side effects (n=32, 91.4%) and what to do if they 
experienced a problem (n=31, 91.2%). 
94.3% (n=33) of patients reported that they had followed advice provided when they felt 
unwell. However, patients contacted a wide variety of health professionals before coming to 
hospital, with only a small proportion (n=5, 14.3%) contacting the acute oncology ward 
directly. 
In addition, the majority of patients had felt unwell for several days before being admitted. 
25.7% (n=9) felt unwell for 2-3 days and a further 31.4% (n=11) felt unwell for 4 days or more. 
Of the 29.7% of patients referred from a routine outpatient appointment, 60.0% (n=6/10) had 
felt unwell for 4 days or more, 30.0% (n=3/10) had felt unwell for 2-3 days and the remaining 
10% (n=1/10) started to feel unwell the day before (missing n=1). 
Table 3.5 RCP questionnaire responses 
 N (Total n=40) % 
Have you been told about any problems that you could develop which are related to side 
effects of any cancer treatment you have had? (missing n=5) 
Yes 32 91.4% 
No 3 8.6% 
Total 35  
Did you feel prepared about what to do and who to contact if you had a problem? (missing 
n=6) 
Yes 31 91.2% 
No 3 8.8% 
Total 34  
Prior to this hospital admission, were you given information on what to do if you became 
unwell? (missing n=6) 
Yes 34 100.0% 
No 0 0.0% 
Total 34  
On this particular occasion, did you follow it? (missing n=5) 
Yes 33 94.3% 
No 2 5.7% 
Total 35  
If you contacted anyone for advice or help before attending hospital, who? (missing n=5) 
Own GP 2 5.7% 
Out of hours GP 1 2.9% 
Cancer Nurse Specialist 6 17.1% 
Hospital consultant/secretary 6 17.1% 




Other 3 8.6% 
Acute oncology ward 5 14.3% 
Came directly from clinic/hospital app 6 17.1% 
District Nurse 2 5.7% 
Total 35  
How were you admitted to hospital? (missing n=3) 
Sent by the GP 2 5.4% 
Referred from hospital clinic that same day 11 29.7% 
I/Carer called an ambulance 4 10.8% 
Drove ourselves in to ward 96/97 12 32.4% 
Other 8 21.6% 
Total 37  
When did you first start to feel unwell before you went to hospital? (missing n=5) 
Same day 12 34.3% 
Day before 3 8.6% 
2-3 days before 9 25.7% 
4 or more days before 11 31.4% 
Total 35  
3.4.2.3 Thematic analysis of interviews 
Results described below broadly map onto the survey responses outlined in Table 3.5. Two 
separate themes were identified– 1) Provision of information on managing side effects 
(reflecting questions 1, 2 and 3) and 2) Pathway to admission (reflecting questions 4, 5, 6 and 
7). 
3.4.2.3.1 Provision of information on managing side effects 
The interview data also supported that patients felt well-informed and were given both 
written and verbal information quite early on about side effects, who they should contact and 
what to do if they felt unwell. 
 ‘At the initial consultation, pre-chemo, I was given sheets of 
information’ 
(Female, 55 years, Colorectal) 
‘The oncology nurse emphasised high temperature being 
important’ 
(Female, 52 years, Breast) 
‘Right at beginning of treatment there was a card with everything 
highlighted - different person to ring during day and night’ 




3.4.2.3.2 Pathway to admission 
However, the interviews also revealed that despite reporting feeling informed about what to 
do and who to contact if they had a problem, patients often found it difficult to apply this 
information to their own situation and decide whether their symptoms were enough of a 
‘problem’ to warrant contacting the hospital, or whether they were a normal part of the 
chemotherapy experience. Subsequently, many patients delayed contacting the hospital. 
‘I was given a number to ring before I started treatment but what all the 
leaflets and booklets don’t do is put things into perspective’ 
(Male, 38 years, Testicular) 
‘I thought it was just par for the course’ 
(Male, 74 years, Upper GI) 
‘It would help if there was a direct line for "phoning in" to ask if something 
is normal or ask for advice’ 
(Female, 59 years, Breast) 
As highlighted by the questionnaire data, the majority of patients who were admitted from a 
routine clinic appointment had been unwell for at least several days prior to their admission. 
This would indicate that patients delayed contacting the hospital if they had an upcoming 
appointment, and this was supported by the interview data. 
‘I had vomiting all last week from chemo and radiotherapy. From Monday 
it was very bad but I had a clinic appointment so I just waited until then’ 
(Female, 71 years, Colorectal) 
‘I didn't consider ringing because I knew about my outpatient 
appointment’ 
(Female, 59 years, Breast) 
For some patients, their condition had deteriorated quite a lot during this wait and they 
regretted not contacting someone earlier. 
‘Yes, coming in earlier would have been better because now I’m very 




(Male, 38 years, Testicular) 
Other patients made a conscious decision about when to contact the hospital in order to fit a 
potential admission around other priorities such as family gatherings. 
‘I’ve had constipation since last week but I had family coming to 
visit so I decided to wait to come in today’ 
(Female, 59 years, Breast) 
‘I’d been unwell since Saturday. I didn't ring over the weekend 
because I had plans and was keen to keep them. I phoned this morning 
because of the nose bleeds, cold, headache and rash on my head’ 





3.5.1 Summary of findings 
The aim of this Chapter was to summarise data from two strands of work to explore factors 
that influence how patients manage and report side effects during chemotherapy, and the 
impact that this can have on their chemotherapy experience. 
The first strand of work described patients’ perception of chemotherapy and their experiences 
in managing and coping with cancer and treatment. Patients often used downward social 
comparison and positive framing to describe their experiences. Most patients felt that they 
were having a relatively easier time with side effects compared to the experiences of friends 
and family who had been through chemotherapy, and compared to representations of 
chemotherapy in the media. Patients commonly describe experiences of chemotherapy in this 
way, and often give quite severe accounts of symptoms and side effects while maintaining that 
experiences are ‘not that bad’, particularly in comparison to other patients, which may be part 
due to a desire to be seen as a ‘good’ patient and not wanting to be seen to complain [24, 149, 
150]. This downward social comparison and positive framing may be beneficial as a coping 
strategy, however there may be negative consequences associated. Although patients 
reported that they felt well informed about what to do and who to contact if they experienced 
problems with their cancer treatment, they often found it difficult to decide when exactly a 
side effect became a ‘problem’ and when it was just a normal part of the treatment 
experience. Patients were sometimes reluctant to seek medical attention for their symptoms 
as they didn’t want to ‘waste’ the time of healthcare staff or take valuable resources away 
from other patients who might have a greater need. This is similar to previous work in this field 
which found that patients are not always confident making decisions about when to seek 





The second strand of work also supported this. The results from the RCP survey indicated that 
although around a third of patients did contact the hospital on the initial day of experiencing 
symptoms a significant proportion had severe symptoms for up to 4 days (sometimes a week) 
before they were admitted to hospital and this was especially true if they had a routine clinic 
appointment approaching. The interview data again indicated that this delay in contacting the 
hospital was most often due to dismissing symptoms as ‘normal’ and being unsure about the 
need for medical attention. However, a couple of patients did report deliberately avoiding 
contacting the hospital about symptoms in order to fit potential hospital admissions around 
family life, highlighting the influence of a wider social context on how patients manage 
symptoms. Again, this is similar to other findings in the field [20, 25, 28]. 
In the first strand of work, many patients reported keeping a diary or journal throughout 
chemotherapy so that they could identify patterns in fluctuations of symptom severity, and 
subsequently identify times during the treatment cycle when they could expect to feel well, 
and plan social events around these times. Previous research has shown that diary keeping 
during chemotherapy can potentially improve patients’ self-efficacy to manage their side 
effects and cope with their cancer treatment [151]. Conversely, other patients reported that 
they preferred not to read too much about potential side effects and preferred just to deal 
with them as and when they experienced them, potentially reflecting a more passive or 
avoidant coping style [152]. Patients who utilise these types of coping styles may have lower 
psychosocial distress but lower quality of life [153, 154]. 
3.5.2 Strengths and limitations 
This work adds to literature on patient experience during cancer treatment and the variation in 
information given and action taken by patients when managing health at home. 
The strengths of the first strand of work, the cognitive interview study, were a relatively large 




disease group, all of whom were currently undergoing, or had recently completed cancer 
treatment. However, this was secondary analysis of the interviews, the main focus of which 
was to evaluate self-report items for the purposes of eRAPID. We asked patients 
retrospectively about their prior expectations and perceptions of chemotherapy, sometime 
after beginning treatment. Patients’ recollections and perceptions are likely to have been 
heavily influenced by their actual experiences during chemotherapy. In addition, the analysis 
did not separate or take into account patients who had previous experience of chemotherapy. 
Again, these previous experiences are likely to have impacted on the experiences reported, 
and on patients’ confidence in managing side effects of treatment. For example, patients who 
are undergoing their second or third line of treatment are likely to be more confident making 
decisions on when they need to contact the hospital for their symptoms. In addition, the 
intention of treatment (curative or disease control) may have a huge influence on how 
patients perceive their symptoms and what they are willing to tolerate [10, 24]. However, this 
data still provides valuable insight into patients’ perceptions and experiences of treatment. 
The strengths of the second strand of research, the audit of acute oncology services were 
again, a relatively large sample for this patient group, with forty patients completing the 
survey and a further twenty six completing the interviews. However, only patients who were 
actually admitted to the unit and were fit and well enough to be interviewed were included in 
the sample. Patients who called the unit and received self-management advice or who 
attended the unit for assessment and were subsequently discharged were not interviewed, 
nor were a number severely ill patients who were admitted. Interviewing these patients may 
have provided a more comprehensive insight into the range of experiences patients had when 
contacting the hospital for symptoms and side effects. In addition, due to the nature of 
patients’ condition, interviews needed to be kept brief, and it was not possible to audio-record 





Patients often experience difficulty managing the uncertainties around when and how to 
report and manage side effects of cancer treatment. Despite being provided with information 
and guidance, patients find it difficult to apply this to their own situations, and often have 
concerns about wasting healthcare resources. Subsequently they may delay contacting the 
hospital when experiencing side effects, which may result in escalation of side effects and 
hospital admission. 
The next step in the eRAPID development work (as briefly described in Chapter 2) was to 
undertake field usability testing of eRAPID in a real life clinical setting. This provided an 





Chapter 4 Field usability study of eRAPID 
4.1 Background 
4.1.1 Overview 
Chapter 2 described the eRAPID system and provided an overview of the development work 
undertaken, including a field usability testing study. The work described in Chapter 3 
highlighted some of the challenges patients face reporting and managing side effects of cancer 
treatment, in particular making decisions about when to contact the hospital and when self-
management of symptoms is appropriate. I was interested in how eRAPID could potentially 
support patients to overcome some of these issues by empowering them to make informed 
decisions about managing side effects. Access to tailored severity dependent symptom advice 
could provide patients with the practical support needed to know when self-management was 
appropriate without the need to ‘bother’ anyone and also, giving ‘permission’ for them to 
contact the hospital when they needed to do so. Similar to keeping a diary, patients could use 
eRAPID to record and monitor fluctuations in symptoms over each cycle of chemotherapy to 
identify times when they were likely to feel well and support planning social activities. 
Field usability testing of eRAPID presented a good opportunity to explore how patients 
engaged with eRAPID and how the system supported them throughout their treatment. This 
chapter describes some of the findings from this testing. I was particularly interested in 
focusing on the patient perspective and the potential psychological benefits that eRAPID might 
have. 
The overall purpose of the usability study was to have the end users (staff and patients) use 
eRAPID in a real life clinical setting. As described in Chapter 2, extensive usability testing had 




the development process following recommended usability principles of agile development 
and formative evaluation [19, 155]. 
A considerable amount of work had also been undertaken to map existing clinical pathways 
and identify where eRAPID might fit in. However, field usability testing can be a useful tool to 
troubleshoot practical issues that may not be identified by standard usability testing [134, 
135]. This was an important step to streamline some of the complex processes of integrating 
eRAPID into clinical practice for both patients and staff, prior to the commencement of the 
RCT. 
Specifically the overall aims of the usability testing were to ensure that 1) training provided to 
both patients and staff was sufficient and feasible, 2) that procedures for patient completion 
and staff access of eRAPID symptom reports were feasible to both parties, 3) that symptom 
advice was useful and relevant to patients and 4) that the safeguards put in place for when 
severe symptoms were reported by patients were safe and reliable. The reliability of the 
eRAPID system from an IT perspective was also assessed. 
For the purposes of this thesis, the usability study also provided an opportunity to explore how 
patients engaged with eRAPID, both in terms of adherence to weekly symptom report 
completions, but also in terms of how they interacted with eRAPID. End of study interviews 
would provide valuable insight into patients perception of how eRAPID impacted on their 
experience of chemotherapy, in order to inform the planning and design of the next stages of 
the thesis. 
4.1.2 Role and original contribution 
I had a key role in the planning, development and implementation of this usability testing. I 
contributed to the protocol and designed the evaluation tools. Specifically I developed the 
patient user manual with feedback questions and the interview schedule to explore patient 




and senior research fellow to ensure that requirements for the main usability testing were also 
met. 
I led the recruitment and follow-up of patients, with support from other members of the 
research team. I analysed the end of study interviews, in addition to the written and verbal 
feedback and collated this into an end of study report, to identify issues prior to the RCT. I 
have written up the full results of the usability testing as a publication which was recently 
published in BMJ Open [156]. I have also briefly described the work in a published paper [157] 
discussing how the eRAPID model of care could potentially be applied to cancer survivorship 
and presented it as a conference poster [158]. 
4.2 Aims and objectives 
The aims of this work were to: 
1) Assess patient engagement with eRAPID over a 12 week period by adherence to 
weekly symptom reports 
2) To explore barriers and facilitators to patient engagement by end of study interviews 






4.3.1 Ethical considerations 
The field usability testing took place within the Breast Oncology Service at St James University 
Hospital, Leeds. The Leeds Teaching Hospitals Trust Research & Innovation department 
approved the project as service evaluation and approval from the local research ethics 
committee was not required. However procedures were undertaken in line with the DPA (Data 
Protection Act) [147] and GCP guidelines [148]. 
4.3.2 Study design 
4.3.2.1 Patient sample and eligibility 
Patients were eligible to take part if they had a diagnosis of early breast cancer and were about 
to begin adjuvant or neo-adjuvant systemic treatment with at least 4 cycles planned. Patients 
were also required to have internet access at home and a sufficient level of English to 
complete the symptom assessment and understand the self-management advice provided. 
Patients could not be exhibiting overt psychopathology, which was assessed by clinical staff. 
4.3.2.2 Recruitment processes 
Eligible patients were identified by a breast oncology research nurse. Prior to starting their 
chemotherapy, patients were approached at clinic appointments by the oncologist or CNS, 
who introduced and briefly explained the eRAPID study. Interested patients were given an 
information sheet and introduced to an eRAPID researcher for further information. If patients 
were willing to speak to the researcher, information and/or training were provided in a private 
room in the clinic. 




Researchers explained the purpose of the testing and gave patients a brief demonstration on 
how to access and use eRAPID. The researcher arranged to meet patients at their first 
chemotherapy visit, when they would be given an eRAPID unique username and password, in 
addition to a user manual. Patients were asked to complete the remote eRAPID symptom 
assessment weekly and when experiencing side effects/symptoms over their 4 cycles of 
chemotherapy treatment. In order to prioritise patient safety, it was strongly emphasised to 
patients that eRAPID was still under development and was not intended to replace any 
information or advice they had already received. Patients were advised to contact their clinical 
team if they had any concerns about symptoms or side effects. 
4.3.2.4 Clinical staff use of eRAPID symptom reports 
All clinical staff involved in the patients care were provided with training on how to access and 
interpret the eRAPID symptom reports. Prior to patients’ scheduled pre-assessment or clinic 
appointments, the researcher prompted clinical staff to access and use available eRAPID 
symptom reports. Clinical nurse specialists (CNSs) tended to see patients for pre-assessment 
appointments before each cycle of chemotherapy. Patients also tended to have at least one 
clinic review appointment with an oncology consultant or registrar during the 12 weeks. 
Patients with more complex needs tended to be seen more often by the oncology consultants. 
4.3.3 Evaluation methods 
4.3.3.1 eRAPID symptom report completions 
Acceptability of the system was assessed by the overall number of symptom report 
completions, and adherence to the weekly completion guidelines i.e. the number of weeks in 
which patients had at least one completion. 




Researchers visited patients on the day ward when they were receiving chemotherapy, and at 
routine hospital appointments to answer queries they might have and to ask for their feedback 
on using eRAPID. Any queries or comments were documented. Patients were also provided 
with email and telephone details to contact the research team with any comments or queries, 
which were also documented. 
The step-by-step user manual provided to patients (kept for the duration of the project) 
included a short assessment consisting of questions about how easy/difficult they had found 
tasks and patients were encouraged to add feedback or comments and return the manual at 
the end of the 12 week period. 
4.3.3.3 Semi-structured interviews 
Patients were interviewed at the end of the 12 week study period to gain more in-depth 
feedback on their experience of using eRAPID. The interview schedule explored patients’ views 
of the accessibility and acceptability of eRAPID, in addition to their general views of using the 
system and how it impacted on the management of their symptoms and side effects during 
chemotherapy. The full interview schedule is outlined below in Table 4.1. 
Table 4.1 Interview schedule for end of field usability study 
Question 
Technical - Did you find the eRAPID system easy to use? Were there any aspects of it 
you found difficult? 
- Did you have any difficulties finding the site, logging in etc? If so, how did 
you resolve them? 
- Do you have suggestions on how we might improve the system? 
- Did you use the user manual we gave you? Do you have any suggestions for 
how we might improve that? 
Practicalities - We asked you to complete the eRAPID questionnaire every week, and at 
any point you felt unwell. Did you find this manageable? Did you find it a 
burden to complete the questionnaire? 
- We approached you at your first clinic appointment, and then saw you 
again at your first chemotherapy appointment. Do you think this is a good 
time to approach patients? Are there any other times when you might 
come in around this time that you think would be more suitable? 
- How did you find the level of information given to you by the research 
team? 
- Did you have any alerts triggered for severe symptoms? Did you feel it was 




General views on 
using the system 
- What were your expectations of using the eRAPID system (if any)? Were 
your expectations met? 
- Were there any advantages to using the system? 
- Were there any disadvantages to using the system? 
- Did you make any specific plans as to when you would complete the 
questionnaire? Did you set any reminders for yourself, or have a specific 
time which you completed it at? 
- Has it been difficult for you to complete the questionnaire on a weekly 
basis? How confident are you that you would be able to access the system 
on a weekly basis throughout the course of your treatment? Is there 
anything we could do to make this easier for you or other patients? 
- What factors might prevent you from using the eRAPID system? What 
factors might help you to access the eRAPID system? 
- Do you think other patients will be likely to use eRAPID? Do you think other 
patients would find it useful? 
- Was there anything you enjoyed or found pleasant about completing the 
questionnaire? Was there anything upsetting or unpleasant about 
completing the questionnaire? 
Self-
management 
- Do you think that the system accurately assessed your symptoms? E.g. The 
types of questions asked, the severity level, etc. 
- Did you find the information on the eRAPID website useful? Did you use 
any of it? 
- Do you think that using the system had any effect on how you managed 
your symptoms and side effects? 
Perceived role of 
staff/carers 
- Did the doctors/nurses in charge of your care use the system in the way 
you thought they would? 
- Do you think the doctors/CNSs in charge of your care found the system 
useful? 
- Do you think that using the system influenced your consultations with the 
doctors/nurses in any way? If so, how? 
- Did anyone else (such as a relative) help you use the system? Do you think 




- Did you have any medications prescribed or changes in treatment because 
of reporting symptoms on the system? 
- (If had any notifications). Do you feel that this was dealt with 
appropriately? If not, how would you have liked it to be dealt with? 
Any other - Do you have any other comments or questions about your involvement 
with eRAPID? 
4.3.3.4 Analysis 
In the first instance a pragmatic approach to analysis was employed to identify usability or 
integration issues which might need to be addressed quickly and discussed with the project 
management team. Verbal feedback and written comments from the user manuals and 
written feedback forms, and issues identified from the end of study interviews were collated 
and subsequently categorised into themes (determined by the aspect of the system) using 




version 9 software. Patient anonymity was maintained by allocating study numbers to 
participants. 
Interviews were then later coded and analysed thematically using an inductive approach (see 
section 3.3.1.4) [146]. The researcher (LW) created an initial framework by coding themes as 
they emerged. An iterative approach was adopted where interview extracts were reread and 
recoded several times to ensure all relevant extracts were included, to clarify themes and 
identify relationships between themes. A second researcher (TH) analysed 10% of the 
interviews separately, where differences occurred these were resolved via consensus to 






The testing period ran from mid-January 2014 to mid-March 2014. 22 patients were 
approached, 14 of which (63.6%) agreed to participate in the usability testing. However, 2 of 
these patients did not access the system at any point and subsequently withdrew, leaving 
12/22 (54.5%) patients who actually participated. Figure 4.1 illustrates the recruitment 
process. 
Figure 4.1 CONSORT diagram of recruitment 
 
4.4.2 Patient sample 
All 12 participating patients were starting adjuvant or neo-adjuvant chemotherapy treatment 
for early breast cancer. Patients had a mean age of 47.5 years (SD=10.3) with an age range of 
33-73 years. Non-participants were of similar age (M=51.7, SD=12.6). Demographic 
information was not collected. 




Patients were asked to complete the eRAPID symptom report at least once a week over the 
12-week period. However, engagement with the system was variable between patients. 42% 
(5/12) of patients completed the symptom report 11-13 times, 33% (4/12) of patients 
completed 7-9 times and 25% (3/12) completed 4-6 times. Adherence to weekly completion 
(i.e. actual/expected completions per patient) ranged from 33% to 92% with an average of 
63%. 
4.4.4 Written and verbal feedback 
All 12 patients provided some form of feedback throughout the duration of the study. A total 
of 25 verbal feedback comments were collected from patients at routine hospital 
appointments. In addition, we received one unscheduled email and one unscheduled phone 
call from two different patients. Only 3/12 patients (25%) returned the user manuals at the 
end of the study. The remaining patients reported that they had not needed to use the 
manuals, so had not provided feedback. 
The majority of comments and feedback collected related to general usability of the system 
and practicalities of completion (e.g. patients forgetting to complete, or informing us they 
were having computer trouble). We also received feedback on specific aspects of the system 
such as the wording of the symptom reports, and the alerts system which resulted in changes 
to eRAPID prior to the RCT. 
4.4.5 Thematic analysis of end of study interviews 
11/12 patients who took part in the usability testing also participated in the end of study 
interviews. One patient was not interviewed as she was too anxious and struggling with the 
burden of chemotherapy at that time. 
Two main themes were identified. The first theme related to patient engagement with eRAPID. 




motivators to patient engagement with eRAPID. The second theme related to the perceived 
benefits of the system described by patients. Three subthemes were identified within this 
which encompassed the impact of eRAPID on patients’ confidence to manage symptoms and 
side effects, and support them in coping with cancer. The main themes and subthemes are 
outlined in Table 4.2. 
Table 4.2 Main themes and subthemes of end of study interviews 
Main theme Subtheme 
Patient engagement with 
eRAPID 
 
Accessibility and acceptability of eRAPID 
Remembering to complete symptom reports 
Health status during chemotherapy  
Perception of staff use of eRAPID 
Perceived benefits of eRAPID 
 
Increasing knowledge and confidence 
Supporting decision-making on contacting the hospital 
Support for coping with cancer 
4.4.5.1 Patient engagement with eRAPID 
The end of study interviews explored some of the common barriers and motivations patients 
experienced for engaging with eRAPID and completing regular symptom reports. 
4.4.5.1.1 Accessibility and acceptability of eRAPID 
Patients generally found the system very easy to use, and none of the patients reported any 
problems with accessing the system, and all of them felt confident that this would be 
something they could continue to do on a weekly basis if they needed to do so. 
“I found it really easy to use and believe me, if I can use it, anybody can.” 
(P02, Female, 44 years, Breast) 
“It was quite easy to use. If I can use it anyone can because I’m not really 
into technology.” 
(P08, Female, 40 years, Breast) 
However, one patient did comment that while she herself found it easy to complete, she 
thought it might be difficult for older, or less computer literate patients, particularly if they 




 “It’s how you feel on chemo. Whether it’s an easy thing for you to 
do in terms of… not just physically but you know… sort of… if you are 
computer savvy and you’re not scared by it. I mean I think about someone 
like my mum and she’d be freaked out and she couldn’t do it. Yeah she 
would find it stressful just to be online and worrying that she’d get it 
wrong.” 
(P04, Female, 49 years, Breast) 
4.4.5.1.2 Remembering to complete symptom reports 
Some patients were not initially clear on how often they should be completing the symptom 
reports. Although all patients were asked to complete once a week, this seemed to get lost 
with all the other information patients were receiving at that time. 
“I didn’t know I had to do it every week, that’s another thing. You 
probably told me, but because of everything else that was going on… 
because I think what I took from talking to you is oh just fill it in when you 
feel unwell. I’ve just cottoned on to that one part, that’s not all you’ve said 
to me, you’ve said do it every week and if you feel unwell and I’ve just 
thought… because if you’re well, you’ll never fill it in will you.” 
(P08, Female, 40 years, Breast) 
In addition, even when patients were aware that they should be completing the symptom 
reports weekly, some reported that they had difficulty remembering to do this, and suggested 
a text/email prompt to remind patients when they needed to complete. 
“I don’t know really…I suppose not unless you could trigger the e-
mail reminder probably, we do check e-mails, yeah. And then people…it’s 
a reminder, and if they do it they do it I suppose, and it’s not a great 
pressure but yeah, it would be more useful, because I must admit, time 
flies by – or a text alert, that might be easier.” 
(P12, Female, 50 years, Breast) 




Some patients described how they felt less inclined to log on and complete the eRAPID 
symptom report when they were feeling well. One patient described how while she found it 
useful when she felt ill, it just wasn’t a priority when she was feeling better as she was too 
busy catching up with other things that she had been unable to do when she was poorly. 
“When you’re poorly, it’s a priority and then it goes out of the door when 
you’re feeling better because you’re doing a hundred and one things to catch up it 
goes kind of…it slips to the back” 
(P12, Female, 50 years, Breast) 
Conversely, other patients reported that they found it more difficult to motivate themselves to 
log on and complete the symptom report when they were feeling more poorly, especially if 
they were feeling tired and lethargic. 
 “I must admit when I was feeling worse, which is probably the times when 
I could do with doing it, I think it’s more lack of energy and stuff, enthusiasm to do 
it, so it’s maybe kind of a couple of days later” 
(P12, Female, 50 years, Breast) 
 “Sometimes you feel so ill that you can’t be bothered to log on” 
(P02, Female, 44 years, Breast) 
4.4.5.1.4 Perception of staff use of eRAPID 
Some patients were aware of clinical staff using their symptom report data when they came to 
hospital for pre-assessment or clinic appointments and felt that having this information 
available to clinical staff was really useful. Patients generally had these appointments every 
three weeks and some commented that was sometimes difficult to remember the symptoms 
they had experienced in the first week. They felt that eRAPID provided clinical staff with a 
better overview of how they were, by prompting discussion of symptoms that they might 
otherwise have forgotten to mention. 
“I think it’s very good for the discussion with patients because you can 




come, to remember what you were like 3 weeks ago. So it’s really good to 
have a record there. I think that’s one of the biggest benefits actually.” 
(P04, Female, 49 years, Breast) 
However, other patients were unsure of whether or not the clinicians were accessing their 
data. One patient thought that it would be useful for staff to be more explicit with patients 
about their use of the data, so that patients would be more motivated to complete regularly. 
 “If it’s that easy for them to just bring it up and then see, they can 
then say to the patient ‘Oh did you have some trouble with whatever, this 
is what advice you have…’ and then the patient would think oh, they 
actually are bothered. So I think it would be a full circle thing.” 
(P10, Female, 33 years, Breast) 
4.4.5.2 Perceived benefits of eRAPID 
Generally, patients found eRAPID a useful and valuable tool to support them throughout their 
chemotherapy. Several themes emerged from patients’ descriptions of their experiences of 
using eRAPID which are described below. 
4.4.5.2.1 Increasing knowledge and confidence 
Patients found the advice provided on how to manage symptoms at home useful and practical, 
and this was a good motivator to complete the symptom report. Patients liked that the 
information was accessible to them at any time so they could look back over it. 
“I found it excellent and that’s even me being a registered nurse. It 
gave really good information. I used it because I had a sore mouth and 
there was some very good hints there about various things. My mouth was 
quite dry which made it painful so things like sucking a pineapple or ice 
lollies.” 
(P05, Female, 60 years, Breast) 
 “Obviously your care team is at the end of the phone but that’s 
actually in front of you and then you can go over it again, and you can go 




(P11, Female, 49 years, Breast) 
Patients described how the self-management advice increased their confidence to self-manage 
their symptoms throughout treatment, and felt that eRAPID would be useful to other patients. 
Patients often used language like ‘comforting’ and ‘reassuring’ to describe how access to 
symptom advice impacted on their experience. 
“I think especially like I say, if people feel more unwell. I think they’d find it 
comforting and useful because it gives you all that information at the end about 
how to manage different stuff. It’s a really good tool.” 
(P10, Female, 33 years, Breast) 
However, one patient did comment that although she did initially find the advice useful, her 
symptoms didn’t resolve. Subsequently she felt frustrated that the information was the same 
each time and found that it became much less useful. Although she did continue to complete 
the symptom reports regularly each week, her attitude towards eRAPID, and her engagement 
with the self-management advice did change over time. 
“If I’d had different responses at different treatments, then I would have 
found it more useful. The first time I did it I found it useful and went through the 
information that it gave and I made sure that I was doing the advice that it gave 
and then after that, it’s the same every time. It wasn’t as useful, I already knew it.” 
(P04, Female, 49 years, Breast) 
The same patient described how her main motivation for continuing to use eRAPID was to use 
it as a tool for self-monitoring. Despite her symptoms remaining relatively similar on a week to 
week basis, she still found it useful to have a visual record of this. 
“I thought the graphs were great. The graphs were really good. It’s nice to 
have that visual look at where you’re at. And partly that was why I did it more 
frequently as well. I wanted to see things coming down. But most of mine stayed 




severe symptoms, and I was seeing them improving as the weeks went, I 
would have liked it even more. But yeah, I thought the graphs were really 
good.” 
(P04, Female, 49 years, Breast) 
This was a view shared by several of the other patients, many of whom also commented that 
their main motivation for regularly completing symptom reports was to maintain an accurate 
record of how their symptoms varied from week to week. 
“I also love the graphs, they are probably my favourite thing. I like 
graphs anyway, I like that visual representation.” 
(P09, Female, 73 years, Breast) 
4.4.5.2.2 Supporting decision-making on contacting the hospital 
In addition to practical advice on how to manage their symptoms at home, patients really 
valued the knowledge that eRAPID would prompt them to contact the hospital if their 
symptoms were more severe and medical intervention was needed. A number of patients 
described this as a ‘safety net’, and said they found it ‘reassuring’ and ‘comforting’. 
“My husband was nattering because I had a temperature so then I 
could say to him, Look. This says I just need to keep a close eye on it. So I 
found that helped me and it stopped me worrying needlessly. Otherwise I 
would have worked myself up so it did have that safety net” 
(P05, Female, 60 years, Breast) 
“It was really, really useful and I think, just so you’re not needing 
to ring up here, but I think if you’re feeling a bit unwell and unsure about 
something, and just, do I need to say – that really does help because it will 
say to you whether it’s mild or whatever, or you need to ring, so no I think 
it’s really good. It’s been very useful to us, especially because we’ve never 
gone through anything like this before… so rather than… either sitting 
there worrying or constantly ringing somebody, it’s been really good” 




However, a couple of patients who did receive advice to contact the hospital for their 
symptoms, and subsequently were contacted by a member of the research team felt that this 
was unnecessary. One patient described how this really frightened her, as she really didn’t 
want to be admitted to hospital, but felt this might happen because of what she had reported 
on eRAPID. This patient subsequently disengaged and did not use eRAPID again following the 
incident. 
“It brought the alert up, and the hospital rang and thought I might 
possibly need an admission, I must admit that scared me a little bit…I said well no 
actually, these symptoms were a few days ago and now I’m absolutely fine… it 
were fantastic that they rang so quickly and I think it’s a great system for that, but 
I just thought oh no, I don’t want to go to hospital”  
(P02, Female, 44 years, Breast) 
4.4.5.2.3 Support for coping with cancer 
In addition to providing practical support which they found ‘reassuring’, a number of patients 
described how they felt eRAPID had helped them to cope better throughout their cancer 
treatment. Quite a few patients commented on the symptom graphs which illustrated the 
changes in their symptoms over the 12 weeks. Some patients were able to identify patterns in 
symptom fluctuations throughout their chemotherapy cycles, and felt this gave them 
motivation to continue, in the knowledge that symptoms would resolve soon. 
“I enjoyed looking at the graphs and comparing them, and looking back to 
the beginning of my treatment to see what my problems were then, and do I still 
have the same problems now…some of them you can see a pattern, that’s always 
week 2 or week 3 so that’s quite nice and its reassuring. For me personally, I just 
think I can’t do this anymore, I don’t like this, this is awful, and I find that I’m very 
disheartened and I can’t see an end to it. Particularly as you get to this stage…I 
know I’m nearly there but not and I know I’ve got to come back again. So you do 




better…and my mouth has got better, and my diarrhoea has stopped 
and… you can see that there is a pattern and that it will get better. It 
makes me feel better.” 
(P05, Female, 60 years, Breast) 
 “I would recommend it to anyone. It’s like a safety net for you and 
gives you the help to keep on going on through your treatment.” 
(P09, Female, 73 years, Breast) 
Another patient described how she had felt like she could ‘offload’ by completing the 
questionnaire, as didn’t want to offload onto her family or worry them about how she was 
feeling. 
 “I enjoyed doing it and it enlightened me… and like I say 
offloading and being knowledgeable about when to call the team and 
when not to call and how to manage it in between so I found it really 
helpful, yeah… I enjoyed doing it and I would probably do it again. Not 
that I want to come round this journey again... You’re sort of chucked into 
a dark tunnel and it’s like a little escape route” 





4.5.1 Summary of findings 
The aim of this work was to explore patient engagement with eRAPID in a field usability study, 
in addition to exploring patient experiences of using the system whilst undergoing 
chemotherapy. Patient engagement with eRAPID and adherence to the weekly symptom 
reports was generally good, but was variable between patients. The end of study interviews 
identified some barriers and facilitators for patient engagement, in addition to some key 
benefits perceived by patients, which are discussed below. The relationship between patient 
engagement with eRAPID and the benefits they reported seemed to be reciprocal, with those 
who were completing symptom reports weekly reporting more benefits. 
Patients found the system easy to use, and weekly completions manageable and reasonable. 
This was encouraging as issues with technology and usability are often cited as a barrier to 
patient engagement with online interventions [159]. The most commonly cited reason for non-
completion was forgetting. Automated prompts have been demonstrated to be effective in 
promoting patient engagement with online interventions and subsequently an email and text 
reminder service was implemented into eRAPID prior to the RCT [160]. 
Some patients found it difficult to complete symptom reports when they were unwell, which is 
to be expected with patients undergoing chemotherapy and has been identified as a barrier in 
previous research [159]. However, some patients also reported that they were less likely to 
complete symptom reports when they felt well, sometimes because they were catching up 
with other things in their lives which had been on hold when they felt poorly. For many 
patients undergoing chemotherapy, retaining a sense of normality is very important, and for 
some patients, this may mean trying to avoid and suppress thoughts about chemotherapy and 
cancer as much as possible [161-163]. However, some patients also didn’t see the point of 




were asked in the initial training to complete at least once a week in order to provide a more 
complete overview to clinicians, patients were not always aware if and when clinical staff were 
using their data, and subsequently some patients may have felt less inclined to complete 
regularly. A qualitative study by Sanders et al explored perceived barriers and facilitators for 
patient engagement with telehealth and telecare systems for patients with complex health 
needs [128] and identified patient expectations of how the system might impact on their 
healthcare as an influential factor in adoption. If patients view eRAPID as influential to their 
care, and are aware of any impact it has on consultations, they may be more likely to engage 
and adhere to weekly completions. As a result of this finding, staff training for eRAPID was also 
amended to emphasise the importance of making patients aware when accessing symptom 
reports. 
Similarly Sanders et al found that the patient’s perceptions of how the system fits with their 
identity, independence and self-care was another influential factor in adoption. Again, this 
seemed highly relevant for eRAPID patients with one patient who had been completing regular 
symptom reports disengaging with the system after receiving advice to contact the hospital 
which she did not feel was warranted. This finding enabled us to adjust the alert system prior 
to the RCT to avoid unnecessary patient worry and burden on clinical staff. 
Patients’ reports of how eRAPID impacted on their experience of chemotherapy were 
generally very positive. Patients reported increased confidence and knowledge in managing 
their symptoms and found the symptom advice useful, particularly the specific advice about 
when to contact the hospital. The language that patients used to describe the impact of this 
was often quite emotive. Some described eRAPID as a ‘safety net’ and said it stopped them 
from worrying continuously and perhaps needlessly throughout their treatment and patients 
often used language like ‘reassuring’ and ‘comforting’ to describe their experiences of using 
eRAPID. This is similar to findings from other interventions which provide tailored specific 




In addition, some patients really valued the graphs depicting the severity of their symptoms 
over time, as this supported them to self-monitor and allowed them to identify patterns of 
fluctuation, giving them more confidence to manage their symptoms and a greater sense of 
control. Some patients also said that being able to identify patterns in symptom fluctuation 
helped them cope and feel more motivated to carry on through their treatment, with the 
knowledge that symptoms were only temporary. Self-monitoring in this way may be an 
effective coping strategy for some patients and can support them to retain the sense of 
normality that many desire, by allowing them to see patterns in symptoms and plan social 
activities and life events around this [13]. However, other patients did not engage with the 
graphs at all. Individuals have different levels of graph literacy, and they may not be useful or 
easily interpretable for all [167, 168]. In addition, self-monitoring may not be a strategy that 
suits all patients, and some may actively want to avoid it, particularly when things are not 
going well [161]. 
4.5.2 Strengths and limitations 
The strengths of the study were the real-life clinical setting and context, and the 
comprehensive methods of evaluation. The limitations of the study were a relatively modest 
consent rate. However, this is likely to be due to the exploratory nature of the recruitment 
processes used. Following feedback from patients and staff, many changes were made to 
these processes going forward into the RCT. However, the low consent rate coupled with the 
fact that the system was only evaluated in one clinic with early breast cancer patients means 
that the sample is likely to be biased. This patient group were relatively young compared to 
many other adult cancer groups [101] and subsequently more likely to be digitally agile. 
However, internet access and use continues to increase [101] and previous work has indicated 
that eRAPID is acceptable to internet users in other cancer groups [130]. In the next stages of 





eRAPID was generally well accepted by patients, but engagement was variable. End of study 
interviews indicated that patients found benefits from using eRAPID over and above improved 
symptom management, such as increased confidence to manage side effects of treatment and 
to cope with cancer and treatment. Furthermore the relationship between patient 
engagement with eRAPID and the benefits they reported seemed to be reciprocal. Those who 
completed symptom reports weekly seemed to experience more benefits such as improved 
symptom monitoring, and felt that the symptom reports were beneficial in their interactions 
with clinical staff. The findings from this study informed the selection of measures to assess 
some of the additional benefits that patients might gain from using eRAPID. The selection and 
justification of measures is fully described in Chapter 6. The results also informed further 
development of the qualitative work described in Chapter 7. 
It was also interesting to note that patients’ positive experiences of using eRAPID seemed to 
be related to specific features of the system, such as the symptom advice and the graphs. I was 
aware that there were other ePROM systems being developed and evaluated worldwide for 
patient use during chemotherapy. The next logical step was to examine available evidence on 
these systems in terms of patient engagement, patient experiences, and particularly whether 




Chapter 5 Systematic review of ePROM systems to support patients to 
manage and report side effects of treatment 
5.1 Background 
5.1.1 Overview 
Chapter 3 highlighted some of the challenges patients experience trying to manage side effects 
during chemotherapy, in particular, the lack of confidence in making decisions about when to 
self-manage and when to contact the hospital. The field usability study described in Chapter 4 
provided a valuable opportunity to assess how eRAPID could potentially support patients to 
overcome some of these issues. The main findings were that although eRAPID was generally 
acceptable to patients, engagement with the system was variable. The emotive language that 
patients used to describe their experiences with eRAPID, such as ‘comforting’ and ‘reassuring’ 
indicated that there are other potential benefits for patients, such as increased self-efficacy 
and a feeling of control over symptoms, in addition to improved physical symptom 
management. Engagement, and some of the benefits that patients described also seemed to 
be related to use of specific system features such as the self-management advice and the 
symptom graphs. I decided that the next logical step was to conduct a systematic review to 
examine available evidence on other ePROM systems available to support patients to report 
and manage side effects of cancer treatment and investigate the engagement levels and any 
known associations with ePROM features and functionality. 
There has been a dramatic increase in the number of these systems developed over the last 
decade [51, 91, 94, 169, 170] but there is considerable variation between systems in the 
approaches used for development, and in the features that they offer to patients. Some 




provide alerts when severe symptoms have been reported [51, 115, 116, 171-173]. Others 
have been developed with a greater focus on patient self-management, delivering tailored and 
automated self-management advice when appropriate, and advising patients to contact their 
healthcare team when necessary [91, 92, 174-177]. Some systems use a combination of both 
approaches [94] and may also include additional features such as facilitating communication 
with medical teams or other patients. 
I was interested in exploring whether the availability or absence of certain features would 
impact on how patients engaged with systems [178, 179]. The terms ‘engagement’ and 
‘adherence’ are often used interchangeably in this context. However, adherence suggests an 
optimal way to use a technology and this is not always easy to define [107]. For the purposes 
of this review, I refer to engagement in a broad sense of levels of patient usage of the 
technology. There is relatively little currently known about the underlying processes, and 
particularly the role that the availability of system features might play. However, there is 
evidence to suggest that individuals vary in the features which they value and utilise most 
[177], and in addition, needs may change over time, as patients become more experienced 
with the system, but also with their disease and treatment [180]. 
I was also interested in the evidence of the benefits that ePROM systems have for patients, for 
all aspects of QoL, but particularly in terms of psychosocial outcomes such as self-efficacy or 
coping. In addition, I wanted to explore whether patient outcomes were related to patient 
engagement with systems, and whether the presence or absence of system features had any 
impact on the level of patient benefit gained from using the system. Changes in behaviour or 
disease outcome have been more often observed with interactive interventions in comparison 
with those that are purely educational [181] while the use of interactive online systems is 
associated with greater self-efficacy (SE), better self-management and more participation in 




interactive communication and progress tracking features [185] and consultation and self-
management support [127]. 
Systematic reviews traditionally focus on high-quality evidence for a specific research question. 
However, increasingly, the value of taking a broader approach to inclusion is being recognised 
as important to answer complex research questions, particularly in the emerging field of online 
health interventions [186, 187]. With this in mind the focus of this review was to take an 
inclusive approach to systematically review and describe the features and functions of existing 
systems. I also wanted to focus on understanding the level of evidence indicating whether key 
system features are associated with better patient system engagement and patient centred 
outcomes. 
5.1.2 Role and original contribution 
This review was undertaken for purpose of this thesis and was not part of the main eRAPID 
work. I was responsible for all aspects of the planning, design and implementation of the 
review, with support from other researchers for double coding and data extraction. I have 
written up the results as a manuscript, which was recently accepted in the Journal of Medical 
Internet Research [188]. Preliminary results have also been presented as a conference poster 
[189]. 
5.2 Aims and objectives 
The aims of this systematic review are to: 
1. Describe the features and functions of existing electronic symptom reporting systems 
developed for patients during cancer treatment. 
2. Explore which features of these systems may be associated with patient engagement 




a. Patient engagement and whether this is related to specific system features (e.g. 
symptom monitoring, tailored self-management advice etc.); 
b. Patient centred outcomes used to evaluate systems and whether better outcomes 





5.3.1 Protocol and registration 
Details of the protocol were registered on the PROSPERO (International prospective register of 
systematic reviews) database and can be accessed at 
www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016035915. There were no 
major deviations from the protocol. However, in order to meet the aims, study selection, data 
extraction and data synthesis evolved into two stages. Stage 1: Identifying and characterising 
available systems and Stage 2: Summarising data on patient engagement and patient centred 
outcomes. 
5.3.2 Eligibility criteria 
The review question and eligibility criteria were developed and refined using PICOS 
(Population, Intervention, Comparator, Outcome, Study design) criteria outlined in Table 5.1. 
For stage 1, in order to collate an overview of all systems available, all relevant publications 
including published abstracts, protocols and qualitative studies were included. However, 
discussion papers or systematic reviews were excluded. For stage 2, in order to review 
evidence available on patient engagement and any patient centred outcomes, feasibility 
studies with any evaluation data of patient use were included, rather than restricting criteria 
to RCTs only. Criteria was piloted by two researchers (LW and KA) on a subset of 10 randomly 
selected papers and subsequently refined and clarified before the next stage. 




- Adults > 18, no upper age limit  
- Males and females 
- Worldwide 
- Any cancer diagnosis 
- Receiving cancer treatment OR within >3 months of completing treatment 
- Cancer treatment to include any treatment with significant side effects (e.g. 
systemic therapies, radiotherapy, biological therapies).  
Intervention  
 
- Online systems for patients to report and/or manage symptoms and side effects 




- Internet based or enabled systems, including mobile apps. Other forms of 
Interactive Health Communication Applications (IHCAs), e.g. DVDs, games were 
excluded.  
- Purely educational systems not interactive in any way were excluded.  
- Systems developed to assess and monitor purely psychosocial symptoms were 
excluded (E.g. Depression, anxiety, emotional coping or stress). Sleep and fatigue 
were included, however. 
- Systems designed to be accessed at one time-point only were excluded, access 
to the system had to be ongoing.  
Comparator 
 
Stage 2 only 





- Dependent on the nature and number of papers found, we aimed to characterise 
systems. For example, we identified if studies included features such as  
- Monitoring of symptoms by Health Care Professionals (HCPs) 
- Alerts for severe symptoms sent to HCPs 
- Monitoring of symptoms by patients (e.g. graphical or tabular) 
- Automated feedback/advice based on responses 
- Access to symptom information  
- Communication with other cancer patients. 
- Direct communication with HCPs (distinct from symptom monitoring by HCPs). 
Stage 2 
- We aimed to collect where available, information on engagement with systems.  
- We also aimed to collect information on any patient centred outcomes, including 
but not restricted to: 
- Any quality of life measures 
- Self-efficacy measures including patient activation, patient empowerment, 
mastery etc. 
- Patient satisfaction 
Study design 
 
Stage 2 only 
- The review was not restricted to RCTs and feasibility studies with any evaluation 
data were included. Patients had to be using the system over time and there had 
to be at least one intended time point of use more than 3 weeks after baseline. 
This timeframe was selected as many standard chemotherapy treatments are 
administered every 3 weeks.  
5.3.3 Information sources 
Studies were identified from systematic searches of MEDLINE, EMBASE, PsychInfo, Web of 
Science, Cochrane Central Register of Controlled Trials and the Health Technology Assessment 
databases in March 2016. Due to the nature of the review, results were limited to those 
published after 2000. No restrictions were imposed on language of publication. Searches were 
updated on 12th September 2017. 
Reference lists of relevant publications were screened to identify papers not picked up by the 




5.3.4 Search strategy 
A detailed example of the search strategy used for MEDLINE is outlined in Table 5.2. This 
search strategy was adapted for each of the databases. 
Table 5.2: Example of search strategy used (Medline) 












(electronic adj2 (Patient report* or Patient-report* or Self report* or Self-report* or Self manage* 
or Self-manage* or Self monitor* or Self-monitor* or Symptom report* or Symptom-report* or 
Symptom manage* or Symptom-manage*)).mp. 
(online adj2 (Patient report* or Patient-report* or Self report* or Self-report* or Self manage* or 
Self-manage* or Self monitor* or Self-monitor* or Symptom report* or Symptom-report* or 
Symptom manage* or Symptom-manage*)).mp. 
(web* adj2 (Patient report* or Patient-report* or Self report* or Self-report* or Self manage* or 
Self-manage* or Self monitor* or Self-monitor* or Symptom report* or Symptom-report* or 
Symptom manage* or Symptom-manage*)).mp. 
(remote* adj2 (Patient report* or Patient-report* or Self report* or Self-report* or Self manage* or 
Self-manage* or Self monitor* or Self-monitor* or Symptom report* or Symptom-report* or 
Symptom manage* or Symptom-manage*)).mp. 
5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
4 and 16 
limit 17 to (humans and yr="2000 -Current") 
5.3.5 Study selection 
For initial screening, a decision for inclusion was made based on title and where available, 
abstract. This was carried out by one researcher (LW) only and for this reason, a cautious 
approach erring on the side of over inclusion was employed. Following this, two researchers 
independently (LW and KA) assessed all remaining papers for relevance. Disagreements were 
resolved by consensus after referring to the protocol. All discussions and decision-making were 
documented. Where there was insufficient information to make a decision, authors were 
contacted for further information. If no response was received within two weeks, a final 




5.3.6 Data items 
5.3.6.1 Basic information 
For Stage 1, basic data was extracted on authors, title, year of publication and country of 
origin, in addition to the name (if any given) and type of system being described (e.g. web 
based or mobile app). If the system did not already have a descriptive name, an arbitrary name 
was assigned (e.g. System A). 
5.3.6.2 Taxonomy of system features 
A preliminary list of common features was created based on known key papers and systems 
([51, 83, 91, 94, 169]. It was initially planned to further develop this list throughout data 
extraction until a comprehensive list of common and or important features was achieved. 
However, no additional system features other than those specified in the original list were 
identified. 
Seven common system features were identified in the preliminary list: 
1) Allowed health professionals to remotely access and monitor patient reported data 
2) Allowed patients to monitor/review their symptom reports over time (e.g. graphs) 
3) Included a function to send alerts to health professionals for severe symptoms 
4) Provided tailored automated patient advice on symptom management 
5) Provided general patient information about cancer treatment and side effects 
6) Included a feature for patients to communicate with the healthcare team 
7) Included a forum for patients to communicate with one another 
Features could be categorised broadly as supporting patients to monitor and manage their 
own symptoms, supporting communication with health professionals and other patients, or 
supporting clinicians to monitor and manage patient symptoms. 
Data was extracted from each publication on the presence of each feature. This was coded as 
‘Yes’ only if it was explicitly described in the publication, otherwise it was coded as a ‘No’. For 
abstracts, if it was unclear whether or not a feature was present by information available in an 




were not contacted for information. However, searches were undertaken for other 
publications related to the same system. 
5.3.6.3 System evaluation 
For Stage 2, data was extracted from studies with some form of system evaluation (patient use 
of system or evaluation of efficacy). This included data on the number of patient participants, 
baseline demographics, disease and treatment type, duration of the evaluation, methods used 
to assess engagement and actual usage or adherence. Where available, data was also 
extracted on any patient centred outcomes used and results of evaluation. 
5.3.7 Data extraction 
Data was extracted using the online Systematic Review Data Repository (SRDR) [190]. The form 
was piloted on 10 randomly selected papers and further refined. For Stage 1, three additional 
researchers (KA, BC, MA) each double coded a number of allocated publications, totalling 36% 
(n=27/77) of the overall included publications. A high level of agreement (86%) was found. 
Discrepancies were resolved by referring back to the protocol and additional publications 
where available. For stage 2, the same 3 researchers again each double coded a proportion of 
the included publications totalling 46% (n=13/29) and 100% agreement was found. 
5.3.8 Risk of bias in individual studies 
Quality was assessed using the Down and Blacks checklist for non-randomised studies [191] 
and was undertaken alongside data extraction. It was deemed appropriate to assess only 
studies which included some feasibility/evaluation data, i.e. publications included in Stage 2. 
Studies are given a score along a possible range of 0 to 26. 
5.3.9 Synthesis of results 
A narrative synthesis was undertaken using the guidelines outlined by the Economic and Social 




information from multiple publications relating to the same systems was pooled to form a 
description of features. Where information was conflicting due to earlier and later iterations of 
systems, the most recent description was used. For stage 2, information was collected on how 
patient engagement was assessed for any feasibility study or trial which included this data. For 
trial studies, information was collected on primary and secondary study outcomes and any 
results recorded. We then summarised this data to explore any relationships with system 





5.4.1 Study selection 
An overview of search and selection procedures is outlined in Figure 5.1. A total of 6727 
publications were identified after removal of duplicate publications, including two publications 
identified from secondary searches (citation and reference lists). All publications were in 
English. 279 publications were assessed for eligibility and a total of 202 papers were excluded 
at this point based on predefined eligibility criteria. (Intervention, e.g. Not home-based or 
web-based, n=132, Population, e.g. Patients not on active treatment, n=41, discussion paper or 
systematic review, n=19, or abstract unavailable, n=10). 77 publications were included in Stage 
1 of the review (systems descriptions). A large proportion (30%, n=23) of these publications 
were abstracts. 29 publications were identified for inclusion in Stage 2 of the review (patient 
engagement and evaluation of systems). These were 21 feasibility studies and 8 controlled 




Figure 5.1 Summary of papers identified and subsequently excluded/included in this review 
 
5.4.2 Quality Assessment 
Along a possible range of 0 to 26, the overall median quality assessment score of studies using 
the Down and Blacks checklist was 17.0 (Mean=16.2, SD=5.3, range 2-24). For the trials 
outlined in Table 5.5, the median score was higher at 20.0 (Mean=20.4, SD=2.6, range 17-24). 
5.4.3 Stage 1: Description of systems 
The 77 publications referred to 41 individual systems. Most originated from the USA (46%, 
n=19/41) or the UK (15%, n=6). Systems were commonly web-based (56%, n=24), 27% were 




for symptom reporting and were provided to patients for the duration of the study. Seven 
common system features were identified in the preliminary list (see section 5.3.6) and no 
additional features were identified following the review. Figure 5.2 below outlines each of the 
features and it’s prevalence in the 41 identified systems. Features could be categorised 
broadly as supporting patients to monitor and manage their own symptoms, supporting 
communication with health professionals and other patients, or supporting clinicians to 
monitor and manage patient symptoms. Over half (58%) of systems had the facility for 
healthcare providers to monitor patient data over time, however, only 46% included the 
facility for patients to monitor and review their own data. Similarly, less than half the systems 
(41%) included a feature for delivering advice to support patients to self-manage symptoms 
and less than a third provided patients with access to general educational information. The 
two least common features were facilities to support communication between patients and 





Figure 5.2 Overall summary of prevalence of identified system features 
 
Table 5.3 provides an overview of each identified system and its associated publications, in 
addition to the presence or absence of each of the features identified in Figure 5.2. ‘’ 
Denotes feature is present, ‘x’ denotes feature is not present and ‘–‘ denotes that it was not 
possible to determine whether feature was present or not. 
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ASYMs (UK)  
Mobile device 
 
Randomised trial [169],  
Secondary analysis of RCT 
[164], 




 x   x x x 
CASSY (USA) 
Web based 
Randomised trial [200] x  x x  x  
CHES (Austria) 
Web based 
Abstract [76] - - - - - - - 
COPE-CIPN (USA) 
Web based 
Other [201] - - - - - - - 
CORA (USA) 
Mobile app 
Development paper [202],  
Protocol [203] 
x  x   x x 
eRAPID (UK) 
Web based 
Protocol [94],  
Abstracts [204-209] 





     x x 
ESRA-C (USA) 
Web based 
Randomised trial [83],  
Secondary analysis of RCT 
[210],  
Qualitative paper [95] 
x  x  x x x 
Healthweaver 
(USA) 
Web based & 
Mobile app 
Feasibility study [211],  
Development paper [212] 
x  x x  x x 
HSM (UK) 
Mobile device 
Feasibility study [213] 
  
 x    x x 
ICT-FP7 (France) 
Mobile device 
Abstract [214]  - - - - - - 
INTERAKTOR 
(Sweden) 
Web based & 
Mobile app 
Protocol [215]      x x 
KAIKU (Finland) 
Web based 
Feasibility study [216] 
  









Abstract [218] - - - - - - - 
Onco-TREC (Italy) 
Mobile app 
Development paper [219],  
Protocol [220] 




Feasibility study [221] 
  
   x x x x 
PaTOS (USA) 
Web based 
Feasibility study [222] 
  
 x x x x x x 
Pit-a-pit (Korea) 
Mobile app 
Feasibility study [74] 
  
 x x x x x x 
PRISMS (Australia) 
Mobile device 
Protocol [223],  
Abstract [224] 









QoC Health Inc 
(Canada) 
Mobile app 
Randomised trial [82],  
Other [226] 




Feasibility study [227] 
  
x x  x x x x 
SCMS (Singapore) 
Web based 
Feasibility study [166],  
Other [228] 
 x x x   x 
STAR (USA) 
Web based 
Randomised trial [51],  
Feasibility studies [75, 115, 
116, 171-173] 
x    x x x 
The Health Buddy 
(R) (USA) 
Mobile device 




Randomised trial [91] 
Secondary analysis of RCT 
[92, 175],  
Qualitative paper[177],  
Other [174, 176] 





 - -  - - - 
System A (USA) 
Web based 
Feasibility study [230] 
  
x x  x x x x 
System B (The 
Netherlands) 
Web based 
Non randomised trial [87],  
Development paper [231],  
Feasibility study [232] 
   x    




- - - - - - - 
System D (Sweden) 
Mobile App 
Feasibility study [60] 
  
     x x 
System E (UK) 
Mobile device 
Feasibility study [234]     x x x 
System F (Canada) 
Web based 




Abstract [237] -  -  - - - 




 x  x x x x 




- - - - - - - 
System J (USA) 
Web based 




Randomised trial [240]   x x x x x 
System L (USA) 
Mobile App 
Feasibility study [241] 
  
 x x x x x x 
System M (USA) 
Mobile App 
Abstract [242] - - - - - - - 
5.4.4 Stage 2: Patient engagement and patient centred outcomes 




Table 5.4 summarises data on patient engagement from the 29 included studies (21 feasibility 
studies and 8 controlled trials). All 21 feasibility studies (100%) reported some data on patient 
engagement, although there was variation in how engagement was defined and measured. 
Three of the eight trials (38%) did not report any data on patient engagement [82, 169, 240]. 
Of the 29 studies, the most common method of assessing engagement was the number of 
symptom report completions or number of times the system was accessed (n=12, 41%) [60, 
83, 87, 115, 200, 211, 213, 216, 222, 230, 232]. This was given as an overall figure for the whole 
sample [60, 115, 200, 216, 232], as an average per patient [115, 172, 213, 222, 232] or with a 
breakdown of the variance [211, 230]. Nine studies (31%) assessed adherence by number of 
actual completions/accesses in comparison to the number of expected completions/accesses 
[51, 74, 75, 172, 173, 221, 227, 234, 241]. This was reported as median or mean adherence of 
the overall sample for the duration of the study period [21, 74, 221, 227, 234, 241], or with a 
breakdown of adherence at different time points [75, 173]. Two studies (7%) categorised 
patients as users or non-users dependent on predefined criteria [116, 171]. Four studies (14%) 
combined results of patients reporting from home and in clinic [115, 116, 172, 173]. Not all 
studies reported on actual usage, and some used evaluation questionnaires with or without 
semi-structured interviews to assess acceptability to patients. [166, 193, 194, 213] 
Due to the variation in the methods of reporting, it was not possible to determine if there was 
any overall association between engagement and specific system features. 
Table 5.4: Overview of patient engagement data 
System name  
Patient group (No of patients 
(N)) 





Brief summary of findings 
Feasibility studies (n=21) 
- ASyMS-R [193] 
- Lung (N=16) 




- Semi structured 
interviews  
- Actual usage not reported 
- Patients perceived it to positively 
impact on care and promote timely 





- ASyMS [194] 
- Colorectal or Lung (N=18) 
- During 2 cycles of chemotherapy  
- Evaluation 
questionnaire 
- Actual usage not reported 
- Patients reported it helped monitor 
symptoms, promote self-care and 
improve symptom management  
- HealthWeaver [211] 
- Breast (N=9) 
- Undergoing active treatment 
- 4 weeks 
- No of 
completions/ 
accesses 
- All patients used website at least 3 
times weekly, 7 patients used it 
almost daily. 
- Phone component used almost daily 
by 5 patients,3 x weekly by 1 patient, 
and 1-2 x weekly by 3 patients 
- HSM [213] 
- Lung or colorectal (N=18) 
- During 2 cycles of chemotherapy 





- All patients completed 1-34 symptom 
reports, average 14 overall (SD = 
10.2).  
- High variation in use of self-
management advice  
- Patients found system easier to use 
and more useful than expected  
- Kaiku [216] 
- Head & neck (N=5) 
- During and a month after 
Radiotherapy 
- No of 
completions/ 
accesses 
- 514 symptoms reported (including 
zero grades) 
- 23 questionnaires completed  
- 38 messages sent 
- PatientViewpoint [221] 
- Breast or Prostate (N=47) 
- Medical oncology treatment  
- UTD - 3 on site visits (not 
specified)  
- No of accesses/ 
expected accesses 
- 190/224 symptom reports completed 
(85%)  
- Median expected questionnaires 
completed by individual patients was 
71%. 
- Majority of questionnaires completed 
offsite (n=160; 87%) 
- PaTOS [222] 
- Any disease site (N=30) 
- Chemotherapy 
- 10 weeks 
- No of 
completions/ 
accesses 
- 28/30 patients observed for 10 weeks 
- Total 231 accesses, 193 fully 
completed 
- Total of 1,870 symptoms observations 
(average: 69 per patient, 1.5 per day). 
- Pit-a-pit [74] 
- Breast (N=30) 
- Neo-adjuvant chemotherapy 
- 90 days 
- No of accesses/ 
expected accesses 
- 1215/2700 responses 
(compliance=45.0 %) 
- Median patient-level reporting rate 
was 41.1% (range 6.7-95.6%)  
- RemeCoach [227] 
- Advanced solid tumours, e.g. 
Colorectal, Gastric-oesophageal, 
and Pancreatic adenocarcinoma 
(N=11) 
- Duration of Teysuno® treatment 
- No of accesses/ 
expected accesses 
- Average daily compliance 91.2 % 
- Could not determine longitudinal 
compliance because of the low 
patient number using the coach for 
an acceptable duration of time 
- SCMS [166] 
- Breast, Lung or Colorectal (N=4) 
- During 4 cycles of chemotherapy 
- Evaluation 
questionnaire 
- All patients completed at least 1 
symptom report 
- Questionnaire revealed patients 
found system useful and easy to use 
- STAR [75] 
- Gynaecologic malignancy (N=49) 
- Laparotomy 
- 6 weeks 
- No of accesses/ 
expected accesses 
- Compliance of patients gradually 
decreased.  
- 92% of patients completed 
preoperative session, and 74% 
completed week 6 session.  
- Majority of patients (82%) completed 




- STAR [116] 
- Gynaecologic malignancy (N=80) 
- Chemotherapy 
- 8 weeks 
- Users/non users  
- (logged in/did not 
log in) 
- Patients could access from home or in 
clinic 
- 25% used only in clinic waiting area, 
remainder logged in from home and 
clinic  
- Most patients with home computers 
(83%) logged in from home without 
reminders. 
- STAR [171] 
- Not specified (N=180) 
- Chemotherapy 
- 8 weeks 
- Users/non users 
(logged in/did not 
log in) 
-  
- Patients could access from home or in 
clinic 
- 2/3 voluntarily logged in from home 
computers without prompting. 
- STAR [172] 
- Thoracic malignancies (N=107) 
- Chemotherapy 
- 16 months 
- No of accesses/ 
expected accesses 
- Patients could access from home or in 
clinic 
- 16 patients (15%) accessed system 
from home.  
- Home users accessed system more 
frequently than those using in clinic 
(avg =23 sessions, range, 3-144) v (avg 
=9, 1-36) respectively. 
- STAR [115] 
- Lung, Gynaecologic, Breast, 
Genitourinary (N=286) 
- Duration of chemotherapy 
- No of 
completions/ 
- accesses 
- Patients could access from home or in 
clinic 
- Total of 8,690 logins (median, 17 
logins per patient) avg 0.9 logins per 
patient per week.  
- 71% from home and 29% from clinic. 
- STAR [173] 
- Gynaecologic malignancy (N=96) 
- Laparotomy  
- Preoperatively & weekly 6-wks 
post laparotomy  
- No of accesses/ 
expected accesses 
- 74% (n=71) completed at least 4/7 
surveys and were considered 
responders.  
- 63% (n=69) completed preoperative 
session. Remaining completed 
subsequent surveys.  
- 9 (9%) patients completed only 1 
survey. 
- System A [230] 
- Hepatobiliary and GI (N=20) 
- Preoperatively and 2 weeks 
after discharge for curative 
resection  
- No of 
completions/ 
- accesses 
- 65% (13/20) completed 8 symptom 
assessments 
- 75% (15/20) completed 4 QOL 
assessments  
- Mean 7 minutes to complete MDASI 
and mean 4 minutes to complete EQ-
5D-5L. 
- System B [232] 
- Head and Neck cancer (N=36) 
- Surgery 
- 6 weeks 
- No of 
completions/ 
- accesses 
- All patients used system (total 
sessions = 982) 
- Avg no of sessions was 27.3 (S.D. 
18.4, range 4-69)  
- Avg session 12 min. longest session 
1h 38m. 
- System D [60] 
- Prostate (N=9) 
- Radiation therapy 
- 2 weeks 
- No of 
completions/ 
- accesses 
- Patients reported for mean of 10 days  
- Estimated time for report 5 min.  
- Self-care advice accessed by 85%, 
who logged 20 views at 34 symptoms. 
- 59 alerts: 55 yellow and 4 red.  
- System E [234] 
- Colon (N=6) 
- Complete resection  
- No of accesses/ 
expected accesses 
- Data entry compliance was excellent 




- During 2 cycles of chemo complete) from all six patients with 
the exception of one question 
- System L [241] 
- Head and Neck (N=22) 
- Duration of Radiation therapy 
(approximately 5 to 7 weeks) 
- No of accesses/ 
expected accesses 
- Median compliance 71% 
(interquartile range [IQR], 45%-80%).  
- 6 patients (27%) compliance ≥80%, 2 
patients (9%) 100% compliant.  
- Median reports submitted 34 (IQR, 
21-53). 
- Controlled trials (n=8) 
- *(n refers to no of patients expected to use the system (i.e. intervention arm) 
- ASyMS [169] 
- Breast, Lung or Colorectal 
(N=56) 
- 4 cycles of chemotherapy 
- Not reported 
-  
- Not reported 
- CASSY [200] 
- Any diagnosis of cancer (N=144) 
- Chemotherapy, radiation or 
surgery 
- 6 months 
- No of 
completions/ 
accesses  
- Total number of page views=1491 
- Total duration in minutes =1813.9 
- Total views and duration given for 
individual patients 
- ESRA-C [83] 
- Diagnosis of cancer (N=374) 
- Any therapeutic regimen 
- UTD, over 4 visits 




- Median access rate of 4 (range, 2-4) 
at study time points  
- Median access rates of 1 (range, 0-8) 
at voluntary times. 
- QoC Health Inc [82] 
- Breast (N=32) 
- Reconstructive surgery 
- 30 days 
- Not reported - Not reported 
- STAR [51] 
- Metastatic Breast, 
Genitourinary, Gynaecologic, or 
Lung (N=286) 
- Duration of chemotherapy 
- No of accesses/ 
expected accesses 
- Computer experienced (home access) 
and inexperienced (clinic access) 
figures combined 
- Avg 73% completed a self-report at 
any given clinic visit (includes clinic 
completions) 
- WebChoice [91] 
- Breast or Prostate (N=162) 
- Surgery plus Radiation, 
Chemotherapy, Hormone 
therapy or a combination 
- 1 year 




- 77% logged on at least once.  
- 23% never logged on. 
- Of 103 (64%) who logged on more 
than once, avg logons= 60 times 
(range, 2-892). 
- System B [87] 
- Head and neck cancer (N=39) 
- Surgery 
- 6 weeks 
- No of 
completions/ 
accesses  
- Avg no of sessions = 27, avg length of 
session= 12mins  
- Avg no of completions = 12.6  
- Avg no of messages =4.5 
- System K [240] 
- Breast cancer (N=95) 
- Adjuvant or neo-adjuvant 
chemo 
- 6 weeks 
- Not reported - Not reported 




All the trials used some measure of patient centred outcome to evaluate system efficacy, most 
commonly validated QoL, symptom and psychosocial outcome measures. Table 5.5 below 
details the measures used for the individual trials and a brief summary of findings. 








- ASYMs [169] 
 
- Population  




- Study design 




- 4 cycles of 
chemo 
-  
- Intervention (N=56) 
- Asked to complete a symptom questionnaire 
integrating Common Toxicity Criteria Adverse 
Events (CTCAE) grading system and 
Chemotherapy Symptom Assessment Scale  
- Symptom information sent in ‘real time’ to 
the study server 
- Patients receive severity dependent tailored 
self-care advice on mobile phone interface 
- Evidence-based risk assessment tool alerts 
clinicians via a dedicated 24-h pager system 
of any severe symptoms 
- Comparator (N=56) 
- Standard care following local guidelines and 
procedures related to the monitoring and 
reporting of chemotherapy-related toxicity 
including written and verbal information from 
the nurses administering chemotherapy. 
- Primary 
outcomes  





on Mean scores 






- Higher reports of 
fatigue (p=0.04) 
and lower reports 
of hand-foot 
syndrome (p=0.03) 




- No difference on 
nausea, vomiting, 
diarrhoea, or sore 
mouth/throat.  











- Study design 




- 6 months 
- Intervention (N=144) 
- Access to psycho-educational website where 
patients could record and monitor symptoms 
via graphs and journal 
- Access chat room to communicate with other 
study patients 
- Audio-visual and resource library including 
relaxation techniques and educational videos  
- Telephone contact (approx. every 2 weeks) 
with a collaborative care coordinator with 
training and experience with cognitive-
behavioural therapy (CBT) and psycho-
oncology.  
- Comparator (N=117) 
- Usual care provided by the medical team in 
addition to the assessment of symptoms and 
blood draws at the same time as intervention 


















- Comparison at 6 
months follow 
up 
- Reductions of 
fatigue at 6 
months (p=0.09).  
- Statistically and 
clinically significant 
changes in overall 
quality of life 
(p=0.05) 
- Reductions in pain 
and depression 
- Medium effect size 





- ESRA-C [83] 
 
- Population 







- Study design 
- Intervention (N=374) 
- Participants completed cancer symptoms and 
quality of life (SxQoL) assessments at each 
study time point and ad lib between visits  
- Summary reports delivered to clinicians 
- Self-management advice given for three 
symptoms 
- Coaching to verbalize issues to healthcare 
team 














- Intervention had 
lower symptom 
distress; mean 
change in SDS-15 
score was 1.27 
([SD], 6.7) in 
control (higher 
distress) and −0.04 














- Patients could monitor symptoms via graphs 
and journal  
- Self-care strategies and coaching available at 
any time. 
- Comparator (N=378) 
- Participants completed assessments at each 
study time point 
- Summary reports delivered to clinicians  
- Research staff verbally notified healthcare 
team of any severe symptoms reported at the 
time of the clinic visit.  
- Both groups were provided the same patient 
education typically available in each clinic. 
- End point was 
change in SDS-
15 total score 
from baseline to 
the end-of-
study time point  
- SDS-15 score 
reduced by 
estimated 1.21 
(95% CI, 0.23 to 
2.20; p=.02) in 
intervention v 
control group. 









- Study design 




- 30 days 
 
 
- Intervention (N=32) 
- Follow up visits at 1 and 4 weeks replaced 
with examination of surgical site via 
photographs submitted through mobile app, 
in addition to completion of pain visual 
analog scale, and quality of recovery 9-item 
questionnaire.  
- Reporting began after discharge from the 
recovery room  
- Email reminder if submission was not 
received.  
- Surgeon used a wireless interface to access 
data and monitor patients’ condition. 
- Severe scores flagged in the database for 
quick viewing. Red flags prompted in-person 
follow-up. 
- Physicians summarized data from mobile app 
using the prototypical subjective, objective, 
assessment, and plan note at 1 or more time 
points during the 30-day monitoring period. 
- Comparator (N=33) 
- Patients in conventional follow-up group had 
planned clinic follow-up at approximately 1 
week and 4 weeks after the operation.  
- Primary 
outcomes 








- Total number of 
telephone calls 
and emails to 
the health care 
team  
- Satisfaction and 
convenience 





- Control group 
more likely to 
attend in-person 
follow-up care first 
30 days after 
surgery (95% CI, 
0.24-0.66; p<.001)  
- Intervention group 
sent more emails 
than control group 
(IRR, 4.13; 95% CI, 
1.55-10.99; 
p=.005) 
- Intervention group 
reported higher 
convenience 
scores (IRR, 1.39; 
95% CI, 1.09-1.77; 
p=.008)  

























- Intervention (N=286) 
- Remote access to a web-based interface 
including questions adapted for patient use 
from CTCAE 
- Triggered e-mail alerts to nurses whenever 
patient-reported symptom worsened by 2 
points or reached an absolute grade 
- Report tracking participant’s symptoms 
printed at each clinic visit for both the nurse 
and treating oncologist.  
- No specific guidance provided to clinicians on 
actions to take in response to alerts or 
printed symptom profiles. 
- Comparators 
- Intervention - Computer inexperienced 
(N=155) 
- Similar to the main intervention group but 
accessed system in clinic only and did not 
have remote access 
- Computer experienced - Usual care. (N=253) 
- Computer inexperienced - Usual care (N=72) 
- Usual care for the computer-experienced and 
computer-inexperienced subgroups consisted 
of standard procedure for monitoring and 
documenting symptoms.  
- Primary 
outcomes 
- EuroQol EQ-5D 
Index 
administered 
via paper at 
clinic visits 







- Survival at 1 
year 
- Time to first ER 
visit and time to 
first 
hospitalization 
- Time receiving 
active cancer 
treatment 











HRQL scores in 
intervention v 
usual care arm 
(34% v 18%) and 
worsened among 
fewer (38% v 53%; 
p<.001) 
- Greater survival in 
intervention arm 
(69% v 75%, p=.05) 
- Fewer ER visits in 
intervention (34% 










- Duration of 
chemo 
- Symptoms are discussed and documented in 
the medical record during clinical encounters 
between patients and their oncologists.  
- Patients encouraged to initiate telephone 
contact between visits for concerning 
symptoms. 
- Number of 
nursing calls to 
patients  
- Intervention 
received chemo for 
longer (8.2 v 6.3 
mths, p=.002) 
- No difference in 
number of nursing 





- Breast or 
Prostate 
cancer 












- Study design 




- 1 year 
- Intervention (N=162) 
- Assessment component to monitor and 
report symptoms, problems, and priorities for 
support along physical, functional, and 
psychosocial dimensions 
- Patients receive automated tailored self-
management advice based on responses 
- Patients receive advice to contact healthcare 
team when appropriate 
- Information can be used to create a self-care 
plan 
- Information section with access to other 
reliable, relevant Web resources 
- Communication section including (a) 
unrestricted support forum for group 
discussion, allowing patients to post 
messages anonymously, (b) question-and-
answer area where patients, in private, can 
ask questions to expert nurses in cancer care.  
- Access to a diary to keep personal notes. 
- Comparator (N=163) 
- In addition to the letter informing them of 
their group assignment, participants receive 
information sheet with suggestions for 
publicly available, cancer-relevant Internet 

























significant for the 
Global Distress 
Index only (t=4.42; 
p=.037).  
- No significant 
differences on the 
other subscales or 









(t=−2.71; p=.007).  
- Control group had 
worsened self-
efficacy (t=−2.82; 
p=.005) and HRQoL 
scores significantly 
(t=−2.77;p=.006),  
- System B 














- 6 weeks 
- Intervention (N=39) 
- Provided with a laptop  
- Patients could be monitored at home (by 
means of electronic questionnaires).  
- Could communicate (send messages) to team 
- Access to information,  
- Communicate with fellow sufferers (via a 
forum) 
- Comparator (N=128) 
- Routine follow-up apps at two and six weeks 
after discharge. 
- Patients could contact their care providers, 

















- Intervention had 
significantly better 
change from 
baseline at 6 wks 
for: state anxiety 
(p=.01), fear 
related to specific 





in swallowing and 
food intake (p=.04) 
and general 
physical 
complaints (p=.02).  











- Intervention (N=49) 
- (App and physician: Patients used mobile app 
and reviewed reported data with treating 
physician at scheduled visits.) 
- Patients could report daily functional activity 
or symptoms with indication of severity.  
- Patients could edit a quick list of their 
preselected symptoms or select any of the 48 

















in contrast to 
intervention but 
not significant 









- Study design 




- 6 weeks 
 
 
- Treating physician enabled access to review 
and discuss electronically reported symptoms 
during scheduled visits.  
- Comparators 
- Attention-control group (N=46) 
- (App only: Patients instructed to use the 
mobile app without physician review.) 
- Control group (N=44) 
















issues than control 
group (P=.002). 











WebChoice [91] and System B [87] both demonstrated a positive impact on self-efficacy. 
WebChoice was evaluated using the Cancer Behaviour Inventory (CBI), a measure which 
assesses self-efficacy for coping with cancer. However, for System B, self-efficacy was only 
assessed as a subscale of a main measure. System K [240] reported an improvement in patient 
empowerment, however this was assessed using a single item regarding using the internet for 
information seeking, which is unlikely to be a reliable measure. 
5.4.4.2.2 Other psychosocial outcomes 
CASSY [200] and WebChoice [91] demonstrated significant reductions in depression in 
intervention compared to control groups. System B [87] demonstrated no difference on the 
depression subscale of a QoL measure but a significant impact on state anxiety and fear 
related to specific head and neck problems. WebChoice demonstrated no impact on social 
support [91]. QoC Health Inc [82] was primarily assessed on number of hospital contacts, but 
also included patient scores of convenience and satisfaction using a simple 5 point Likert scale 
and found an impact for convenience, but not for patient satisfaction. 
5.4.4.2.3 Global QoL 
CASSY [200] and STAR [51] interventions both demonstrated improvements in overall quality 




care co-ordinator with experience in cognitive behavioural therapy and psycho-oncology, 
which is likely to have contributed to the efficacy. In the STAR study, patients were allocated to 
computer experienced and inexperienced groups prior to randomisation and only the 
computer experienced group had access to the system from home. Results are pooled 
together, making it different to assess efficacy for our purposes. No significant impact on QoL 
was found for WebChoice [91]. 
5.4.4.2.4 Physical symptoms 
An overall reduction of symptom distress was found in the studies assessing ESRA-C [83] and 
WebChoice [91]. However, in addition to the online intervention, ESRA-C also included a 
communication coaching component to improve symptom disclosure to physicians. System B 
[87] was found to have significant positive impact on the general physical complaints subscale 
compared to the control group. 
ASyMs [169] and CASSY [200] both demonstrated positive impact on levels of fatigue while 
System K [240] demonstrated a lesser decline in functional activity in contrast to the control 
group but this was not significant. Both ASYMs and System K were evaluated using the same 
measure as used to assess symptoms in the intervention which may have impacted on results. 
Due to the considerable variation in outcomes used, and study design; it was not possible to 





5.5.1 Summary of findings 
The main aim of this review was to systematically describe and assess the features and 
functions of current ePROM systems available for patients to report and manage side effects 
of cancer treatment, in addition to understanding the level of evidence indicating whether key 
system features are associated with better patient engagement and outcomes. 
In Stage 1 of the review, a total of 41 individual systems were identified. There was significant 
variation between systems, though published descriptions of systems were often limited. A 
taxonomy of features was developed which classified systems into those supporting clinicians 
to deliver patient care in an innovative way and those aimed to support patients to better self-
manage their condition and identify when medical input may be needed. This was successfully 
applied to describe the presence or absence of common individual features in each system. 
The review of features highlighted some interesting findings. It was surprising to note that 
while over half (58%) of systems had the facility for healthcare providers to remotely monitor 
patient data, fewer than half (46%) included the facility for patients to monitor and review 
their own data. Given the available evidence suggesting that self-monitoring is generally 
beneficial to support patients’ self-management [18, 181, 185], this feature could be very 
important to improve efficacy of systems and in most cases, may be relatively easy to 
implement. Similarly, less than half the systems (41%) included a feature for delivering advice 
to support patients to self-manage symptoms and less than a third provided patients with 
access to general educational information. The two least common features were facilities to 
support communication between patients and healthcare providers (15%) and communication 
between patients themselves respectively (10%). Previous research has indicated that these 
features are highly valued and utilised by patients [81, 177, 179, 185]. It is likely that these 
features are less common due to complexities in their implementation and maintenance. For 




this way, and there are ethical considerations around the need to moderate patient forums 
that are endorsed by a healthcare facility. 
In Stage 2 of the review, little agreement was found in how patient engagement with systems 
was defined, measured or reported meaning it was not possible to compare levels of 
engagement across studies or make any conclusions on relationships with system features. In 
addition, reasons for engagement or lack of engagement were not routinely reported or 
explored. The review also indicated heterogeneity in terms of outcomes used to evaluate 
systems. Even of those that focused on symptoms or global quality of life, the variation in 
methods and measures used made meaningful comparison impossible. 
Due to the heterogeneous nature of reporting engagement and outcomes, it was not possible 
to explore any relationships with system features. These findings are similar to other reviews 
undertaken in this area, which have also found that poor assessment and reporting of patient 
engagement with systems makes comparison between studies difficult. Brower et al made 
quantifiable and comparable reports of engagement part of the inclusion criteria for their 
review, and results indicated that facility for communication with other patients may be a very 
influential factor in patient engagement and needs careful consideration during system design 
[179]. However, other oncology specific reviews have found that methods of assessing and 
reporting patient engagement were too heterogeneous to make meaningful conclusions [86, 
243]. Only eight trials (7 randomised and 1 non-randomised) evaluating systems were 
identified, none of which reported any analysis on relationships between engagement and 
outcomes, and three of which did not report any data on patient engagement at all. This does 
not seem to be unique to oncology. Donkin et al [244] set out to review the impact of patient 
engagement with e-therapies across a range of disease groups, and similarly found that this is 
not a link that is routinely explored. 
Robust evidence supporting the value of systems for patient centred outcomes was limited, 




used some measure of patient centred outcome to evaluate systems, a wide range of 
assessment tools were used, again making comparison difficult. In addition, two of the studies 
used the same measure for symptom assessment as part of the intervention, as for the 
outcome measure. Only three trials reported any measure of self-efficacy, one of which used a 
study specific non-validated measure [82], and another which was assessed using a subscale of 
a global QoL measure [87] and finally one assessing coping self-efficacy [91]. The reviewed 
systems generally demonstrated positive outcomes for patients as has been found in other 
reviews [183]. 
Due to the heterogeneous nature of study designs and methods of reporting engagement and 
outcomes, it was not possible to explore any relationships with system features. This is a field 
of research that is still in its infancy, and the large number of feasibility studies and abstracts 
identified are likely to be indicative of this. A number of protocols for planned quality trials 
were identified which may contribute to understanding of associations between system 
features, adherence and outcomes in more depth in the future [94, 170, 203, 215, 220, 223]. 
5.5.2 Strengths and limitations 
One of the main strengths of this review was the development of the taxonomy of system 
features which was successfully applied to the systems identified. This taxonomy may be 
useful to consider for future development and evaluation of ePROM system. Taxonomies such 
as the Classification of Digital Health Interventions and the Behaviour Change Technique 
Taxonomy have been useful in creating a common language and allowing better comparison of 
interventions to establish what works [245, 246]. However, these taxonomies are by design 
quite broad and more tailored and specific taxonomies such as the one described in this 
chapter are also necessary to streamline the processes of comparison for specific types of 
intervention. To my knowledge, this is the first systematic review in this field to identify and 




cancer treatment, in addition to evidence relating to patient engagement and patient centred 
outcomes. 
In order to meet the aims of the review, many publications were included which had limited 
information available and some of which were of poor quality. However, this was necessary in 
order to meet the aims of the review and evaluate all evidence. 
5.5.3 Conclusion 
The systematic review indicated that even when feasibility testing was undertaken to explore 
patient engagement or adherence with systems, reasons for engagement, or lack of, were not 
routinely explored. Neither was the potential impact of patient engagement on benefits of the 
system, or evaluative outcomes. 
There were only a small number of RCTs evaluating systems, and the outcomes chosen for 
evaluation varied dependent on the approach used for design with the majority focusing on 
symptom control. Patients using eRAPID in our usability study indicated that they found 
benefits from using the system over and above symptom management. The language that they 
used (e.g. ‘reassuring’, ‘comforting’, ‘a lifeline’) indicated that it improved their confidence to 
manage symptoms, cope with their treatment and some patients felt it improved their 
interactions with their healthcare teams. However it was surprising how few trials assessed 
psychosocial outcomes such as self-efficacy. Only three trials reported any measure of self-
efficacy, and only one of these used a validated measure. 
The next step of the thesis was to further explore patient engagement with eRAPID, and the 
psychological benefits that patients might derive from using eRAPID throughout their cancer 
treatment. With a planned RCT of more than 500 patients, there was an opportunity to explore 





Chapter 6 Quantitative analysis to explore the patient perspective of 
using eRAPID during chemotherapy 
6.1 Background 
6.1.1 Overview 
Chapter 3 described some of the challenges patients face managing side effects of 
chemotherapy. Despite guidance from their healthcare team, patients reported they were 
often uncertain about when self-management was appropriate, and when they needed to 
contact the hospital. Chapter 4 described patients’ experiences of using eRAPID during 
chemotherapy in a field usability study. In the end of study interviews, patients often 
described eRAPID as ‘reassuring’ and reported that the advice provided increased their 
confidence in managing symptoms appropriately, and also provided support coping with their 
cancer treatment. However, adherence to weekly reporting was varied and the majority of 
patients reported that they did not use the eRAPID advice website. 
Chapter 5 described a systematic review of systems available to support patients to report and 
manage side effects of cancer treatment and synthesised the available evidence on patient 
engagement and evaluating systems. Feasibility studies often reported on patient 
engagement, but there was much variation in how this was defined and measured and little 
exploration into potential predictive factors. Similar to findings in other chronic disease groups 
[244], few of the RCTs we identified reported any data on patient engagement with systems 
and none reported any analysis on the relationship between engagement and outcomes. 
While there was some evidence of potential in terms of patient outcomes, robust evidence 
was limited with few RCTs and very few of these assessed the impact of systems on patient 




Chapter 2 described the methodology of a large RCT with an internal pilot to evaluate eRAPID 
in systemic therapy in terms of improving the safe delivery of chemotherapy. The work 
described in this Chapter was integrated into the design of the RCT, and builds on previous 
work to further explore the potential of eRAPID to improve patient experience throughout 
chemotherapy. The impact of patient engagement with eRAPID is also explored, in addition to 
examining factors which may predict adherence to weekly symptom reports. 
6.1.1 Patient engagement with eRAPID 
Chapter 4 described the variability we observed in the usability study in terms of patient 
engagement with weekly symptom reports and use of the eRAPID website. While 42% (5/12) 
of patients completed the weekly symptom reports regularly throughout the study, adherence 
to weekly completion (i.e. actual/expected completions per patient) ranged from 33% to 92% 
with an average of 63%. End of study interviews also indicated that patients use of the eRAPID 
self-management advice was varied, with some patients reporting accessing the advice 
regularly, and others reporting never accessing it at all. 
In this Chapter, we will further explore patient engagement with eRAPID in terms of adherence 
to weekly symptom report completions, and assess use of the eRAPID self-management advice 
website using web analytics. In addition to descriptively reporting on patient engagement, we 
will also be exploring the impact that engagement has on the outcomes described above of 
self-efficacy to self-manage throughout chemotherapy, coping self-efficacy and patient 
activation (PA). In other words, do patients who are more engaged with the system derive 
more benefit from it? 
Engagement is a complex and multi-faceted issue and as outlined in Chapter 5, the evidence 
on adherence and engagement with systems such as eRAPID is limited. Medication adherence 
literature suggests that it is likely to be influenced by patients’ attitudes and beliefs, clinical 




demographic variables [247, 248]. We will explore the role of some of these variables in 
predicting patients’ adherence to weekly symptom report completions and their use of the 
eRAPID website. 
In addition to clinical and demographic variables and PA, we also plan to explore the role of 
clinicians’ use of data and patient experiences of chemotherapy. Clinician use of eRAPID data 
in routine consultations is likely to impact on patients’ attitudes and beliefs towards the 
system and its perceived usefulness, not just as a tool to facilitate self-management, but as a 
tool to provide useful information to their healthcare team and facilitate care. Patients’ 
negative experiences during chemotherapy such as hospital admissions and treatment changes 
may also impact their use of eRAPID. However, this relationship is likely to be complex. 
Patients who have more of a symptom burden may be less likely to use eRAPID if they feel very 
unwell, but conversely, eRAPID is likely to be more useful to patients experiencing symptoms, 
than those who remain feeling well throughout their treatment. 
6.1.2 The impact of eRAPID on the patient experience of chemotherapy 
Three main themes were identified from the end of study interview analysis in Chapter 4, 
following patients’ use of eRAPID in a usability study. The themes were: 
1. Increasing knowledge and confidence 
The self-management advice empowered patients by providing the information and 
support they needed to manage symptoms on their own terms. Patients felt confident 
doing this in the knowledge that the system would provide a ‘safety net’ if they 
needed to contact the hospital. 
2. Supporting decision-making 
Patients felt that using the eRAPID system helped reduce their worry by aiding 
decision-making about when they needed to contact the hospital and when it was 




3. Coping strategy 
Some patients found eRAPID useful to identify symptom patterns which helped 
reassure them that symptoms were temporary. This helped them to cope and gave 
them motivation to continue through treatment. 
In order to assess the potential benefit of eRAPID to increase patients’ knowledge and 
confidence in managing treatment side effects and support coping with their cancer 
treatment, three constructs and corresponding outcome measures were selected which fit the 
themes above. The constructs are not intended to directly map onto the themes, but rather 
encompass them as a whole. An overview of the outcome measures selected is illustrated in 
Figure 6.1. A full description of the properties of each of the selected measures is included in 
the methods in Section 6.3.4. 
Figure 6.1 Overview of selected outcome measures 
 
6.1.2.1 Self-efficacy for managing symptoms 
Self-efficacy is defined as ‘a belief of how well one can execute courses of action required to 
deal with prospective situations’. Self-efficacy theory posits that individuals with high levels of 
self-efficacy are more likely to initiate effort towards a goal and to sustain that effort in the 
face of obstacles and failures [249]. The increasing drive in healthcare towards self-
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Individuals with chronic illnesses such as diabetes or chronic kidney disease are required to 
perform self-management behaviours daily. Higher self-efficacy in these populations has 
consistently been demonstrated to be associated with better diet, exercise, self-monitoring 
and adherence to medication [250-253]. 
Self-efficacy for cancer patients has been described as the belief that one can successfully 
execute behaviour required to produce an expected outcome in relation to cancer and its 
treatment [254]. As cancer is increasingly being described as a chronic illness, self-
management is becoming more important, particularly with cancer survivor populations, but 
also within the acute treatment phase. As discussed in previous chapters, patients are required 
to self-manage in between routine appointments during chemotherapy and make decisions 
about when to contact the hospital. The impact of chemotherapy on individual patients is 
often unpredictable and patients can experience severe symptoms even if they are very 
effective at self-management. However, one would propose that patients who feel informed 
and confident in their ability to manage throughout treatment will be more likely to be able to 
effectively manage problems they may experience. There is some evidence to suggest that 
higher self-efficacy during chemotherapy is associated with lower symptom burden, however, 
due to the cross-sectional nature of studies, the nature of this relationship is unclear [255, 
256]. eRAPID has the potential to increase patients’ self-efficacy to manage the side effects of 
their cancer treatment effectively by the provision of tailored information and advice, in 
addition to the ‘safety net’ of alerts to contact the hospital if symptoms are severe. 
6.1.2.2 Self-efficacy for coping with cancer 
Coping self-efficacy assesses patients beliefs about maintaining a positive attitude, coping with 
stress and managing their emotions. Cancer patients who have higher levels of coping self-
efficacy demonstrate better adjustment to their disease, better long term emotional outcomes 




feel more confident about their ability to cope with their cancer and treatment often report 
better symptom management [260]. 
eRAPID has the potential to increase coping self-efficacy by normalising symptoms and side 
effects for patients, and by providing the facility for patients to monitor their symptoms, 
identify patterns in symptom fluctuation and consequently providing motivation to continue 
with treatment. 
6.1.2.3 Patient Activation 
Patient Activation (PA) is a concept which assesses how engaged a patient is in their own 
healthcare. It is comprised of the knowledge, skills, beliefs and behaviours that a patient needs 
to effectively manage a chronic illness [261]. While it is related to self-efficacy, it is a broader 
and more general concept, reflecting attitudes and approaches to self-management and 
engagement with health and healthcare, rather than being tied to specific behaviours. 
PA is still a relatively new concept and within oncology and its role is still uncertain. Studies are 
scarce and those that exist are cross-sectional or poor quality [262-264]. Evidence from the use 
of PA in other chronic illness populations such as diabetes suggests that low levels of PA are 
associated with higher use of hospital resources [265] and high levels of PA are associated with 
an array of improved health behaviours and health outcomes [261, 266, 267]. In addition, 
online interventions targeted at supporting self-management can have a positive impact on 
activation levels [268]. eRAPID has the potential to increase patients’ knowledge and skills in 
managing side effects of treatment and to subsequently influence engagement with self-
management and health. 
However, patients who are more engaged and activated may also be more likely to engage 
with eRAPID in the first instance. Patients high in PA are more likely to seek out information 




intervention such as eRAPID which offers tailored information about their treatment and 
management of side effects. We will explore the role of PA as a predictor of use of eRAPID. 
6.1.3 Role and original contribution 
As a part of the core eRAPID team, I led recruitment in the breast clinic and was responsible 
for recruitment and follow-up of patients, data collection and day to day management in this 
clinic, in addition to supporting my colleagues in other clinics when needed. I also assisted in 
the planning, development and preparation of the protocol and am a co-author on this 
publication [94]. I completed the online ethics application, with supervision from the senior 
researcher on the study. I developed the methods for evaluation of engagement, working with 
the IT manager in the group to develop reports for assessing adherence to symptom reports 
and web analytic reports to track usage of the eRAPID website. I selected the outcome 
measures for assessing the impact on patient self-efficacy for managing symptoms, self-
efficacy for coping and patient activation, and worked with the senior researcher and principal 
investigator to integrate these into the trial design. This aspect of the trial was included in the 
main protocol and ethics application. I planned and executed all of the analysis described in 
this Chapter. I have also presented preliminary work from the internal pilot phase of the trial 
as a conference poster [270]. 
6.2 Aims and Objectives 
The aims of this Chapter are: 
1) To identify potential predictors of patient engagement with eRAPID. 
2) To evaluate the impact of eRAPID on patient self-efficacy to manage their disease and 
treatment, coping self-efficacy and patient activation. 
3) To explore if impact of eRAPID on these outcomes is related to patient engagement 





6.3.1 Design, participants, and procedure 
All of the data was collected as part of the large scale RCT to evaluate eRAPID in systemic 
therapy. Patients were recruited from Breast, Gynae and Colorectal clinics and were 
randomised to receive eRAPID intervention or usual care. The study period was 18 weeks, 
which started at patients’ first chemotherapy cycle. 
The full methodology for the eRAPID RCT is outlined in Chapter 2. The outcome measures 
chosen specifically for this PhD are described below. 
6.3.2 Evaluation of patient engagement 
6.3.2.1 Adherence with weekly symptom reports 
Patients in the eRAPID intervention arm of the study were asked to complete the eRAPID 
symptom report weekly over the 18 week study period and were sent a reminder by text or 
email. 
A score was calculated in order to assess adherence with weekly reporting. This score was 
calculated from each week within which there was at least one completion report in relation 
to the number of weeks a completion report was expected (calculated one week from when 
the reminder was sent). If a patient completed more than once within a given week, additional 
completions were not counted. E.g. If a patient completed 4 times in week 1, but did not 
complete for the rest of the 18 weeks, this would be calculated as 1/18. This was then 
converted to a percentage of the overall expected completions. (E.g. 1/18 = 5.6%). 
6.3.2.2 Use of the eRAPID website 
Patients in the eRAPID intervention arm of the study could access the eRAPID website anytime 
and view advice on managing symptoms and side effects, keeping healthy during their cancer 




the website using their unique username and web analytics were used to track the pages 
visited. 
6.3.3 Clinical process measures 
As part of the RCT, clinical process measures were collected for all patients (intervention and 
usual care) on any changes to their treatment plan during the study period (e.g. dose 
reduction, delay, drug changed), the number of unplanned hospital admissions, number of 
days spent in hospital and the number of triage events. Triage events included patient phone 
calls to the acute oncology unit, for which the nurse would complete a triage assessment to 
determine the course of action, in addition to physical assessments on the unit, where patients 
would be assessed to determine if there was a need for admission. 
6.3.4 Outcome measures 
6.3.4.1 6 item self-efficacy scale (CSES) 
Self-efficacy to manage disease and treatment during chemotherapy was assessed using this 6-
item scale containing items taken from several self-efficacy scales. It covers several domains 
that are common across many chronic diseases such as symptom control, role function, 
emotional functioning and communicating with physicians. Each item is rated on a scale of 1 
(not at all confident) to 10 (totally confident). The summary score for the scale is the mean of 
the six items and can range from 1-10. The score is only calculated if there are two or less 
missing items. Higher number indicates higher self-efficacy. 
The CSES has been demonstrated to have a reliable internal consistency (Cronbach’s alpha 
coefficient ranging from of .91 to .93) and good convergent construct validity to other 
measures of self-efficacy (r=0.578, P < 0.001). The scale has a unidimensional structure [271, 
272]. 




Coping self-efficacy was assessed using the Cancer Behaviour Inventory-Brief Version [273], a 
14-item unidimensional instrument designed to assess the coping self-efficacy of cancer 
patients. Specifically, the CBI-B assesses areas important to coping with cancer including (a) 
the respondent’s beliefs about maintaining independence and a positive attitude, (b) belief in 
their ability to participate in medical care, (c) skills important for coping and stress 
management, and (d) their capacity to manage their emotions/affect in difficult situations. 
Each of the 14 items is rated on a scale of 1 (Not at all confident) to 9 (Totally confident). The 
CBI-B score is calculated as the sum of all 14 answered items and can range from 28-126. 
Higher scores mean higher coping self-efficacy. Scores are calculated regardless of the number 
of missing items so long as at least one item has been answered. 
The CBI-B has been demonstrated to have good internal consistency across different samples 
(Cronbach’s alpha coefficient ranging from .84 to .88) and good external validity demonstrated 
by positive correlations with measures of quality of life and optimism and negative correlations 
with measures of depression and sickness impact. The shortened measure (CBI-B) correlates 
highly with the full measure (CBI-L) (r=.95) [259, 273]. 
6.3.4.3 Patient Activation Measure (PAM) 
Patient activation was assessed using the Patient Activation Measure (PAM) [274], a tool for 
measuring the level of patient engagement in their healthcare. It was designed to assess an 
individual’s knowledge, skill and confidence for self-management. The PAM 13-item scale 
explores beliefs, knowledge and confidence for engaging in health behaviours. Each item is 
rated on a four point scale from strongly disagree to strongly agree and an option for ‘non 
applicable’ is provided. To calculate the total PAM score, the summary score is divided by the 
number of items answered (excepting non-applicable items) and multiplied by 13. This score is 
then transformed to a scale with a theoretical range 0–100, based on calibration tables, with 




into one of four activation categories ranging from 1- Low activation to 4- High activation. The 
summary score is only calculated if there are less than 4 items missing or with an N/A 
response. 
The PAM has been demonstrated to have a reliable internal consistency with a Cronbach’s 
alpha coefficient ranging from 0.84 to 0.907 [266, 275, 276]. External validity has been 
demonstrated by positive correlations with measures of optimism, hope, self-efficacy and 
internal locus of control [276]. The PAM has usually been found to be unidimensional in 
healthy populations [274, 275], but research with patients in mental health settings revealed 
underlying structures of two or more factors [276, 277]. 
6.3.4.4 Completion of measures 
Patients were asked to complete these outcome measures on paper forms both at baseline, 
before they commenced chemotherapy, and then again at the end of the study (18 weeks). 
The measures were integrated into questionnaire packs which also included other measures 
and information required for the main RCT. Specific information about these questionnaire 
packs at baseline and 18 weeks is given below. 
6.3.4.4.1 Completion of measures at baseline 
Patient completed measures while the researcher was completing the randomisation 
procedures (see section 2.4.4.2). This usually took place in a private room at the hospital 
following patients’ pre-assessment appointment prior to starting chemotherapy. Alternatively, 
some patients requested to complete the randomisation procedures and the baseline 
measures at their first chemotherapy appointment. Where possible patients were asked to 
come in early before their chemotherapy appointment and this was undertaken in a private 
room next to the chemotherapy day unit. However, some patients were unable to come in 




chemotherapy ward whilst undergoing treatment. This was generally in a room shared with 
other patients. 
Patients were required to complete two questionnaire packs at this time point. The first was a 
brief socio-demographic and computer usage questionnaire (see section 2.4.5.1.1) and the 
second was the ‘Baseline questionnaire pack’. This questionnaire included the primary 
outcomes and some of the secondary outcomes for the main RCT, in addition to the outcome 
measures described above (see section 2.4.5.1). The measures appeared in the following 
order: FACT-G, EQ-5D, CSES, CBI-B, PAM and the EORTC QLQC30. The order of questionnaires 
was not rotated. 
6.3.4.4.2 Completion of measures at 18 weeks 
If patients had a clinic or chemotherapy appointment at around the time their 18 week 
questionnaire was due, they were seen in person by a member of the research team if possible 
and asked to complete the questionnaire there and then. This would be in a clinic waiting 
room, or more often on the chemotherapy day ward. However, if the patient did not have a 
hospital appointment around this time, or if a member of the research team was not available, 
questionnaire packs were posted out to patients with a stamped addressed envelope to return 
it. If the questionnaire was not received back, up to two postal reminders were sent out 
(including the questionnaire pack and SAE) over the next two weeks. 
Again, the questionnaire packs included other measures for the main RCT and appeared in the 
following order: FACT-G, EQ-5D, CSES, CBI-B, PAM, EORTC QLQC30 and the Use of Resources 
Form. Again, the order of questionnaires was not rotated. 
6.3.5 Analysis 




All data was inputted into a local data management system (DMS) by the research team over 
the course of the study. Then data was then exported directly into IBM SPSS version 22. All 
analyses were completed using SPSS. Descriptive statistics were assessed using crosstabs. 
Due to the limited use of the selected measures in cancer populations undergoing active 
treatment, all 3 outcome measures were subjected to factor analysis (see section 6.4.3). A 
series of ANCOVAs were used to assess the impact of eRAPID on the selected outcomes, linear 
regression analyses were used to assess the impact of patient engagement on the outcomes 
and logistic regression was used to predict patient adherence to weekly symptom reporting. 
6.3.5.2 Data validation 
A second research assistant (ZR) validated a 10% proportion of all data by cross checking SPSS 
files with source data, in addition to checking a proportion of scoring for the CSES, the CBI-B 
and the PAM at both baseline and 18 weeks to ensure that this had been correctly calculated. 
Some initial issues were identified due to the different treatment of missing data of the three 
measures. Specifically, scores were calculated for the CSES regardless of missing data. This was 
addressed by recalculating all scores for this measure and following a revalidation and 
checking of data. No additional issues were identified and the data was deemed to be of 






6.4.1.1 Recruitment, withdrawals and missing data 
The eRAPID RCT was not due to end until approximately October 2018. Due to the timing of 
this thesis, it was necessary to begin analysis before this time. Data was extracted on 5th 
January 2018 at which point 354 patients had completed the study. An additional 76 patients 
were on study at this point, but had not completed their 18 week follow up and are not 
included in the main analyses. The last of the 354 patients was consented to the study on 1st 
September 2017. Figure 6.2 illustrates the number of patients identified, ineligible and 
approached up until this date, in addition to information on any of the 354 patients who left 
the trial before their 18 week study period was completed. Only 13% (137/1055) of potential 
patients identified were ineligible because of a lack of internet or computer access. The 
consent rate for the study was 73% (354/488). The attrition rate was 13% (47/354). The return 
rate for 18 week questionnaires was 86% (265/307). Due to the different requirements for 
each stage, the number of patients included in each phase of analysis differ, and this is 




Figure 6.2 Flow diagram of the progress through the phases of the randomised trial 
 
Descriptive data for patients who left the trial or who did not return their 18 week 
questionnaires in displayed in Table 6.1 below. The majority of patients (70.2%, n=33) who left 
the trial were on the intervention arm of the study as intervention patients who were not 
actively using eRAPID were generally identified by research staff during the 18 week study 
period and given the option to leave the trial if they wished. There were no obvious 
demographic differences between patients who stayed on study and those who left trial, 
although there were a slightly higher proportion of patients who left in the lowest and highest 
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age groups and in the lowest education level group. A description of withdrawal procedures 
for the trial is included in section 2.4.4.6. 
Table 6.1 Withdrawals and missing data  
 Left trial 
(n=47) 
Did not return 






 Mean SD Mean SD Mean SD Mean SD 
Age (years) 
Mean & standard 
deviation 
57.5 14.4 54.0 10.9 55.9 11.9 55.9 11.9 
 N % N % N % N % 
Age group 
Up to 34 years 6 12.8% 1 2.4% 15 5.7% 22 6.2% 
35-49 years 5 10.6% 12 28.6% 56 21.1% 73 20.6% 
50-59years 17 36.2% 17 40.5% 96 36.2% 130 36.7% 
60-69 years 8 17.0% 9 21.4% 67 25.3% 84 23.7% 
70+years 11 23.4% 3 7.1% 31 11.7% 45 12.7% 
Total 47  42  265  354  
Study arm 
eRAPID intervention  33 70.2% 20 47.6% 126 47.5% 179 50.6% 
Usual care 14 29.8% 22 52.4% 139 52.5% 175 49.4% 
Total 47  42  265  354  
Gender 
Male 8 17.0% 14 33.3% 51 19.2% 73 20.6% 
Female 39 83.0% 28 66.7% 214 80.8% 281 79.4% 
Total 47  42  265  354  
Education (missing n=11) 
Up to school leaving age 22 47.8% 14 35.0% 74 28.8% 110 32.1% 
Beyond school leaving 
age 
8 17.4% 10 25.0% 64 24.9% 82 23.9% 
Degree/prof 
qualification 
16 34.8% 16 40.0% 119 46.3% 151 44.0% 
Total 46  40  257  343  
Cancer type 
Breast  14 29.8% 18 42.9% 118 44.5% 150 42.4% 
Gynae 17 36.2% 3 7.1% 63 23.8% 83 23.4% 
Colorectal 16 34.0% 21 50.0% 84 31.7% 121 34.2% 
Total 47  42  265  354  
Marital status (missing n=4) 
Married/Civil 
Partnership 
25 54.3% 25 61.0% 172 65.6% 222 63.6% 
Cohabiting 6 13.0% 6 14.6% 24 9.2% 36 10.3% 
Separated/Divorced 6 13.0% 3 7.3% 25 9.5% 34 9.7% 
Widowed 5 10.9% 1 2.4% 12 4.6% 18 5.2% 
Single 4 8.7% 6 14.6% 29 11.1% 39 11.2% 
Total 46  41  262  349  




Patients who left the trial (n=47) were removed from the dataset leaving a total sample of 
n=307 (Intervention n=146, Usual care n=161). 
Chi-square analysis were run to identify any differences between the intervention and usual 
care groups on baseline demographic and clinical data and computer usage. There were no 
significant differences at the p<.01 level between groups on gender, age, marital status, 
education, IMD, performance status at first chemotherapy, chemotherapy intent 
(curative/non-curative), whether the patient had chemo previously or any of the computer 
usage questions. 
6.4.1.2.1 Demographic data 
Data is presented in Table 6.2 for each study arm and as an overall total. The overall sample 
was majority female (78.8%). The mean age of the overall sample was 55.6 years (SD=11.5, 
range (18-82), and this was the same in both study arms. 
45.5% of the overall sample had a degree or equivalent professional qualification and 24.9% 
had some education beyond school leaving age. Patients were grouped into quintiles from 20% 
least deprived to most deprived based on the national Index of Multiple Deprivation (IMD) 
scores [278]. There were a higher percentage of patients in the two 20% least deprived 
quintiles (24.5% and 26.8%) than in the two 20% most deprived groups (17.0% and 17.0%). 
There were no differences on any variables between study arms. 
Table 6.2 Demographic data by study arm 
 eRAPID 
intervention 
Usual care Total 
 Mean SD Mean SD Mean SD 
Age (years) 
Mean and standard deviation 55.6 12.2 55.6 10.9 55.6 11.5 
 N % N % N % 
Age group 
Up to 34 years 10 6.8% 6 3.7% 16 5.2% 
35-49 years 32 21.9% 36 22.4% 68 22.1% 
50-59years 50 34.2% 63 39.1% 113 36.8% 
60-69 years 37 25.3% 39 24.2% 76 24.8% 




Total 146  161  307  
Gender 
Male 35 24.0% 30 18.6% 65 21.2% 
Female 111 76.0% 131 81.4% 242 78.8% 
Total 146  161  307  
Marital status (missing n=4) 
Married/Civil Partnership 102 70.8% 95 59.7% 197 65.0% 
Cohabiting 9 6.3% 21 13.2% 30 9.9% 
Separated/Divorced 12 8.3% 16 10.1% 28 9.2% 
Widowed 6 4.2% 7 4.4% 13 4.3% 
Single 15 10.4% 20 12.6% 35 11.6% 
Total 144  159  303  
Education beyond school leaving age? (missing n=10) 
Up to school leaving age 43 30.1% 45 29.2% 88 29.6% 
Beyond school leaving age 34 23.8% 40 26.0% 74 24.9% 
Degree/professional qualification 66 46.2% 69 44.8% 135 45.5% 
Total 143  154  297  
Index Multiple Deprivation (IMD) quintile (missing n=6) 
20% most deprived 28 19.2% 24 15.0% 52 17.0% 
20% to 40% most deprived 18 12.3% 34 21.3% 52 17.0% 
20% middle deprived 22 15.1% 23 14.4% 45 14.7% 
20 to 40% least deprived 38 26.0% 44 27.5% 82 26.8% 
20% least deprived 40 27.4% 35 21.9% 75 24.5% 
Total 146  160  306  
6.4.1.2.2 Clinical data 
Data is presented in Table 6.3 on cancer type, performance status at baseline as measured by 
the ECOG (Eastern Cooperative Oncology Group) measure, chemotherapy intent 
(curative/non-curative) and whether patients had received chemo previously (yes/no). There 
were a higher proportion of participants from the Breast clinic (44.3%) than in the Gynae 
(21.5%) and Colorectal clinics (34.2%). The majority of patients (68.9%) had a normal 
performance status at baseline, with only 3.7% in the two poorest status groups combined. 
The majority of patients were being treated with curative intent (72.2%) and had not had 
chemotherapy previously (75.6%). There were no differences on any variables between study 
arms. 
Table 6.3 Clinical data by study arm 
 eRAPID 
intervention 
Usual care Total 
 N % N % N % 
Cancer type 




Gynae 26 17.8% 40 24.8% 66 21.5% 
Colorectal 55 37.7% 50 31.1% 105 34.2% 
Total 146  161  307  
Performance status (at first chemo cycle), missing (n=5) 
0 - WHO - Normal 100 69.9% 108 67.9% 208 68.9% 
1 - WHO - Light Work 36 25.2% 47 29.6% 83 27.5% 
2 - WHO - Ambulatory >50% 6 4.2% 3 1.9% 9 3.0% 
3 - WHO - Ambulatory < 50% 1 0.7% 1 0.6% 2 0.7% 
Total 143  159  302  
Chemotherapy intent (missing n=1) 
Curative 104 71.2% 117 73.1% 221 72.2% 
Non-curative 42 28.8% 43 26.9% 85 27.8% 
Total 146  160  306  
Previous chemo received 
No 110 75.3% 122 75.8% 232 75.6% 
Yes 36 24.7% 39 24.2% 75 24.4% 
Total 146  161  307  
6.4.1.2.3 Computer usage 
Data is presented in Table 6.4 from the baseline demographic and computer usage 
questionnaire on how long patients had been using a computer for, how often they used a 
computer and how easy they found it. High levels of computer usage were reported with the 
majority of patients reporting they had been using a computer for more than five years 
(83.7%), that they used one daily (96.1%) and found it easy to use (88.0%). There were no 
differences on any variables between study arms. 
Table 6.4 Computer usage by study arm 
 eRAPID 
intervention 
Usual care Total 
 N % N % N % 
Level of computer usage (missing, n=1) 
Can only use a computer if I have help 9 6.2% 9 5.6% 18 5.9% 
Using a computer for less than a year 0 0.0% 1 0.6% 1 0.3% 
Using a computer for 1 - 2 years 6 4.1% 4 2.5% 10 3.3% 
Using a computer for 2 - 5 years 9 6.2% 12 7.5% 21 6.9% 
Using a computer for more than 5 years 122 83.6% 134 83.8% 256 83.7% 
Total 146  160  306  
How often do you use a computer? (missing n=7) 
Daily 141 96.6% 152 95.6% 293 96.1% 
Weekly 2 1.4% 3 1.9% 5 1.6% 
Monthly  0 0.0% 1 0.6% 1 0.3% 
Very rarely 3 2.1% 3 1.9% 6 2.0% 
Total 146  159  305  
How do you find using a computer in general? (missing n=6) 




Sometimes difficult 17 11.7% 11 7.1% 28 9.3% 
Difficult 3 2.1% 4 2.6% 7 2.3% 
Impossible 0 0.0% 1 0.6% 1 0.3% 
Total 145  156  301  
6.4.1.3 Clinical staff 
The roles of participating staff in each clinic are displayed below in Table 6.5. The majority of 
staff using the system were oncology consultants or specialist registrars. 
Table 6.5 Clinical staff information 
 Breast Gynae Colorectal Total 
 N % N % N % N % 
Oncology consultants 5 50.0% 4 40.0% 4 44.4% 13 44.8% 
Specialist registrars 3 30.0% 3 30.0% 0 0.0% 6 20.7% 
Staff grade doctors 0 0.0% 0 0.0% 2 22.2% 2 6.9% 
Clinical Nurse Specialists 2 20.0% 3 30.0% 0 0.0% 5 17.2% 
Pre-assessment nurses 0 0.0% 0 0.0% 3 33.3% 3 10.3% 
Total 10  10  9  29  
6.4.2 Patient engagement with eRAPID 
6.4.2.1 Descriptive data 
Patients who left the trial (n=47) and Usual care patients (n=161) were removed from the 
dataset. This left a total dataset of n=146 intervention patients. The majority of non-users 
were identified during the study period and given the option of leaving the trial if they no 
longer wished to participate. However, there were a small number of patients who did not 
wish to leave the trial, but did not ever use the system (n=3). These patients were considered 
to be passive withdrawals and were also excluded from the final dataset, leaving a total of 
n=143. 
6.4.2.1.1 Completion of eRAPID symptom reports 
The overall distribution of completion frequency is illustrated below in Figure 6.3. Patients 
were sent a weekly reminder by phone or email to complete a symptom report and were on 




of the distribution is from 13-19 completions. However, there are a number of outliers, both at 
the lower and upper ends of the distribution. 
Figure 6.3 Distribution of no of symptom reports 
 
Some of the demographic information for these outliers is displayed in Table 6.6, excluding 
those who never used the system at all (n=3). Outliers were identified as those approximately 
in the upper and lower 10% of completers. This was coded as those completed 4 or less times 
in the lower 10% group (n=14, 9.6%) and those with 20 or more completions in the upper 10% 
group (n=12, 8.2%). 
There were a higher proportion of high completers in the Colorectal group (n=6, 50%) 
compared to the Breast (n=2, 16.7%) and Gynae groups (n=4, 33.3%). There were also a higher 
proportion of lower completers in the younger age groups. This may be reflective of those with 
young families, as there were also a higher number of patients with children (75%) in the lower 
completers group. There were no obvious patterns for computer usage in the groups. 
Table 6.6 Demographics and computer usage of lowest 10% and highest 10% of completers 

































Mean & standard 
deviation 
48.4 10.6 54.4 9.6 56.6 12.3 5.7 12.2 
 N % N % N % N % 
Age group 
Up to 34 years 2 14.3% 1 8.3% 7 5.8% 10 6.8% 
35-49 years 6 42.9% 2 16.7% 24 20.0% 32 21.9% 
50-59years 3 21.4% 5 41.7% 42 35.0% 50 34.2% 
60-69 years 3 21.4% 4 33.3% 30 25.0% 37 25.3% 
70+years 0 0.0% 0 0.0% 17 14.2% 17 11.6% 
Total 14  12  120  146  
Gender 
Male 4 28.6% 2 16.7% 29 24.2% 35 24.0% 
Female 10 71.4% 10 83.3% 91 75.8% 111 76.0% 
Total 14    120  146  
Children under 18 in household 
Children  6 75.0% 3 42.9% 25 25.3% 34  
No children 2 25.0% 4 57.1% 74 74.7% 80  
Total         
Education beyond school leaving age? (missing n=3) 
Up to school leaving age 2 15.4% 2 16.7% 39 33.1% 43 30.1% 
Beyond school leaving age 4 30.8% 3 25.0% 27 22.9% 34 23.8% 
Degree/professional 
qualification 
7 53.8% 7 58.3% 52 44.1% 66 46.2% 
Total 13  12  118  143  
Index Multiple Deprivation (IMD) quintile 
20% most deprived 2 14.3% 0 0.0% 26 21.7% 28 19.2% 
20% to 40% most 
deprived 
0 0.0% 2 16.7% 16 13.3% 18 12.3% 
20% middle deprived 4 28.6% 2 16.7% 16 13.3% 22 15.1% 
20 to 40% least deprived 2 14.3% 5 41.7% 31 25.8% 38 26.0% 
20% least deprived 6 42.9% 3 25.0% 31 25.8% 40 27.4% 
Total 14  12  120  146  
Level of computer usage 
Can only use a computer 
if I have help 
2 14.3% 0 0.0% 7 5.8% 9 6.2% 
Using a computer for less 
than a year 
0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Using a computer for 1 - 2 
years 
0 0.0% 0 0.0% 6 5.0% 6 4.1% 
Using a computer for 2 - 5 
years 
0 0.0% 0 0.0% 9 7.5% 9 6.2% 
Using a computer for 
more than 5 years 
12 85.7% 12 100.0
% 
98 81.7% 122 83.6% 
Total 14  12  120  146  
Cancer type 
Breast  4 28.6% 2 16.7% 59 49.2% 65 44.5% 
Gynae 5 35.7% 4 33.3% 17 14.2% 26 17.8% 
Colorectal 5 35.7% 6 50.0% 44 36.7% 55 37.7% 
Total 14  12  120  146  
6.4.2.1.2 Usage of eRAPID self-management advice website 




The eRAPID website is set out in three main sections: 
1. ‘Managing treatment symptoms and side effects’ which offers self-management 
advice for common symptoms and side effects of chemotherapy. 
2. ‘Keeping healthy during cancer treatment’ which offers more general advice on diet, 
exercise and self-care. 
3. ‘Coping with cancer and your treatment’ which offers information about relaxation 
and local services and support that are available. 
All website pages were viewed at least once. The most commonly visited pages for ‘Managing 
treatment symptoms and side effects’ were ‘tiredness and fatigue’ (7.0%) and ‘tingling or 
numbness in fingers and toes’ (5.1%). 
Table 6.7 Overview of website usage 
 
No of times page 
viewed 
% of overall page 
views 
Managing treatment symptoms and side effects 
tiredness-or-fatigue 44 7.0% 
tingling-or-numbness-in-fingers-or-toes 32 5.1% 
feeling-or-being-sick 28 4.4% 
pain-aches-and-discomfort 27 4.3% 
temperature-chills 26 4.1% 
shortness-of-breath 23 3.6% 
sore-mouth-or-tongue 23 3.6% 
swelling-of-the-tummy-abdomen-ascites 21 3.3% 
diarrhoea 20 3.2% 
constipation 18 2.8% 
difficulty-sleeping 17 2.7% 
low-mood 17 2.7% 
lack-of-appetite 11 1.7% 
sore-hands-and-feet-hand-and-foot-syndrome 10 1.6% 
anxiety 10 1.6% 
pain-and-inflammation-of-the-vein-phlebitis 9 1.4% 
recognising-problems-and-signs-of-central-line-infection 9 1.4% 
heartburn-and-indigestion 7 1.1% 
having-a-stoma 7 1.1% 
Keeping healthy during cancer treatment 
physical-activity-and-exercise 39 6.2% 




mouth-care 27 4.3% 
fluid-intake 24 3.8% 
eating-well 21 3.3% 
Coping with cancer and your treatment 
distracting-occupying-your-mind 29 4.6% 
relaxation 26 4.1% 
complementary-therapies 23 3.6% 
local-services-you-can-access 22 3.5% 
massage 17 2.7% 
clinical-psycho-oncology-service 16 2.5% 
Total 
 633 100% 
59% (86/146) of patients on the intervention arm of the study accessed the website at least 
once during the 18 week period. Of those that did access the website, most accessed it less 
than 10 times over their 18 week study period. The distribution of the number of page views 
per patient is illustrated in Figure 6.4 below. 
Figure 6.4 Frequency of eRAPID website usage 
 
6.4.2.1.3 Clinician engagement with eRAPID 
Clinicians were prompted to use patients’ eRAPID data in routine consultations and complete a 
feedback form each time to report if and how they used the data. A total of 533 forms were 





Figure 6.5 illustrates the percentage of forms in each clinic (e.g. Breast, Gynae and Colorectal 
clinics) on which clinicians reported ‘Yes’ or ‘No’ to the question ‘Did you look at the patient’s 
eRAPID symptom information in PPM before/during consultation?’. The majority of forms 
completed reported ‘Yes’ to this question across all three clinical groups, however, a lower 
proportion of forms from the Breast clinic reported ‘Yes’ than forms completed in the Gynae 
and Colorectal clinics (74.0% versus 89.4% and 88.6% respectively). 
Figure 6.5 Did clinicians look at eRAPID data? 
 
Figure 6.6 illustrates the percentage of forms in each clinic which reported ‘Not at all’, ‘A little’, 
‘Somewhat’, ‘Quite a bit’ or ‘Very much’ to the question ‘Did you use the eRAPID symptom 
information in the clinic discussion?’. There were a higher proportion of forms reporting ‘Not 
at all’ in the Breast and Gynae clinics than in the colorectal clinic (18.9% and 16.2% versus 
7.7%). However, there was also a higher proportion of forms reporting ‘Very much’ in Breast 
and Gynae clinics compared to the Colorectal clinic (9.7% and 8.6% versus 4.8%). A large 
proportion of the forms completed in the colorectal clinic (52.9%) reported ‘Somewhat’ for 
this question. 
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Figure 6.7 illustrates the percentage of forms in each clinic on which clinicians reported ‘Not at 
all’, ‘A little’, ‘Somewhat’, ‘Quite a bit’ or ‘Very much’ to the question ‘Did you find the eRAPID 
symptom information useful?’. Again this followed a similar pattern to the previous question 
with a lower percentage of forms reporting ‘Not at all’ and ‘Very much’ in the Colorectal clinic 
(4.4% and 9.7%) and a high number reporting ‘Somewhat’ (51.9%). A higher percentage of 
forms completed in the Gynae clinic reported ‘Very much’ or ‘Quite a bit’ (26.2% and 21.4%). 
Figure 6.7 Was the information useful? 
 
Figure 6.8 illustrates the ways in which clinicians reported that they found the data useful if 
they had answered yes to this question. Clinicians could select more than one way in which the 
information was useful, so percentages do not add up to 100%. Clinicians reported that 
eRAPID data confirmed their knowledge of patients problems 63.3% of the time and provided 
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additional information 34.3% of the time. It helped identify issues and problems for discussion 
30.1% of the time but only contributed treatment management decisions 11.7% of the time. 








6.4.2.1.4 Clinical process measures 
The frequency of unplanned hospital admissions for the whole sample is shown below in Table 
6.8. The majority of patients (n=220, 71.7%) did not have any unplanned hospital admissions 
during their 18 week study period. 15.3% (n=47) had one admission and 11.7% (n=36) had two 
or more admissions. 14.9% (n=45) spend between 1-4 days in hospital, and 12.5% (n=51) 
spend 5 or more days in hospital during the 18 week study period. 
Table 6.8 Unplanned hospital admissions during 18 week study period 
 N % 
No of admissions (missing n=4) 
No admissions 220 72.6% 
One admission 47 15.5% 
Two or more admissions 36 11.9% 
Total 303  
No of days in hospital (missing n=4) 
None 220 72.6% 
1-4 days in hospital 45 14.9% 
5 or more days in hospital 51 12.5% 
Total 303  
Table 6.9 below displays the number of triage events per patient during their 18 week study 
period. Again, the majority of patients did not have any triage events (n=172, 56.8%). 27.4% 
(n=83) had just one or two triage events and 15.8% (n=48) had 3 or more triage events. 
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Table 6.9 Triage events during 18 week study period 
 N % 
No of triage events (missing n=4) 
None 172 56.8% 
1 triage event 51 16.8% 
2 triage events 32 10.6% 
3 or more triage events 48 15.8% 
Total 303  
Table 6.10 below shows a summary of patients who had changes to planned treatment over 
the 18 week study period. The majority of patients did not have any changes to planned 
treatment (n=180, 59.4%). 
Of those that had changes to planned treatment (n=123, 40.6%), 100% had a dose reduction in 
chemotherapy and 93.5% had a delay in treatment. Fewer patients had their chemotherapy 
drug changed (n=30, 24.4%) or had their chemotherapy stopped early (n=36, 29.3%). 
Table 6.10 Changes to planned treatment over the 18 week study period 
 N % 
Treatment delivered as planned? (missing n=4) 
Yes 123 40.6% 
No 180 59.4% 
Total 303  
Details of changes to treatment (n=123) 
Chemotherapy dose reduced 123 100.0% 
Treatment delayed 115 93.5% 
Chemotherapy drug changed 30 24.4% 
Chemotherapy stopped early 36 29.3% 
6.4.2.2 Logistic regression model to predict adherence 
A binary logistic regression was planned to examine predictors of whether or not patients were 
adherent to the weekly eRAPID symptom report completions. 
6.4.2.2.1 Dependent variable (Adherence) 
An adherence score was calculated from each week within which there was at least one 
completion report in relation to the number of weeks a completion report was expected 
(calculated one week from when the reminder was sent). Please see section 6.3.2.1 for more 




Initially, a linear regression was planned. However, a large proportion of patients had high 
levels of adherence and on examination of the variable, it was highly positively skewed 
(skewness =-.869, SE=.201). The Kolmogorov-Smirnov test was significant at p<.001, indicating 
that the assumption of normality of distribution had not been met. Transforming the variable 
using techniques such as exp and reflective log recommended for negatively skewed variables 
did not improve the distribution. It was decided to dichotomise the variable into ‘adherent’ 
and ‘non-adherent’ users using a median split. 
Figure 6.9 Frequency of distribution of Adherence to eRAPID symptom report variable 
 
Levels of adherence were generally high, with 40% of the sample being 100% adherent. The 
median percentage of adherence was 78%, so all patients with 78% or more were categorised 
as adherent, and all those with less than 78% were categorised as non-adherent. 
6.4.2.2.2 Predictor variables (Demographic data) 
Cross-tabs were used to assess demographic data for adherent and non-adherent users 
(presented in Table 6.11). Patients in the non-adherent group were slightly younger (M=52.66, 




adherent group were also more likely to have children under 18 living in the household (38.6% 
versus 21.1%). There were also more single people in the non-adherent group (15.2% versus 
6.4%). There were no other obvious differences between groups on the other demographic 
variables. 







 Mean SD Mean SD Mean SD 
Age (years) 
Mean and standard deviation 52.66 12.82 58.21 11.10 55.64 12.20 
 N % N % N % 
Age group 
Up to 34 years 7 10.4% 3 3.8% 10 6.8% 
35-49 years 20 29.9% 12 15.2% 32 21.9% 
50-59years 19 28.4% 31 39.2% 50 34.2% 
60-69 years 15 22.4% 22 27.8% 37 25.3% 
70+years 6 9.0% 11 13.9% 17 11.6% 
Total 67  79  146  
Gender 
Male 16 23.9% 19 24.1% 35 24.0% 
Female 51 76.1% 60 75.9% 111 76.0% 
Total 67  79  146  
Marital status (missing n=2) 
Married/Civil Partnership 44 66.7% 58 74.4% 102 70.8% 
Cohabiting 3 4.5% 6 7.7% 9 6.3% 
Separated/Divorced 6 9.1% 6 7.7% 12 8.3% 
Widowed 3 4.5% 3 3.8% 6 4.2% 
Single 10 15.2% 5 6.4% 15 10.4% 
Total 66  78   144 
How many children live in your house? (under 18) (missing n=31) 
No children 35 61.4% 45 78.9% 80 70.2% 
Children 22 38.6% 12 21.1% 34 29.8% 
Total 57  57  114  
Education beyond school leaving age? (missing n=10) 
Up to school leaving age 21 31.8% 22 28.6% 43 30.1% 
Beyond school leaving age 16 24.2% 18 23.4% 34 23.8% 
Degree/professional qualification 29 43.9% 37 48.1% 66 46.2% 
Total 66  77  143  
Index Multiple Deprivation (IMD) quintile (missing n=6) 
20% most deprived 12 17.9% 16 20.3% 28 19.2% 
20% to 40% most deprived 8 11.9% 10 12.7% 18 12.3% 
20% middle deprived 13 19.4% 9 11.4% 22 15.1% 
20 to 40% least deprived 13 19.4% 25 31.6% 38 26.0% 
20% least deprived 21 31.3% 19 24.1% 40 27.4% 
Total 67  79  146  




The clinical data for adherent and non-adherent users in displayed in Table 6.12 below. 
Although there were only a small number of patients (n=7) in the two poorer performance 
groups (2 and 3), the majority of these patients were in the non-adherent group (6.1% v 2.6%, 
1.5% v 0.0%). There were no other obvious differences between groups on the other clinical 
variables. 







 N % N % N % 
Cancer type 
Breast 31 46.3% 34 43.0% 65 44.5% 
Gynae 11 16.4% 15 19.0% 26 17.8% 
Colorectal 25 37.3% 30 38.0% 55 37.7% 
Total 67  79  146  
ECOG performance status (missing n=3) 
0 - WHO - Normal 49 74.2% 51 66.2% 100 69.9% 
1 - WHO - Light Work 12 18.2% 24 31.2% 36 25.2% 
2 - WHO - Ambulatory >50% 4 6.1% 2 2.6% 6 4.2% 
3 - WHO - Ambulatory < 50% 1 1.5% 0 0.0% 1 0.7% 
Total 66  77  143  
Chemotherapy intent 
Curative 50 74.6% 54 68.4% 104 71.2% 
Non-curative 17 25.4% 25 31.6% 42 28.8% 
Total 67  79  146  
Previous chemotherapy 
No 52 77.6% 58 73.4% 110 75.3% 
Yes 15 22.4% 21 26.6% 36 24.7% 
Total 67  79  146  
6.4.2.2.4 Predictor variables (Computer usage) 
Table 6.13 below shows the baseline levels of computer usage for patients in the adherent and 
non-adherent groups. There were no clear differences between either groups on baseline 
computer usage. 
Table 6.13 Level of computer usage at baseline for adherent and non-adherent users 
 Non-adherent Adherent Total 
 N % N % N % 
Level of computer usage 
Can only use a computer if I have help 5 7.5% 4 5.1% 9 6.2% 
Using a computer for less than a year 0 0.0% 0 0.0% 0 0.0% 
Using a computer for 1 - 2 years 6 9.0% 0 0.0% 6 4.1% 




Using a computer for more than 5 years 54 80.6% 68 86.1
% 
122 83.6% 
Total 67  79  146  
How often do you use a computer? (missing n=2) 
Daily 62 95.4% 78 98.7
% 
140 97.2% 
Weekly 2 3.1% 0 0.0% 2 1.4% 
Monthly 0 0.0% 0 0.0% 0 0.0% 
Very rarely 1 1.5% 1 1.3% 2 1.4% 
Total 65  79   144 
How do you find using a computer in general? (missing n=1) 
Easy 57 85.1% 68 87.2
% 
125 86.2% 
Sometimes difficult 8 11.9% 9 11.5
% 
17 11.7% 
Difficult 2 3.0% 1 1.3% 3 2.1% 
Impossible 0 0.0% 0 0.0% 0 0.0% 
 67  78  145  
6.4.2.2.5 Predictor variables (Clinician use of patient data) 
Each patient was expected to have 6 forms completed, as these were scheduled to coincide 
with 3 weekly appointments throughout the study period (3 weeks, 6 weeks, 9 weeks, 12 
week, 15 weeks and 18 weeks). However, there were several reasons why forms may not 
always have been completed at these appointments. For example, Breast patients rarely had 
an appointment at 18 weeks, or occasionally the date of appointments would be changed and 
the researcher would not be aware to prompt the clinician to complete a form. Another 
common reason was that if the patient had not completed any eRAPID symptom reports, a 
form would not be given to the clinician to complete. 
These reasons were not truly related to clinician use of patient data, and so another measure 
was calculated based on the question ‘Did you look at the patient’s eRAPID symptom 
information in PPM before/during consultation?’. A score was calculated for each ‘Yes’/total 
number of forms received per patient and converted to a percentage. For example if a patient 
had 6 forms completed by their clinician at their consultations, but the clinician only reported 
using the data in 3 of the consultations, this would be calculated as 3/6=50%. 




Predictor variables were selected partially based on the descriptive data, and partially based 
on a more simple, pragmatic approach to considering what variables might impact on patient 
adherence. The predictor variables chosen were age at study entry, previous computer usage, 
PAM baseline score, cancer type, performance status at baseline, chemotherapy intent, 
summary of admissions (none, one, two, three or more), summary of triage events (none, one, 
two, three or more), and clinician use of eRAPID data score. We initially planned to include the 
variable ‘Children under 18 living in your household’ but due to the high level of missing data, 
this would have made the sample size inadequate. The sample size after inclusion of all 
variables was n=136, which was adequate [279]. 
6.4.2.2.7 Binary regression 
Previous computer usage, disease group, performance status at baseline, chemotherapy 
intent, summary of admissions and summary of triage events were categorical or ordinal 
variables and dummy coding was applied using the SPSS indicator option. Collinearity 
diagnostics were used and both tolerance and VIF values were well within range for all 
predictor variables, indicating that the assumption of multicollinearity was met. 
When all predictor variables were held constant, the model correctly classified 55.1% of the 
cases (0% non-adherent, 100% adherent). 
In Step 1, after all predictor variables were added to the model, the model was significantly 
improved (p=.001), explaining 35% of the variance (r2=.350). 75.7% of cases were correctly 
classified into the adherent/non-adherent groups (67.2% non-adherent and 82.7% adherent). 
Table 6.14 below displays the contribution of individual variables in predicting the likelihood of 
a patient being adherent to eRAPID completions. The only significant predictor of adherence to 
weekly completions was clinician use of eRAPID data in consultations (ExpB=7.57, 95% CI: 1.56-
36.60, p=0.12). The overall contribution of the number of triage events was not significant 




who had no triage events (ExpB=4.81, 95% CI: 1.09-21.25, p=0.38) or only one triage event 
(ExpB=6.05, 95% CI: 1.06-34.49, p=0.43) more likely to be adherent than those with three or 
more triage events. 
Table 6.14 Exp (B) values, confidence intervals and p values for individual predictor variables 
 95% CI for exp b 
 B (SE) Lower Exp(B) Upper p 
Age 
Age at study entry 1.03 .99  1.08 .119 
Computer usage 
I can only use a computer if I have help     .881 
I have been using a computer for 1-2 years -22.60 .00 .00 . .999 
I have been using a computer for 2-5 years .73 .15 2.08 29.17 .587 
I have been using a computer for more than 5 years -.051 .14 .95 6.55 .958 
Patient activation measure (PAM) 
PAM Baseline Summary Score .010 .98 1.01 1.04 .576 
Cancer type 
Colorectal     .261 
Breast  .82 .76 2.26 6.75 .144 
Gynae -.13 .26 .88 3.03 .838 
Performance status at first chemo cycle 
0-Normal     .115 
1-Can do light work 1.14 .32 3.12 29.96 .325 
2-Ambulatory > 50% of time 2.09 .75 8.08 87.60 .086 
Chemo intent 
None curative      
Curative -.76 .13 .47 1.64 .235 
Number of Admissions during study period 
More than 3     .270 
Two admissions 2.56 .23 12.88 710.43 .212 
One admission 2.66 .30 14.29 687.36 .178 
No admissions 1.53 .11 4.61 194.04 .423 
Number of Triage events during study period 
Three or more triage events     .095 
Two triage events .45 .29 1.56 8.49 .607 
One triage events 1.80 1.06 6.05 34.49 .043 
No triage events 1.57 1.09 4.81 21.25 .038 
Clinician use of data 
 (% of consultations) 2.02 1.56 7.57 36.60 .012 
6.4.2.2.8 Examination of residuals 
Cooks distance, leverage and standardised residuals were examined to identify any cases 
which were exerting undue influence on the model. One case was identified which had a Cooks 




standardised residual of 4.94, exceeding the recommended limit of 2. Six more cases were 
identified which exceeded recommended limits for standardised residuals and leverage. The 
model was rerun with the identified cases removed. 
6.4.2.2.9 Adjusted model 
The adjusted model was significant at p<.001, explaining 44% of variance. Clinician use of the 
data remained the strongest predictor (ExpB=15.62, 95% CI: 2.52-96.74, p=.003). Age was also 
found to be a significant predictor in that older patients were more likely to be in the adherent 
group (ExpB=1.05, 95% CI: 1.00-1.09, p=.043). Performance status was also a significant 
predictor (p=0.028), however, due to the very small numbers in the poorer 2 (n=6) and 3 (n=0) 
performance status groups, this was unlikely to be meaningful. None of the other variables 
were significant overall. 
6.4.3 Impact of eRAPID on outcome measures 
The aim of this section of analysis is to assess whether the eRAPID intervention group had a 
greater improvement in scores at the end of the 18 week study period on the CSES, CBI-B, and 
PAM than the usual care group, controlling for baseline scores. 
Due to the limited use of measures in cancer populations undergoing active treatment, all 3 
measures were subjected to factor analysis. All available data was used for the factor analysis, 
including the baseline data for the 76 patients who had consented to the study but had not 
completed. This equated to a total sample size of 430 (n=354 patients who had completed plus 
n=76 patients still on study), well exceeding the recommended sample size required [279]. 
6.4.3.1 Self-efficacy for managing chronic disease scale (CSES) 
6.4.3.1.1 Factor analysis 
The 6 items of CSES were subjected to principal components analysis (PCA) using SPSS version 




of the correlation matrix revealed the presence of many coefficients of 0.3 and above. The 
Kaiser-Meyer-Oklin value was .897, well exceeding the recommended value of 0.6 and the 
Barlett’s Test of Sphericity [280] reached statistical significance (p=0.000), supporting the 
factorability of the correlation matrix. Principal components analysis revealed the presence of 
only one component with a eigenvalue of 4.59 which explained 76.5% of the variance in the 
data. All items loaded positively onto this single factor (from .865 to .899). The six item scale 
had a high Cronbachs alpha (α= .939). 
Table 6.15 Pattern Matrix with factor loadings for the 6 items of the CSES 
  Loadings 
No Item Factor 1 
5 How confident are you that you can do the different tasks and activities needed to 
manage your health condition so as to reduce your need to see a doctor? 
.899 
4 How confident are you that you can keep other symptoms or health problems you 
have from interfering with the things you want to do? 
.880 
6 How confident are you that you can do things other than just taking medication to 
reduce how much your illness affects your everyday life? 
.871 
2 How confident are you that you can keep the physical discomfort or pain of your 
disease from interfering with the things you want to do? 
.867 
3 How confident are you that you can keep the emotional distress caused by your 
disease from interfering with the things you want to do? 
.867 
1 How confident are you that you can keep the fatigue caused by your disease from 
interfering with your life? 
.865 
6.4.3.1.2 Descriptive data 
The descriptive statistics of the CSES at baseline and at 18 weeks for each study arm are 
displayed below in Table 6.16. The possible range of scores was anywhere from 1.00 (not at all 
confident ) to 10.00 (totally confident). The actual range of scores at baseline corresponded to 
this with responses ranging from 1.00 to 10.00. However, the range for 18 week scores was 
slightly higher at 1.33 - 10.00 for usual care patients, and 2.50 – 10.00 for eRAPID intervention 
patients. The mean score improved slightly from baseline to 18 weeks in both groups (M=6.83 
vs M=7.28, change of 0.45), although this improvement was slightly higher in the intervention 
group (M=6.97 vs M=7.65, change of 0.68) than in the usual care group (M=6.70 vs M=7.28, 




Table 6.16 Descriptive data for the CSES at baseline and 18 weeks 
 Study arm N Mean SD Actual range 
CSES Baseline 
Total sample 302 6.83 1.86 (1.00-10.00) 
eRAPID intervention 145 6.97 1.75 (1.00-10.00) 
Usual care 157 6.70 1.95 (1.00-10.00) 
CSES 18 weeks 
 
Total sample 252 7.28 2.00 (1.33 – 10.00) 
eRAPID intervention 123 7.65 1.81 (2.50 – 10.00 
Usual care 129 6.93 2.10 (1.33 – 10.00) 
6.4.3.1.3 ANCOVA to assess impact of eRAPID on change from baseline scores 
A one-way analysis of covariance (ANCOVA) was conducted to determine if there was a 
statistically significant difference between the eRAPID intervention group and the usual care 
group on CSES scores at 18 weeks, controlling for baseline CSES score. 
Evaluation of the assumptions of normality of distribution, linearity, homogeneity of 
regression and reliability of covariates were satisfactory. Levene’s test of equality of variances 
was non-significant (p=.663) indicating that the assumption of homogeneity of variances had 
been met and there were no outliers of concern. The total sample size with valid baseline and 
18 week scores was n=248, well exceeding requirements [279]. 
The covariate, baseline CSES score, was significantly related to 18 week CSES scores (F (1, 245) 
=51.91, p<.001). There was also a significant effect of randomisation group after controlling for 
baseline scores (F (1,245) = 6.02, p=.015). However, effect sizes were modest ω2=.20. 
6.4.3.2 Cancer Behaviour Inventory (CBI-B) 
6.4.3.2.1 Factor analysis 
The 14 items of the CBI-B were subjected to principal components analysis (PCA) using SPSS 
version 23. Prior to performing PCA the suitability of data for factor analysis was assessed. 
Inspection of the correlation matrix revealed the presence of many coefficients of 0.3 and 
above. The Kaiser-Meyer-Oklin value was .92, well exceeding the recommended value of 0.6 
[281]and the Barlett’s Test of Sphericity [280] reached statistical significance (p=0.000), 




the presence of two components with eigenvalues exceeding 1, which was supported by 
inspection of the screeplot. 
To aid in the interpretation of these two components, Direct Oblimin rotation was performed. 
The rotated solution revealed the presence of simple structure, with both components 
showing a number of strong loadings above 0.5 and all variables loading on only one 
component. The two-component solution explained a total of 64% of the variance, with 
component 1 contributing 55.5% and component 2 contributing 8.5%. Components were 
significantly correlated to one another (r=.673, p<.001). Internal reliability was high for 
component 1 (9 items, α=.918), component 2 (5 items, α=.876) and for the full 14 item scale 
(14 items, α=.937). 
The items in Factor 1 encompassed a theme of the individual’s belief in their own personal 
resources for coping. The highest loading items were ‘Trying to be calm throughout treatments 
and not allowing scary thoughts to upset me’ and ‘Maintaining a positive attitude’. 
The items in Factor 2 encompassed a theme of individual’s belief in their own ability to access 
support from friends and family, and communicate with their healthcare team. The two 
highest loadings in this factor were for ‘Seeking social support’ and ‘Sharing my worries or 
concerns with others’. 
Heitzmann et al conducted psychometric analysis of the CBI-B in three large samples of 
American cancer patients. The samples included both patients undergoing active treatment 
and cancer survivors and revealed four factor structure [273]. These factors were 1) 
maintaining independence and a positive attitude (items 1, 2 and 3), 2) participating in medical 
care (items 8 and 9), 3) Coping and stress management (items 6, 7, 12 and 13), and 4) 
managing affect (items 4, 10 and 11). Items 5 and 14 were excluded as they did not load clearly 




Our Factor 1 broadly encompasses the items in 1) maintaining independence and a positive 
attitude and 3) Coping and stress management and our Factor 2 encompasses the items in 2) 
participating in medical care and 4) managing affect. 
Proxy measures were created to represent both factors and the impact of the intervention on 
both factors was explored (see section 6.4.3.2.4). 
Table 6.17 Pattern Matrix with factor loadings for the 14 items of the CBI-B 
  Loadings 
No Item Factor 1 Factor 2 
7 Trying to be calm throughout treatments and not allowing scary 
thoughts to upset me 
.974 -.190 
2 Maintaining a positive attitude .897 -.012 
6 Maintaining activities (work, home, hobbies, social) .806 -.013 
5 Putting things out of my mind at times .798 -.006 
3 Maintaining a sense of humour .744 .106 
12 Managing nausea and vomiting (whether or not I have had these 
problems in the past) 
.700 .090 
13 Coping with physical changes .656 .156 
14 Trying to be calm while waiting at least one hour for my appointment .641 .062 
1 Maintaining independence .611 .120 
10 Seeking social support -.092 .929 
11 Sharing my worries or concerns with others -.011 .896 
9 Asking physicians questions .031 .778 
4 Expressing feelings about cancer .165 .658 
8 Actively participating in treatment decisions .218 .628 
6.4.3.2.2 Descriptive data 
The descriptive statistics of the CBI-B at baseline and at 18 weeks for each study arm are 
displayed below in Table 6.18. The CBI-B score is calculated as the sum of all 14 answered 
items and can range from 28-126 with 28 being the lowest possible coping self-efficacy and 
126 being the highest. The actual range of scores at baseline corresponding with this for the 
full sample (28-126) and for the usual care group (28-126) but were slightly higher for the 
eRAPID intervention group (38-126). At 18 weeks, the ranges for the whole sample were 
slightly higher (33-126), and again were higher for the intervention group (53-126) than for the 




The mean score improved from baseline at 18 weeks for the whole sample (M=97.75 vs 
M=100.03, change of 2.28). Patients in the eRAPID intervention group had slightly higher 
scores at baseline compared to the usual care group (M=99.68 vs 95.98). Improvements in 
scores from baseline to 18 weeks were slightly higher in the intervention group (M=99.68 vs 
102.88, change of 3.2) and the usual care group (M=95.98 vs 97.36, change of 1.38), even 
when baseline differences were taken into account. 
Table 6.18 Descriptive data for the CBI-B at baseline and 18 weeks 
 Study arm N Mean SD Actual range 
CBI-B Baseline 
Total sample 306 97.75 19.34 (28-126) 
eRAPID intervention 146 99.68 17.94 (38-126) 
Usual care 160 95.98 20.43 (28-126) 
CBI-B 18 weeks 
 
Total sample 254 100.03 19.34 (33-126) 
eRAPID intervention 123 102.88 17.55 (53-126) 
Usual care 131 97.36 20.59 (33-126) 
6.4.3.2.3 ANCOVA to assess impact of eRAPID on change from baseline scores 
A one-way analysis of covariance (ANCOVA) was conducted to determine a statistically 
significant difference between the eRAPID intervention group and the usual care group on CBI-
B scores at 18 weeks, controlling for baseline scores. 
Results of evaluation of the assumptions of normality of distribution, linearity, homogeneity of 
regression and reliability of covariates were satisfactory. Levene’s test of equality of variances 
was non-significant (p=.466) indicating that the assumption of homogeneity of variances had 
been met and there were no outliers of concern. The total sample size with valid baseline and 
18 week scores was n=253, well exceeding requirements [279]. 
The covariate, baseline CBI-B scores, was significantly related to 18 week CBI-B scores (F (1, 
250) =135.17, p<.001). There was no significant effect of randomisation group after controlling 
for baseline CBI-B scores (F (1,250) = 1.32, p=.208). 




Based on the two factor solution found for the CBI-B in our sample, two proxy measures were 
calculated to represent each factor by calculating the mean score for the individual items in 
Factor 1 (items: 1, 2, 3, 5, 6, 7, 12, 13, 14) and Factor 2 (4, 8, 9, 10, 11). 
A MANCOVA was conducted to determine a statistically significant difference between the 
eRAPID intervention group and the usual care group on the CBI-B factor proxy scores at 18 
weeks, controlling for baseline scores. There was no significant effect of randomisation group 
after controlling for baseline scores on combined proxy scores (F(2, 248)=.995, p=.530)) and 
similarly, no impact on individual score measures for Factor 1 (F(1, 249)=1.265, p=.262)) nor 
Factor 2 (F(1, 249)=.694, p=.406)). 
6.4.3.3 Patient Activation Measure (PAM) 
6.4.3.3.1 Factor analysis 
The 13 items of the PAM were subjected to principal component analysis (PCA) using SPSS 
version 23. Prior to performing PCA the suitability of data for factor analysis was assessed. 
Inspection of the correlation matrix revealed the presence of many coefficients of 0.3 and 
above. The Kaiser-Meyer-Oklin value was .904, well exceeding the recommended value of 0.6 
[281] and the Barlett’s Test of Sphericity [280] reached statistical significance (p=0.00), 
supporting the factorability of the correlation matrix. Principal components analysis revealed 
the presence of two components with eigenvalues exceeding 1, which was supported by 
inspection of the screeplot. 
To aid in the interpretation of these two components, Direct Oblimin rotation was performed. 
The rotated solution revealed the presence of a simple structure, with both components 
showing a number of strong loadings above 0.5 and all variables loading on only one 
component. The two-component solution explained a total of 56% of the variance, with 
component 1 contributing 45% and component 2 contributing 11%. Components were 




component 1 (7 items, α=.847), component 2 (6 items, α=.826) and for the full 13 item scale 
(13 items, α=.885). 
The items in Factor 1 encompassed a theme of ‘Engagement and activation to change and 
maintain lifestyle behaviours and belief in own role in health’, while the items in Factor 2 
broadly encompassed a theme of ‘Knowledge and self-efficacy about understanding health 
and treatment’. 
The PAM has usually been found to be unidimensional in healthy populations [274, 275], but 
research with more ill patients in mental health settings also revealed a two factor structure, 
albeit slightly different to ours [277]. 
Proxy measures were created to represent both factors and the impact of the intervention on 
both factors was explored (see section 6.4.3.3.4). 
Table 6.19 Pattern Matrix with factor loadings for the 13 items of the PAM 
  Loadings 
No Item Factor 1 Factor 2 
13 I am confident that I can maintain lifestyle changes, like eating right and 
exercising, even during times of stress 
.809 -.074 
3 I am confident I can help prevent or reduce problems associated with 
my health 
.798 -.054 
12 I am confident I can figure out solutions when new problems arise with 
my health 
.746 .025 
10 I have been able to maintain (keep up with) lifestyle changes, like 
eating right or exercising 
.704 .015 
2 Taking an active role in my own health care is the most important thing 
that affects my health 
.658 .057 
11 I know how to prevent problems with my health .658 .100 
1 When all is said and done, I am the person who is responsible for taking 
care of my health 
.617 .022 
6 I am confident that I can tell a doctor concerns I have even when he or 
she does not ask 
-.027 .766 
4 I know what each of my prescribed medications do -.117 .756 
7 I am confident that I can follow through on medical treatments I may 
need to do at home 
.065 .736 
5 I am confident that I can tell whether I need to go to the doctor or 
whether I can take care of a health problem myself 
-.012 .724 
9 I know what treatments are available for my health problems .191 .630 
8 I understand my health problems and what causes them .144 .625 




The descriptive statistics of the PAM at baseline and at 18 weeks for each study arm and for 
the full sample are displayed below in Table 6.20. The potential range of scores is 0 to 100, 
with 100 being the highest level of activation and 0 being the lowest. The baseline range of 
scores for the whole sample corresponded with this (0.00 – 100.00) with the eRAPID 
intervention group having a slightly higher range (39.30 – 100.00) than the usual care group 
(0.00 – 100.00). 
There was no discernible improvement in scores at 18 weeks, with the mean score for the 
overall sample actually slightly higher at baseline than at 18 weeks (M=64.27 vs 62.95, change 
of – 1.32). This was similar across both the eRAPID intervention group (M=64.60 vs M=63.67, 
change of -0.93) and the usual care group (M=63.96 vs M=62.29, change of -1.67). 
Table 6.20 Descriptive data for the PAM at baseline and 18 weeks 
 Study arm N Mean SD Actual range 
PAM Baseline 
Total sample 296 64.27 14.86 (0.00 - 100.00) 
eRAPID intervention 143 64.60 13.74 (39.40 – 100.00) 
Usual care 153 63.96 15.89 (0.00 - 100.00)  
PAM 18 weeks 
 
Total sample 254 62.95 14.23 (34.20 – 100.00) 
eRAPID intervention 121 63.67 13.17 (38.10 – 100.00) 
Usual care 133 62.29 15.15 (34.20 -100.00)  
PAM levels at baseline and 18 weeks for each study arm are displayed in Table 6.21 below. 
Levels of activation at baseline were high for all patients, with the majority falling into the 
Level 3 and Level 4 categories. The distribution of levels at 18 weeks was similar to baseline, 
although there were slightly less patients falling into the Level 4 category overall. 
Table 6.21 Levels of PAM at baseline and 18 weeks 
 Study arm Level 1 Level 2 Level 3 Level 4 
  N % N % N % N % 
PAM levels 
Baseline 
eRAPID intervention 8 5.6% 21 14.7% 74 51.7% 40 28.0% 
Usual care 20 13.1% 16 10.5% 67 43.8% 50 32.7% 
PAM levels 
18 weeks 
eRAPID intervention 11 9.1% 17 14.0% 65 53.7% 28 23.1% 
Usual care 19 14.3% 19 14.3% 64 48.1% 31 23.3% 




A one-way analysis of covariance (ANCOVA) was conducted to determine a statistically 
significant difference between the eRAPID intervention group and the usual care group on 
PAM scores at 18 weeks, controlling for baseline scores. 
Results of evaluation of the assumptions of normality of distribution, linearity, homogeneity of 
regression and reliability of covariates were satisfactory. Levene’s test of equality of variances 
was not significant (p=.088) indicating that the assumption of homogeneity of variances had 
been met and there were no outliers of concern. The total sample size with valid baseline and 
18 week scores was n=245, well exceeding requirements [279]. 
Descriptive statistics on 18 week PAM scores, are displayed in Table 6.22 below. The 
intervention group had higher scores (M=63.88, SD=13.8) than the usual care group (M=62.80, 
SD=14.85). 
Table 6.22 Descriptive statistics for 18 week PAM scores 
Randomisation result Mean SD N 
eRAPID intervention 63.88 13.18 119 
Usual care 62.80 14.85 126 
Total 63.33 14.04 245 
The covariate, baseline PAM scores, was significantly related to 18 week PAM scores (F (1, 242) 
=13066.62, p<.001). There was no significant effect of randomisation group after controlling 
for baseline PAM scores (F (1,242) = 12.94, p=.765). 
6.4.3.3.4 MANCOVA to assess the impact of eRAPID on change from baseline on PAM 
factors 
Based on the two factor solution found for the PAM in our sample, two proxy measures were 
calculated to represent each factor by calculating the mean score for the individual items in 
Factor 1 (items: 1, 2, 3, 10, 11, 12, 13) and Factor 2 (items: 4, 5, 6, 7, 8, 9). 
A MANCOVA was conducted to determine a statistically significant difference between the 
eRAPID intervention group and the usual care group on the PAM factor proxy scores at 18 




after controlling for baseline scores on combined proxy scores (F(2, 249)=.374, p=.688) and 
similarly, no impact on individual scores measures for Factor 1 (F(1, 250)=.290, p=.591)) nor 
Factor 2 (F(1, 250)=.750, p=.387)). 
6.4.4 Relationship between patient engagement with eRAPID and outcome 
measures 
The aim of this section of analysis is to assess whether patient engagement with eRAPID 
(adherence to weekly completions and use of the eRAPID website) had any impact on their 
outcome measure scores (CSES, CBI-B and PAM) at 18 weeks when controlling for baseline 
scores. 
6.4.4.1 Regression analyses to assess whether patient engagement with eRAPID impacted 
on outcome measures 
Hierarchical linear regression analyses were run to explore whether patient engagement with 
eRAPID had an impact on 18 week scores on the CSES, the CBI-B and the PAM. 
3 separate regression analyses were run using the forced entry method, with baseline scores 
entered in the first block and patient adherence score and no of pages viewed on website 
entered in the second block. 
6.4.4.1.1 CSES 
Table 6.23 below shows the mean, standard deviation and n for each of the variables in the 
regression analyses. The mean score for CSES was slightly higher at 18 weeks than at baseline. 
The mean percentage of adherence to the weekly completions was almost 75%. The mean 
number of eRAPID website page views per patient was just over 3, but with a standard 
deviation of more than 4, illustrating the variation in how often patients used the website. 
Table 6.23 Descriptive statistics of variables in the regression analysis to predict CSES score 
 Mean SD N 
Outcome variable    
18 week CSES Score 7.64 1.82 122 




Baseline CSES Score 7.12 1.66 122 
Adherence to symptom report completions (%) 74.58 24.14 122 
eRAPID website page views (n) 3.13 4.19 122 
Table 6.24 shows correlations between all variables. 18 week CSES score was correlated 
significantly with both baseline CSES score (r=.266, p=.002) and adherence to symptom report 
completions (r=.315, p<.001). None of the predictor variables were significantly correlated 
with one another, meaning the assumption of multicollinearity was met. 
Table 6.24 Correlations between variables using Pearson correlation (r) 






18 week CSES 1.000 .266** .315*** .004 
Baseline CSES .266** 1.000 .011 -.044 
Adherence to symptom report 
completions 
.315*** .011 1.000 .062 
eRAPID website page views .004 -.044 .062 1.000 
 *significant at < .05, **significant at <.010, ***significant at <.001 
The Durbin-Watson statistic for the model was 1.89, indicating a lack of correlation of residual 
terms, meeting the requirements for the assumption of independent errors. Inspection of 
residual plots indicated that the normality, linearity and homoscedasticity were met. 
Inspection of residual statistics indicated only 5/122 (4%) of cases with standardised residuals 
less than -2 or more than 2. Of these cases, none were less than -3, or more than 3 indicating 
than there were no cases exerting undue influence on the model. The total sample size after 
inclusion of the 3 variables in the model was 122, well exceeding recommendations [279]. 
After Step 1, with baseline CSES in the equation, a significant regression equation was found (F 
(1,120) = 9.110, p < .01), with an R2 of .071. 
After step 2, with adherence to weekly symptom reports and number of page visits to the 
eRAPID website added, R2 increased to .168 (F (1,118) = 7.936, p<.001). 
The beta values, standard error values and standardised betas for individual predictor 
variables are displayed below in Table 6.25. Adherence to the weekly symptom report 




efficacy score (β=.262, p<.01). The number of visits to the eRAPID website did not add any 
significant predictive value (β=.004, p=.959). 
Table 6.25 Beta values, standard error values and standardised betas for each step of the 
model 
  B SE B β p 
Step 1 Constant 5.579 .703   
 Baseline CSES score .290 .096 .266 .003 
Step 2 Constant 3.862 .823   
 Baseline CSES score .286 .092 .262 .002 
 Adherence to symptom report 
completions 
.023 .006 .312 .000 
 eRAPID website page views -.002 .036 -.004 .959 
6.4.4.1.2 Cancer Behaviour Inventory (CBI-B) 
Table 6.26 below shows the mean, standard deviation and n for each for each of the variables 
in the regression analyses. 
Table 6.26 Descriptive statistics of variables in the regression model to predict CBI-B score 
 Mean SD N 
18 week CBI-B Score 102.9 17.55 123 
Baseline CBI-B Score 101.2 16.96 123 
Adherence to symptom report completions (%) 74.6 24.05 123 
eRAPID website page views (n) 3.13 4.18 123 
Table 6.27 shows correlations between all variables. 18 week CBI-B was correlated significantly 
with both baseline score (r=.560, p<.001) and adherence to symptom report completions 
(r=.217, p=.008). None of the predictor variables were significantly correlated with one 
another, meaning the assumption of multicollinearity was met. 
Table 6.27 Correlations between variables using Pearson correlation (r) 










18 week CBI-B Score 1.000 .560*** .217** .019 
Baseline CBI-B Score .560*** 1.000 .017 -.034 
Adherence to symptom report completions .217** .017 1.000 .062 
eRAPID website page views .019 -.034 .062 1.000 
 *significant at < .05, **significant at <.010, ***significant at <.001 
The Durbin-Watson statistic for the model was 1.648, indicating a lack of correlation of 




Inspection of residual plots indicated that the normality, linearity and homoscedasticity were 
met. Inspection of residual statistics indicated only 7/123 (5.7%) of cases with standardised 
residuals less than -2 or more than 2. Of these cases, none were less than -3, or more than 3 
indicating than there were no cases exerting undue influence on the model. The total sample 
size after inclusion of the 3 variables in the model was 123, well exceeding recommendations 
[279]. 
After Step 1, with baseline CBI-B score in the equation, a significant regression equation was 
found (F (1,122) = 55.23, p < .001), with an R2 of .313. 
After step 2, with adherence to weekly symptom reports and number of page visits to the 
eRAPID website added, R2 increased to .357 (F (3,122) = 22.04, p<.001). 
The beta values, standard error values and standardised betas for individual predictor 
variables are displayed below in Table 6.28. Baseline CBI-B score added the most predictive 
value (β=.557, p<.001), followed by adherence to the weekly symptom report completions 
(β=.206, p<.01). The number of visits to the eRAPID website did not add any significant 
predictive value (β=.026, p=.730). 
Table 6.28 Beta values, standard error values and standardised betas for each step of the 
model 
  B SE B β p 
Step 1 Constant 44.288 . 7.993   
 Baseline CBI-B score .579 .078 .560 .000 
Step 2 Constant 33.010 8.763   
 Baseline CBI-B score .577 .076 .557 .000 
 Adherence to symptom report 
completions 
.150 .054 .206 
.006 
 eRAPID website page views .107 .310 .026 .730 
6.4.4.1.3 Patient Activation Measure (PAM) 
Table 6.29 below shows the mean, standard deviation and n for each for each of the variables 




Table 6.29 Descriptive statistics of the variables in the regression model to predict PAM 
score 
 Mean SD N 
18 week PAM Score 63.9 13.2 119 
Baseline PAM Score 65.3 13.8 119 
Adherence to symptom report completions (%) 74.5 24.2 119 
eRAPID website page views (n) 3.2 4.2 119 
Table 6.30 shows correlations between all variables. 18 week PAM score was correlated 
significantly with both Baseline PAM score (r=.579, p<.001) and adherence to symptom report 
completions (r=.206, p=.012). Baseline PAM score was significantly correlated with adherence 
to symptom report completions (r=.184, p=.023). However, the correlation was modest, 
meaning the assumption of multicollinearity was not violated. 
Table 6.30 Correlations between variables using Pearson correlation (r) 










18 week PAM Score 1.000 .579*** .206* -.052 
Baseline PAM Score .579*** 1.000 .184* -.124 
Adherence to symptom report 
completions 
.206* .184* 1.000 .059 
eRAPID website page views -.052 -.124 .059 1.000 
 *significant at < .05, **significant at <.010, ***significant at <.001 
The Durbin-Watson statistic for the model was 1.968, indicating a lack of correlation of 
residual terms, meeting the requirements for the assumption of independent errors. 
Inspection of residual plots indicated that the normality, linearity and homoscedasticity were 
met. Inspection of residual statistics indicated only 7/119 (5.8%) of cases with standardised 
residuals less than -2 or more than 2. This included one case greater than 3. Casewise 
diagnostics were examined for all 7 cases. Cook’s distance, Mahalabonis distance and centred 
leverage values were all well within criterion, indicating that none of the cases were exerting 
undue influence and all cases were retained in the dataset. The total sample size after 
inclusion of the 3 variables in the model was 119, well exceeding recommendations [279]. 
After Step 1, with baseline PAM score in the equation, a significant regression equation was 




After step 2, with adherence to weekly symptom reports and number of page visits to the 
eRAPID website added, R2 increased to .346 (F (3,118) = 20.25, p<.001). 
The beta values, standard error values and standardised betas for individual predictor 
variables are displayed below in Table 6.31. Baseline PAM score added the most predictive 
value (β=.579, p<.001). Neither adherence to symptom report completions (β=.102, p=.187) or 
the number of visits to the eRAPID website (β=.012, p=.879) added any significant predictive 
value. 
Table 6.31 Beta values, standard error values and standardised betas for each step of the 
model 
  B SE B β p 
Step 1 Constant 27.782 4.802   
 Baseline PAM score .553 .072 .579 .000 
Step 2 Constant 24.607 5.422   
 Baseline PAM score .536 .074 .562 .000 
 Adherence to symptom report 
completions 
.056 .042 .102 .187 






6.5.1 Summary of findings 
The aims of this chapter were to quantitatively assess patient engagement with eRAPID and 
identify potential predictors, to explore the impact of eRAPID on patients’ self-efficacy to 
manage symptoms and side effects, self-efficacy for coping with cancer and levels of 
activation, and to explore whether these outcomes were related to patient engagement. 
Patient engagement with eRAPID was generally very good, with 40% of the sample having 
100% adherence to weekly completions over the 18 weeks and a median adherence level of 
78%. Usage of the eRAPID website was somewhat lower than expected, with only 59% of 
patients accessing the website at least once. 
In a logistic regression model to predict adherence to weekly symptom reports, clinician use of 
patient data was the only significant predictor. None of the demographic and clinical variables 
included in the model were associated with adherence and nor was previous computer usage. 
There is a common perception that older and more economically disadvantaged patients are 
less likely to engage in eHealth. However, this is not always found to be the case, particularly 
with more recent studies, and many argue that the ‘digital divide’ is disappearing [180, 182, 
282, 283]. A feasibility study by Basch et al [116] previously identified computer experience as 
a predictor of engagement to their intervention. However, this study was in 2005, when 
computer and internet usage were much less common, and may be less of an issue going 
forward. In fact a more recent study by the same researchers which provided older patients 
with devices to complete from home, actually found that this group had the most benefit from 
the intervention [51]. Baseline PAM scores were correlated significantly with adherence to the 
intervention, suggesting it might have predictive value, however this was not found to be the 
case in the logistic regression model, indicating that the correlation was confounded by other 




data in consultations, highlighting the importance of this for patient engagement. However, 
this relationship is likely to be bi-directional. 
eRAPID had a significant impact on CSES scores with patients in the intervention arm showing 
higher improvement in scores than those in the usual care arm at 18 weeks. As outlined in 
Chapter 5, self-efficacy is not often included in evaluations of online systems to support 
patients during chemotherapy, and those that have included it have not always used high 
quality measures [82, 87]. However, evaluation of online systems for cancer survivors and 
other chronic illnesses such as diabetes have demonstrated a similar positive impact on self-
efficacy for managing symptoms [96, 183-185, 268]. Similarly research on the role of self-
efficacy with patients undergoing chemotherapy is limited and generally of cross sectional 
nature [255, 256]. However, in other chronic illnesses such as diabetes, self-efficacy is related 
to better self-management behaviour and objective medical outcomes, in addition to better 
emotional well-being [250, 252, 253, 284-286]. Furthermore, results have been found to be 
consistent across different socio-demographic groups and levels of health literacy [251]. In 
addition, research with cancer survivors has indicated that high levels of self-efficacy can have 
continuing benefits for patients in their follow-up and recovery, with lower symptom burden 
and distress and higher HRQoL [254, 258, 287]. Higher adherence to weekly symptom reports 
was associated with improved CSES scores. As outlined in Chapter 5, the relationship between 
engagement and outcomes is rarely reported in evaluations of online systems. However, these 
results support the importance of sustained engagement with systems and the need for 
researchers to evaluate and report on engagement, in addition to the relationship between 
engagement and outcomes. 
There was no significant impact of the eRAPID intervention on CBI-B scores, although higher 
adherence to weekly symptom reports was associated with improved scores. In Chapter 4, end 
of study interviews from field usability testing of eRAPID indicated that some patients used the 




may indicate that patients who were using eRAPID in this way, and were therefore more 
adherent to weekly reports, did find this benefit. However, it may also be that eRAPID does 
not fit with more passive coping strategies. Some people may prefer not to monitor symptoms, 
particularly when things are not going well [161]. It was initially planned to use analytics to 
assess patients’ use of symptom graphs during eRAPID, but this was not possible due to 
practical limitations of the systems. 
In addition, it may simply be that a more targeted intervention is necessary to positively 
impact on self-efficacy for coping, due to the specific stresses and anxieties that patients 
experience while undergoing chemotherapy. Although the eRAPID website does provide 
specific advice to patients on coping with cancer, levels of usage of this section of the website 
were low, as was usage of the website generally, suggesting that is unlikely to have had a great 
impact. In addition, the CBI-B had a different factor structure in our population than found in 
previous research, which has validated the measure in mixed samples of cancer patients at 
different stages of the cancer trajectory [273]. Again this difference in factor structure may be 
reflective of the specific concerns of patients undergoing active chemotherapy. Evaluation of 
the impact of eRAPID on the proxy measures for individual factors did not indicate significant 
results either. 
There was no significant impact of the eRAPID intervention on PAM scores. Furthermore, there 
was no association found between changes in PA and levels of adherence to weekly symptom 
reports. Levels of activation were high in this sample at baseline, which may have had an 
impact. However, it may also be that this is not a suitable measure for use in this population. 
Much of previous research has focused on other chronic illnesses such as diabetes, where the 
measure has demonstrated potential in predicting a range of positive health outcomes and 
behaviours [261, 265-267]. However, the role of the measure in cancer populations, and in 
particular those undergoing chemotherapy is less clear and studies are cross-sectional with 




6.5.2 Strengths and limitations 
The main strengths of this study are a large sample size and a prospective randomised 
controlled design. However, this study did have some limitations. In order to model predictors 
of adherence to weekly symptom reports, it was necessary to dichotomise the variable and 
conduct a logistic regression. There are criticisms of using logistic regression when the 
dependent variable is not truly dichotomous, as was the case in this analysis [279]. The 
possibility of using ‘absolute adherence’ (100%) was considered. In fact, a high number of 
patients in this sample (40%) did have 100% adherence. However, this would classify patients 
who missed one completion as non-adherent. Given that patients are often admitted to 
hospital during treatment, or experience severe side effects which may prevent them from 
completing, this did not seem like a true reflection of adherence. However, there were also 
issues with the arbitrary nature of dichotomising the variable using a median split as we are 
differentiating between patients, some of whom in reality had similar levels of adherence. 
Alternative methods such as using non-parametric analysis or using more extreme cut-offs for 
adherence were considered. However, these methods would have been less informative, or 
would have resulted in a reduced sample size for analysis, and dichotomising the variable was 
deemed to be the best course of action. 
In addition, the requirement for patients to complete symptom assessments once a week is 
also somewhat arbitrary. This frequency was decided after consultation with both clinicians 
and patients and was deemed to be useful to clinicians and acceptable to patients in terms of 
burden. However, there is no evidence to demonstrate that this is the optimal frequency of 
completion in terms of potential benefits for patients, and other ePROM systems vary in their 
recommendations [51, 193]. These issues may need careful consideration in future evaluations 
of adherence. 
Another limitation of this work is that patients who had left the trial were not included in the 




trials. In this scenario, all patients who have been randomised are included in the final analysis, 
regardless of subsequent withdrawal, missing outcomes etc. The benefits of ITT analyses are 
that it avoids overestimation of the efficacy of interventions and prevents bias. However, there 
are also some criticisms of this approach. ITT analysis includes patients who may not ever have 
had any experience of the intervention being evaluated, and as such can dilute evidence of 
benefits and lead to an increased likelihood of Type II error. In addition, ITT is easier to 
implement when it has been integrated into the design of the trial and outcomes can be 
collected for patients who withdraw. It is much more difficult to implement where outcomes 
essential for evaluation are missing [288, 289]. 
The withdrawal procedures for eRAPID were changed part way through the main trial (see 
section 2.4.4.6) to allow for continued collection of outcomes for withdrawn patients where 
possible. However, outcome measures and clinical process data were not available for a large 
sample of the patients included in this dataset who withdrew before these procedures were 
introduced. In addition, there were varied and complex reasons why patients withdrew from 
the trial, such as deteriorating health and disease progression, or changes to treatment plan, in 
addition to some patients who withdrew because they did not want to use the intervention. 
Due to practical complexities in identifying which of these patients were suitable for inclusion, 
all patients who left the trial were excluded. Future analysis on the full sample will include ITT 
analyses in addition to PP (Per protocol) analysis. 
The measure used to assess clinician use of eRAPID data in consultations had some limitations. 
The feedback forms were not given to clinicians to complete if patients had not completed a 
symptom report in a significant amount of time (approximately eight weeks or more), as there 
was no relevant data for them to view. In addition, forms were sometimes missed if 
appointments times and dates were changed. In order to try to overcome these issues, a 
percentage score was calculated from the number of forms completed, rather than the 




adherence being excluded from the analysis. A more objective measure of clinician 
engagement, for example, a measure to assess their use of eRAPID data in consultations more 
generally, may be preferable, but on the other hand, it may also fail to pick up differences in 
individual consultations. Alternatively previous research within the PCOR group has focused on 
audio-recording consultations and using qualitative methods such as consultation analysis to 
assess patient use of data during consultations. Data can also be quantified by assessing how 
symptoms are discussed, who raises discussions and assessing when PROMs data is explicitly 
mentioned. These methods can provide valuable insight but are costly and resource intensive 
[43, 44]. 
The impact of other variables, such as symptom burden, on patient engagement with eRAPID 
was not explored. As outlined in previous Chapters, data on symptom experience is not 
routinely collected from patients undergoing chemotherapy, and is reliant on clinician 
interpretation and documentation in patient records [14, 35, 36]. Extraction of this data would 
be complex, and likely to be unreliable and as such, the clinical process measures were 
deemed to be a more appropriate proxy assessment of symptom burden. 
There are potential limitations on the validity of the outcome measures relating to how the 
measures were administered to patients. The outcome measures were included as part of a 
larger questionnaire pack which included the primary outcomes and some of the secondary 
outcomes for the main RCT (see section 6.3.4.4). This context may have influenced patients’ 
responses. For example, it is commonly acknowledged that the order in which questions or 
questionnaires are presented to respondents can influence how they are answered [290, 291]. 
This can be as a result of response fatigue, where participants simply become tired or bored 
when completing questionnaires, and are less likely to answer accurately. It may also be as a 
result of order effects, where preceding questions which may ‘prime’ the participant to 
respond a certain way. For example, in the questionnaire pack, patients were completing QoL 




the QoL measures may have influenced patients’ perception of how they were managing with 
their treatment and side effects, and subsequently influenced their completion of the 
remaining measures. 
In addition, the environment in which patients were completing the questionnaires may also 
have influenced their responses. For example, some patients completed the eighteen week 
questionnaire pack whilst undergoing chemotherapy on the day unit, whilst others were 
completing in their own homes, often a week or two after completing chemotherapy. The 
setting for completion was not recorded, and as such, it was not possible to undertake any 
analysis to evaluate whether this had any impact. 
Future evaluations could rotate the order of questionnaires and record the environment in 
which patients completed the measures to allow for the possibility of later analysis to evaluate 
response fatigue and order effects. 
The impact of symptom burden or other clinical variables on the end of study scores of the 
outcome measures (CSES, CBI-B and PAM) was not explored. Although it is likely that there are 
many factors which may predict end of study scores, the focus of this analysis was only to 
determine the role of engagement with eRAPID. However, future analysis is planned to explore 
other predictors of improvements in these outcomes. 
6.5.3 Conclusions 
Levels of engagement with eRAPID were high, demonstrating acceptability to patients. An 
exploration of predictors of engagement revealed that the only reliable predictor was clinician 
engagement with patient data during routine consultations. There was a positive impact of the 
intervention on patient self-efficacy to manage side effects of treatment, but not on self-
efficacy to cope with cancer or on PA. Within the intervention group, adherence to weekly 
completions was a significant predictor of improvement in self-efficacy for both managing 




evaluate and report on engagement when evaluating online systems. Barriers and motivators 
for engagement with eRAPID and patients’ perception of clinician use of eRAPID will be 




Chapter 7 Qualitative exploration of the patient perspective of using 
eRAPID during chemotherapy 
7.1 Background 
7.1.1 Overview 
The work described in this chapter builds further on that described in Chapter 4 and in the 
previous chapter. Chapter 6 described quantitative analysis to explore the patient perspective 
of eRAPID. Patient engagement with eRAPID was explored in more depth, and validated 
measures were used to assess the impact of eRAPID on patient self-efficacy to manage side 
effects of treatment, self-efficacy to cope with cancer and their levels of PA. The main findings 
were that levels of engagement and adherence were generally high and eRAPID was well 
accepted by patients. A logistic regression model to predict engagement with eRAPID revealed 
that the only significant predictor was a measure of clinician use of patient data during routine 
consultations. There was a positive impact of the intervention on patient self-efficacy to 
manage side effects of treatment, but not on self-efficacy to cope with cancer or on PA. 
The qualitative methods described in this chapter aim to complement the quantitative data 
and provide more in-depth understanding of the patient perspective of using eRAPID. Barrier 
and facilitators for engagement were explored, in addition to the impact eRAPID had on 
experience of chemotherapy. This extends upon on the previous qualitative work described in 
Chapter 4. The interview schedule was reviewed and refined based on the previous findings 
and we were able to interview a greater number of patients, across three different disease 
groups, using eRAPID over a longer period of time. 
As highlighted in the systematic review in Chapter 5, many newly developed ePROM systems 




studies have used qualitative methods to explore patient perspective. Research on patient 
engagement with ePROM systems is still in its infancy and qualitative research can provide 
valuable insight into how patients interact with systems to identify potential motivators and 
barriers for engagement, in addition to exploring patients’ perceptions about how systems 
impact on their care [46]. Those that have used qualitative methods have reported intrinsic 
motivations such as ‘reassurance’ and support for managing symptoms and side effects as an 
important motivator for engagement, similar to the findings reported from the field usability 
testing of eRAPID described in Chapter 4 [72, 165, 166]. 
In other chronic illness groups such as diabetes, qualitative research has been used more 
frequently to inform system evaluation and development, but it still relatively uncommon. 
Those that have used qualitative methods have reported that technological and usability issues 
are commonly cited as barriers to engagement, as is poorer health status [159]. However, a 
qualitative study by Sanders et al [128] indicated that of equal, if not more importance is the 
patients’ perceptions of how the system fits with their identity, independence and self-care. 
Some of the patients in their study reported that they felt the interventions gave them less 
independence and control. The majority of patients in their sample had chronic illnesses such 
as diabetes, which have very different processes of self-management and care than patients 
undergoing chemotherapy, but this may also be a relevant factor for eRAPID. 
eRAPID symptom reports may highlight to clinicians if chemotherapy is not being well-
tolerated, which subsequently may result in a decision to reduce the dose or delay treatment. 
While intuitively, this seems like a positive thing for patients, it may not be that 
straightforward. Patients often have anxieties around changes to planned treatment and 
patients differ in their willingness to tolerate side effects [292]. This is also likely to be 
influenced by the intention of treatment and how it is discussed with patients. For example, 
adjuvant treatment is sometimes described to patients an ‘insurance policy’, and patients may 




patients will be more likely to tolerate side effects if the aim of treatment is curative but value 
QoL over survival if the aim of the treatment is to stabilise disease [32, 293, 294]. 
This chapter describes qualitative work undertaken to explore these issues, in addition to 
informing the quantitative work described in the previous chapter. 
7.1.2 Role and original contribution 
I had a lead role in planning and implementing the qualitative component of the eRAPID trial. 
In addition to working as part of the core eRAPID team conducting and analysing interviews, I 
was responsible for development of the interview schedule and the analysis framework, 
working with the senior researcher and principal investigator to ensure that the schedule also 
covered the necessary topics for the main trial. This aspect of the trial was included in the 
main protocol and ethics application for the eRAPID RCT [94]. Preliminary results have been 
presented as a conference poster [295]. 
7.2 Aims and Objectives 
The overall aim of the work described in this chapter was to qualitatively explore: 
1) Barriers and facilitators for patient engagement 
2) Patient experiences of using eRAPID, specifically 
a. perceptions of how eRAPID impacted on their self-management and 
chemotherapy experience 
b. perceptions of clinician use of eRAPID symptom reports and the impact this 





7.3.1 Recruitment and patient sample 
Eligible patients were those who had taken part in the internal pilot phase of the RCT(n=87) to 
evaluate eRAPID in systemic therapy and had been randomised to the intervention arm of the 
study (n=36). The full details for patient eligibility and recruitment processes for the eRAPID 
RCT are described in Chapter 3. A subset of patients were approached at the end of their 18 
week study period and asked to take part in a semi-structured interview about their 
experiences of using eRAPID. Patients were approached consecutively as they completed the 
study, with an aim to interview 5-10 patients overall from each disease group. 
7.3.2 Interview setting 
Interviews took place in a private room in the oncology outpatient clinic at St James University 
Hospital, Leeds. Interviews were usually arranged to coincide with patients’ clinic 
appointments to avoid the need for additional trips to the hospital, and generally took place 
after their clinic appointment. 
7.3.3 Interview schedule 
The interview schedule was based on that used for the end of study interviews in the eRAPID 
usability in the breast clinic (Chapter 4). However, as a result of this work, some amendments 
were made. Due to the variance in patient engagement observed in the usability study, 
questions were added on motivators and barriers for engaging with eRAPID. These questions 
were specifically targeted to patients’ level of engagement. For example, patients who 
completed regularly every week were asked about their main motivations for doing so, while 
patients who had completed sporadically were probed on the main barriers they experienced. 
Specific questions were also added on patients’ use of the symptom graphs, which allowed 




in the usability study. The usability study indicated that patients did not always follow the 
advice to contact the hospital, so questions were added to explore this. Some general 
questions about patients’ experiences of hospital admissions and treatment changes during 
chemotherapy were also added. Questions about the recruitment procedures were removed, 
as these were specific to the aims of the usability study. The full amended interview schedule 
is outlined below in Table 7.1. 
Table 7.1 End of study interview schedule for pilot phase of the eRAPID RCT 
Usability of eRAPID 
- Did you find the eRAPID system easy to use? 
- Were there any technical aspects of it you found difficult? 
- Did you have any difficulties finding the site, logging in etc.? 
- If so, how did you resolve them? 
- Do you have suggestions on how we might improve the system?  
- Did you use the user manual we gave you? 
- Do you have any suggestions for how we might improve that? 
Completion of symptom reports 
If patient initially started using the system but then stopped. 
- You initially used the system regularly but then you stopped. 
- Can you remember the reasons why this was? 
- Did you intend on using the system again in the future? 
- Is there any support we could have given you to help you to complete at this time?  
If patient has completed intermittently 
- You used the system intermittently throughout the study. 
- Can you remember the reasons why you didn’t complete at this time? 
- Is there any support we could have given you to help you to complete at this time? 
- What made you start using the system again? 
If the patient used the system regularly throughout the study.  
- You used the system regularly.  
- Can you tell us what your main motivations were for doing this? (For example, the graphs, self-
management advice or for the clinicians) 
General views on using the system 
- What were your expectations of using the eRAPID system (if any)? 
- Were your expectations met? 
Were there any advantages to using the system? 
- Were there any disadvantages to using the system? 
- Did you complete the system when you received reminders, or did you have your own set time to 
complete? 
- Has it been difficult for you to complete the questionnaire on a weekly basis? 
- How confident are you that you would be able to access the system on a weekly basis throughout 
the course of your treatment? 
- Is there anything we could do to make this easier for you or other patients? 
- What factors might prevent you from using the eRAPID system? 
- What factors might help you to access the eRAPID system? 
- Do you think other patients will be likely to use eRAPID?  




- Was there anything you enjoyed or found pleasant about completing the questionnaire? 
- Was there anything upsetting or unpleasant about completing the questionnaire? 
Self-management advice 
- Do you think that the system accurately assessed your symptoms? E.g. the types of questions 
asked, the severity level, etc. 
- Did you find the information on the eRAPID website useful? 
- Did you use any of it? 
- Do you think that using the system had any effect on how you managed your symptoms and side 
effects? 
- Did you receive advice to contact the hospital at any point? 
- Did you follow this advice? If not, what were your reasons for not following the advice?  
Graphs 
- Did you look at/use the graphs at the end of questionnaire? 
- If not, can you tell us the reason (e.g. didn’t find them useful, too complicated) 
- If so, did you find them useful? In what way? 
- What did you like about them? 
- What did you not like about them? 
Perceived role of staff 
- Did the doctors/CNS use the system at your clinic appointments? 
- Do you think they found the system useful? 
- Do you think they would be likely to use this system regularly? 
- Do you think that using the system influenced your consultations in any way? 
- If so, how? 
Perceived role of carers 
- Did anyone else (such as a relative) help you use the system? 
- Do you think they found it useful? 
- Did you speak to any of your friends or family about your involvement in eRAPID? 
- What did they think of it? 
Perceived influence on treatment/care 
- Do you think you had any medications prescribed or changes in treatment because of reporting 
symptoms on the system? 
- Were you happy with these changes? 
Alerts  
- When you received the advice to contact the hospital, did you do so? 
- If not, what action did you take and why? 
- Did anybody contact you? 
- Did they discuss your eRAPID results with you? 
- What were the consequences of that contact? (E.g. Were you asked to come into hospital? Visit 
your GP? etc.) 
Hospital admissions and triage calls 
- Can you tell us a bit about your admission to hospital and what happened in the lead up to that? 
(Ask patient to “think aloud” about how things happened). 
- For example, how long did you feel unwell for before you rang the hospital? 
- Did you use the eRAPID system before you contacted the hospital? 
- If not, did you consider using the eRAPID system before you contacted the hospital? 
- Did the staff on the acute ward mention eRAPID to you, or did you mention it to them? 
- Did your admission have any effect on your treatment? (e.g. delays, dose reduction) 
Outcome measures (paper questionnaire completions) 
- How did you find completing the paper questionnaires every 6 weeks? 
- Were the questions relevant to you? 
- How long did they take to complete? 





- Do you have any other comments or questions about your involvement with eRAPID? 
7.3.4 Interview analysis 
Interviews were transcribed verbatim and managed in NVivo version 10 software. The 
interviews were analysed using thematic analysis [146]. An initial framework of themes was 
developed based on the interview schedule, and the previous results from the usability 
interviews. After listening to initial interviews, the coding framework was amended as needed. 
A analysis team was assembled (LW, KA, SP, BC, MH, ZR, KK and RM). The framework was 
reviewed by the analysis team and some minor amendments were made. Interviews were 
assigned to members of the research team and each interview was coded by at least 2 
researchers. An iterative approach was adopted so that changes could be made to the coding 
framework as new themes and relationships between themes emerged. Regular meetings 
were scheduled to discuss any queries or discrepancies, and these were resolved by group 





7.4.1 Recruitment and patient sample 
Although initially, it was planned to interview 5-10 patients from each disease site, recruitment 
in the breast clinic was substantially higher than in colorectal and gynae clinics. As a result, a 
higher proportion of patients were recruited from the breast clinic to reflect the overall patient 
sample. Patients were recruited consecutively until data saturation was reached. The 
breakdown of potentially eligible patients in each group and those interviewed is outlined 
below in Figure 7.1 below. Interviews were 24 minutes long on average and ranged from 8 to 
47 minutes. 
Figure 7.1 CONSORT diagram of eligibility and recruitment of patient sample 
 
7.4.2 Demographic and clinical info 
Table 7.2 displays demographic and clinical information for patients who participated in the 
end of study interviews and the remaining sample (including usual care patients and those 
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who left the trial). Proportionally, less patients in the 50-59 years and 60-69 year age 
categories (30.4% versus 42.2% and 13.0% versus 26.6%) and lowest IMD deprivation group 
(13.0% versus 22.2%) and more patients in the two youngest age groups (8.7% versus 4.7% and 
39.1% versus 20.3%) and highest level of education group (60.9% versus 40.4%) were 
interviewed. 
Table 7.2 Demographic data for interviewed patients and remaining pilot sample 
 Interviewed patients 
(n=23) 
Remaining pilot sample 
N=(64) 
 Mean SD Mean SD 
Age (years) 
Mean and standard deviation 51.6 10.9 55.2 10.7 
 N % N % 
Age group 
Up to 34 years 2 8.7% 3 4.7% 
35-49 years 9 39.1% 13 20.3% 
50-59years 7 30.4% 27 42.2% 
60-69 years 3 13.0% 17 26.6% 
70+years 2 8.7% 4 6.3% 
Total 23  64  
Gender 
Male 4 17.4% 6 9.4% 
Female 19 82.6% 58 90.6% 
Total 23  64  
Cancer type 
Breast  14 60.9% 36 56.3% 
Gynae 4 17.4% 17 26.6% 
Colorectal 5 21.7% 11 17.2% 
Total   64  
Marital status 
Married/Civil Partnership 18 78.3% 42 65.6% 
Cohabiting 1 4.3% 6 9.4% 
Separated/Divorced 0 0.0% 7 10.9% 
Widowed 1 4.3% 3 4.7% 
Single 3 13.0% 6 9.4% 
Total     
Education (missing=1) 
Up to school leaving age 6 26.1% 21 32.8% 
Beyond school leaving age 3 13.0% 14 22.2% 
Degree/professional qualification 14 60.9% 28 44.4% 
Total 20  63  
IMD Quintile (missing=1) 
20% most deprived 3 13.0% 14 22.2% 
20-40% most deprived 3 13.0% 6 9.5% 
20% middle deprived 6 26.1% 7 11.1% 
20-40% least deprived 5 21.7% 19 30.2% 
20% least deprived 6 26.1% 17 27.0% 




7.4.3 Thematic analysis of interviews 
Four main themes were identified in relation to patient engagement with the system, and the 
main benefits of the system for patients. A thematic map of themes and subthemes and 
relationships between them is outlined in Figure 7.2. The themes were as follows; 1) General 
barriers and facilitators of engagement. This theme encompassed factors which impacted on 
patient engagement with eRAPID, but were not directly related to patients’ perceptions of 
how eRAPID impacted on their chemotherapy experience. 
2) Supporting self-management of symptoms. This theme describes patient experiences of 
how eRAPID supported self-management by the provision of tailored severity dependent 
advice, in addition to some situations where patients felt this support was lacking. This theme 
also describes how patients engaged with eRAPID as a tool for monitoring the fluctuation and 
pattern of symptoms throughout chemotherapy. 
3) Perceived influence on clinical care. This theme describes patients’ experiences of the 
impact of eRAPID on their consultations with clinical staff, and subsequently on their clinical 
care. 
4) Supporting coping with cancer treatment. This theme focuses on the more psychological 




Figure 7.2 Thematic map of themes and subthemes identified 
 
7.4.3.1 General barriers and facilitators of engagement 
7.4.3.1.1 Level of IT literacy 
Patients generally found eRAPID easy to use, access and navigate. The majority of patients we 
interviewed considered themselves to have a good level of IT literacy. However, they also 
thought that eRAPID would be easy for patients with even basic IT skills to access and use 
regularly. 
“Anybody who is reasonably IT literate wouldn’t have a problem 
with it at all. So, yeah, I can’t see why anybody wouldn’t really use it.” 
(00002, Female, 52 years, Breast) 
“I used to design systems and I thought it was too easy to be 
honest… but then you'd have some patients not very good with computers 
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(00082, Male, 48 years, Colorectal) 
A small number of patients reported that they were not confident accessing and using IT 
generally. However, these patients still managed to participate in the study and complete the 
weekly symptom reports with some support from family members. One patient had support 
from her son who visited regularly and would help her to complete the symptom reports. 
However, she was confident in accessing the reading the advice, once the symptom report was 
completed. 
“I read the advice but he just had to put the information on because I’m 
not very good on the computer really.” 
(00010, Female, 59 years, Breast) 
Another patient described how his wife supported him to complete the symptom reports, and 
they went through the self-management advice together. Although neither of them were 
confident in using IT, they were able to manage together. 
“The wife and I did it between us. She might have struggled on her own 
and I might have struggled on my own, but our combined effort… but I think it was 
good, well designed really” 
(00044, Male, 70 years, Colorectal) 
Some patients did express that while they themselves had found the system easy to use and 
navigate, they felt that other patients, in particular, older patients might struggle with it, and 
this would need to be taken into account for future implementation. 
“Depending what age you are you might not. So for example my parents 
wouldn’t want to do it because one false move and they’d think they’d blown it up 
and they wouldn’t use it at all, but I think everybody else would you know, the next 
generation.” 
(00043, Female, 52 years, Breast) 




In the previous usability study, the most common reason for non-completion of the weekly 
symptom reports identified was that patients simply forgot. Subsequently, we implemented a 
text and/or email reminder service. Reminders were automatically set to be sent out once a 
week from three days after the patient’s first chemotherapy. Patients found the reminders 
very helpful, although most patients said that they did not tend to complete the symptom 
reports in line with when the reminders were received. However, patients said that receiving 
regular reminders helped to keep eRAPID at the forefront of their mind during treatment. This 
was important, as many reported that it was difficult to keep track of time and days when out 
of routine and trying to manage chemotherapy side effects, and many referred to suffering 
from ‘chemo brain’. 
“When I got the text, I didn’t go and log on straightaway. It was 
just so that I thought, I still had it in the front of my mind, kind of all the 
time so it was helpful in that respect.” 
(00034, Female, 24 years, Breast) 
“You’d get a bit fuzzy, I dunno like chemo brain or you’d become a 
bit scatty… because you’re in this bubble with treatment and 
appointments and things, the days don’t seem to mean much and then all 
of a sudden it’s like ‘I thought I’d done that’ or ‘I meant to do that’ and 
then a reminder would come up. So as we went on the reminder was good 
cos it’s like ‘I completely forgot about that, yes I need to do that’ and it 
would prompt me.” 
(00017, Female, 48 years, Breast) 
7.4.3.1.3 Health status during chemotherapy 
Some patients found it difficult to complete eRAPID symptom reports when they were feeling 
unwell, ‘grotty’ or tired from chemotherapy as they didn’t feel up to it. The majority of 
patients still managed to complete regularly but found they had to work this around when 
they were feeling better. However, some patients did find this too difficult and subsequently 




“It just wasn’t a priority cos I was feeling so grotty. So a lot of things went 
by the by really and unfortunately that was one of them.” 
(00023, Female, 45 years, Colorectal) 
One patient felt that eRAPID was an added pressure when she was already struggling to cope 
with managing family life. 
“I think it was just dealing with my illness which I found really difficult. I 
didn’t have a lot of help at home and I was just struggling to manage my 
symptoms, my emotions, things that I still needed to do for my children, so they, it 
was just a lot of pressure on me and I felt really bad about not doing it” 
(00032, Female, 47 years, Gynae) 
One patient commented that although it would potentially be very useful to complete a 
symptom report when they were feeling ill in order to receive advice on managing symptoms 
and provide an accurate record, they were less motivated to log and access the system during 
these times. 
“If you’re not feeling well, maybe that’s the time when you really need to 
be filling it in, but you’re less inclined to fill it in then. It’s very… it is rather a vicious 
circle.” 
(00037, Female, 62 years, Breast) 
Conversely, other patients reported that they were less motivated to access eRAPID and 
complete symptom reports when they felt well and were not experiencing very many 
symptoms or side effects. Some patients said that they delayed completing symptom reports, 
with the intention to complete in a few days if they did start experiencing side effects. 
“I was thinking well I'll wait until I've had a few more symptoms 'cos I 
didn't have a great deal. So it was like I'll wait until I've got a few more you never 
know what might happen tomorrow so I'll leave it another day and another day 
and then I'd get like 2 weeks into the cycle, actually I really think I should fill it in, 
but that's what it was because I didn't have a great deal to fill in” 




One patient who had initially used the system, but used it less as she progressed through 
chemotherapy reported that she didn’t want to access eRAPID when she felt well, as she just 
wanted to get on with things and not be reminded of the hospital. 
“The more well you feel, the less likely you want to go on it and 
then I think ‘oh I've not done it’ and I'm thinking that's a good thing I've 
not gone on it. So to go on and tell you that I'm feeling really well to me 
was a bit of a waste of time and reminds me of the hospital which you 
kind of want to forget if you're feeling well.” 
(00001, Female, 43 years, Breast) 
7.4.3.1.4 Participation in research 
When asked about their main motivations for using eRAPID, some patients reported that 
contributing to research was an important motivator for them. Although most patients felt 
that they also derived some personal benefit from their participation in the trial, this 
motivation was independent of that. Patients spoke about wanting to ‘give something back’ 
and hoping that their contribution would help other cancer patients in the future. 
“I think without being cushy about, it could also help somebody 
else in a similar situation, it is no extra effort” 
(00044, Male, 70 years, Colorectal) 
“It was a win-win and I thought well I like participating in the trial, 
I love what this hospital does, if I’ve been contributing all the better, it’s a 
minor pay back for everything that’s coming my way, but also I just hoped 
that it would be useful” 
(00035, Female, 47 years, Breast) 
7.4.3.2 Supporting management of symptoms 
Patients reported that the advice for managing symptoms was one of the most useful features 
of the system, and one of the main motivators for engaging with eRAPID. There were two main 




advice which they received for milder symptoms, and secondly, the advice to contact the 
hospital for more severe symptoms. 
7.4.3.2.1 Perceived value of self-management advice 
Patients found the self-management advice practical and helpful. Although patients received 
similar information in paper form from their oncology nurses at the beginning of treatment, 
they found the eRAPID information easier to access as it was specifically tailored to their 
symptom reports. 
“I felt a bit nauseous but you knew it was there to go through, you know, 
you might try ice cubes and stuff like that. We had ice lollies. There’s all this 
information there and you didn’t have to go searching, it would just automatically 
come up with any problems that you had.” 
(00017, Female, 48 years, Breast) 
“It reminded me actually of a couple of things, things about the eating or 
things about managing cos that was a big problem, eating’s a big problem and so 
just reminding you about you know little and often or I can't remember what. The 
small things like getting somebody else to cook” 
(00025, Female, 65 years, Gynae) 
Some patients felt that without the availability of eRAPID advice, they would have needed to 
contact the hospital for routine self-management advice or reassurance. Most patients valued 
the fact they could manage symptoms on their own terms with reliable guidance. 
“You can get the help without having to ring up the hospital every five 
minutes… Yeah because on the occasions where something different came up, I 
got the advice from that rather than having to call up and speak to one of the 
nurses.” 
(00015, Male, 58 years, Colorectal) 




Patients placed high value on the knowledge that eRAPID would prompt them to take action if 
their symptoms were at a severe enough level, and felt reassured by this. 
“It gave you a little, you know, a medical evaluation, which was 
actually quite helpful and quite useful. So rather than ring somebody up, 
or go to the hospital you had sensible information at your fingertips after 
you filled it in. It noticed immediately what was wrong with you, and gave 
you advice, and then suggested phoning the hospital, you know, if it was 
at a critical point, you know?” 
(00035, Female, 47 years, Breast) 
Patients were aware that some treatment side effects were to be expected and commonly, 
patients expressed that they would be reluctant to contact the hospital for fear of ‘bothering’ 
people or wasting time or resources. However, they were also trying to balance this with 
challenges of dealing with unfamiliar symptoms and side effects which could potentially 
require medical intervention and did not feel confident in making judgements about the 
importance or severity of the symptoms they were experiencing. 
“You’re always got that dilemma of, well, is this normal, am I 
wasting somebody’s time, so … yeah, so to have some really clear 
instructions that are based on what you’ve just reported are really good 
and then you know it’s the right course of action.” 
(00002, Female, 52 years, Breast) 
“You don’t like to just phone the hospital cos you feel like you’re 
bothering people and you think ‘This is just normal’… but when you went 
along the journey with eRAPID, it gave you an idea of at what point you 
should contact the hospital” 
(00017, Female, 48 years, Breast) 
Patients also felt that if they were advised by eRAPID to contact the hospital, this would give 
them ‘permission’ without having to feel guilty or worry that they were calling unnecessarily. 
“I think it was terrible stomach pains and they were quite severe 




this continues contact…’ It didn’t so that was all right. But it gives you permission 
and that’s what I liked about it because you’re thinking, am I making a fuss?. It 
actually gave you permission to contact.” 
(00007, Female, 62 years, Breast) 
“There were a few times I thought am I supposed to phone the hospital? 
But I don’t think … I’m kind of borderline but I don’t feel overly bad but I think, you 
know, it would give you that confidence to say ‘hi, my eRAPID says I should call’.” 
(00017, Female, 48 years, Breast) 
7.4.3.2.3 Perceived value of advice over time 
Some patients reported that they experienced a similar pattern of symptoms throughout all of 
their chemotherapy cycles. As their symptom reports were very similar on a week to week 
basis, they were receiving the same self-management advice from eRAPID each week, which 
subsequently became less useful over time. As a result, some patients who had found that the 
self-management advice was initially a motivator for completing symptom reports found that 
this became less of a motivator as they progressed through treatment. 
“Yeah, I mean the only thing that was a little bit frustrating was that 
obviously the advice doesn’t change, so mine were fairly… my responses were 
fairly similar all the way through, probably getting a little bit more acute if you 
like, but the response from the system was the same all the way through and 
actually that’s understandable logically, but you’re kind of looking for another 
answer, you’re like, somebody tell me how I can stop it… I understand why that 
would be, it’s just you’re sort of seeking something aren’t you that’s probably not 
going to come” 
(00072, Female, 33 years, Gynae) 
“I only had the same things to say and then it said the same things to me. 
So initially that was ok because… I didn't remember everything and it was good to 
refresh what to do about this tingle something like that. Um but then I had a bit of 
a down time because the treatment wasn't working and… I wasn't well basically so 





(00025, Female, 65 years, Gynae) 
Patients also reported becoming gradually more confident in their ability to self-manage 
symptoms as they progressed through treatment. They also became more confident in making 
their own judgements on when they needed to contact the hospital. Occasionally patients 
even reported that they ignored advice from eRAPID to contact the hospital, if they felt it was 
unnecessary. As a result, patients became less reliant on the symptom advice as they 
progressed through treatment, and again, this seemed to reduce motivation to engage with 
eRAPID. 
“I had previously contacted the hospital, and they had told me ‘Do 
this, this, this’. So I kind of knew what they were going to say because it 
was the same old thing again. So I kind of knew what the answer was 
going to be, so I didn’t go into emergency mode” 
(00035, Female, 47 years, Breast) 
“On the eRAPID it kind of sort of says it quite soon to phone the 
hospital and especially if it’s like Saturday or Sunday you think should I? I 
don’t really want to be calling an out of hours number. I think if I’d have 
had the temperature, I think that would have been more of an issue 
because of the infection and you are aware it’s your immune system and 
you do need to come in but I think it’s one of the things, I’ll just see if it 
subsides.” 
(00017, Female, 48 years, Breast) 
7.4.3.2.4 Preferences for clinician contact 
A small number of patients felt that in the case of experiencing a problem, they would prefer 
to just contact the hospital directly. They felt that logging on to complete a symptom report 
would be an additional, and perhaps unnecessary step if somebody was already feeling unwell. 
“You have to remember, got get that password thing or remember 
it and then log in which is simple to do but… it's just not as simple as 




(00001, Female, 43 years, Breast) 
“For example say my stoma starts bleeding, do I need to log on? But I 
wouldn't, the first thing I would do is ring the oncology hot line because… you 
don't want to be ill or in pain and think oh now I need to log on and go through all 
the questionnaire and see if I get a response” 
(00082, Male, 48 years, Colorectal) 
A couple of patients also expressed concerns that eRAPID might be intended as a replacement 
for clinical care. It is worth noting that the patients who expressed this concern were the first 
patients on the study, so it is possible that these concerns were reflective of some initial 
concerns by clinical staff on the purpose of eRAPID. 
“Is it about trying to not have as much personal contact, sort of sending 
off people? I don't know it's really what's the objective because if it is about 
stopping people calling all the time with the same questions… but people need 
that don't they?” 
(00001, Female, 43 years, Breast) 
“I wonder if people might feel they were being fobbed off a little bit by, 
you know, that they might not feel they’re getting the same medical care, but I 
don’t know, I certainly didn’t feel that” 
(00002, Female, 52 years, Breast) 
7.4.3.2.5 Self-monitoring 
Patients were provided with graphs at the end of each symptom report completion which 
depicted the level of severity for each symptom over time. Some patients used these graphs as 
a tool to monitor how their symptoms fluctuated throughout their treatment. One patient 
described how she found this useful to self-manage symptoms, by identifying strategies that 
had previously been helpful. 
“If I had a worse week than the previous week then I’d sit down and think 
to myself right what didn’t I do this week that I did last week or what can I do now 
to make that factor the same as it was the week before so in that respect it 




something right but if it was worse, then it gave me an opportunity to sit 
down and think right what didn’t I do, and what do I need to do? That’s 
what helped me self-manage my symptoms” 
(00022, Female, 47 years, Breast) 
However, for other patients the most useful aspect of the graphs was that they were able to 
have a visual representation of how the severity of their symptoms did fluctuate, and that this 
was particularly useful at the times when symptoms were at their worst, as it reassured them 
that symptoms were temporary. 
“You’d sort of think, I’m sure this is a lot tougher than it was last 
time, but then when you look you’d go, actually no you felt similar, maybe 
for 24 hours or less but you felt similar in terms of the severity. So it kind of 
gave you like you say that push to say, it’ll be gone again in 24 hours… 48 
hours… just keep pushing through so it was useful in that sense to see 
those graphs.” 
(00072, Female, 33 years, Gynae) 
“You can see actually that on that week I felt particularly bad but 
on the second week I didn't have those symptoms at all. So it will go… so 
there was some optimism” 
(00006, Female, 51 years, Breast) 
7.4.3.3 Perceived influence on clinical care 
7.4.3.3.1 Enhanced communication with clinicians 
Most patients felt that eRAPID facilitated and improved their communication with their 
healthcare team. Some patients felt that eRAPID positively influenced their consultations with 
clinicians, as clinicians could access the patient’s eRAPID symptom reports before the 
appointment, and already have a good idea of how the patient was before the consultation 
started. Patients felt that this was really valuable as they felt that the clinicians were more 





“If the patient has written this down beforehand, then you can read up on 
the notes before they even get there, and you know, at least get how the patient’s 
going to be, or be on the same wavelength about how their symptoms have been, 
how the chemo’s going. So I think, yeah, I think that’s a good idea, because they’d 
know in advance, you know ‘Oh you’ve not had a good time this time, have you?’ 
for example.” 
(00035, Female, 47 years, Breast) 
“They would use that to say ‘Oh you’ve had problems with a sore mouth 
this week, let’s get you this prescribed’ or… they’d look at that and see that there 
was problems with and then they’d say ‘Well was there anything else?’. But it’s 
kind of like they already had the information prepared.” 
(00034, Female, 24 years, Breast) 
Sometimes clinicians were very explicit with patients about using the symptom reports during 
consultations while other times they were less so. The acknowledgement by clinicians of the 
value and the use of the symptoms reports patients provided was an important motivator for 
patient engagement. 
“Our chemotherapy doctor, he would bring it up every time and show us it 
and talk me through any concerns that he had, so yeah I was… and again that re-
incentivised me to use the system because you know it’s not just a waste of time, 
somebody’s looking at it.” 
(00072, Female, 33 years, Gynae) 
However, some patients were not aware of clinicians using or accessing their symptom reports 
during consultations, and subsequently, felt much less engaged to continue using eRAPID 
throughout their treatment. 
“Some sort of acknowledgement it's being looked at, carry on using it… I 
could log them all on there and maybe when I have my meeting with (doctor), he 
could say right let's look at all the information you’ve put over the last 6 months 
and I see this has happened this has happened etc. but if they don’t say anything, 
you know, why are you using it?” 




7.4.3.3.2 Recall of symptoms 
For many patients, the most important motivator for completing symptom reports each week 
was to provide a record for clinicians. Commonly, patients expressed that without having this 
record, they didn’t feel that they would be able to provide an accurate picture of their 
symptom burden to clinicians, as it was too difficult to remember how they’d been, giving that 
their consultations were not always frequent. Many patients also felt that chemotherapy 
impacted on their memory, which made it even more important to have an accurate record. 
“I knew that the oncologist would look at it before clinic so I 
thought it’s good to try and do it every week so that it’s as accurate as 
possible because when they come to ask you how your symptoms are, you 
can’t necessarily remember how you were like four weeks ago or 
something or even maybe six weeks.” 
(00034, Female, 24 years, Breast) 
“Even before I had the chemo I don’t always remember things that 
I did two or three weeks ago, and what they term chemo brain, that 
effects it and made it even worse. So to have that information there, like I 
say it helps whoever is looking at it, have that information of what has 
gone on, but when they then reiterate it back to the patient it then jogs 
their memory, prompted me anyway, to say yes this was what happened” 
(00022, Female, 47 years, Breast) 
7.4.3.3.3 Influence on symptom disclosure 
In addition to helping patients recall what symptoms they had experienced, some patients also 
felt that eRAPID impacted on what symptoms they disclosed to their clinical team. Most 
commonly because patients were not always sure of the relevance or importance of 
symptoms. 
“I tend not to fuss over little niggles or minor pains, you know, I 
tend to push those to the back of my mind and try and ignore them and 




made my care better because I was mentioning them and then they could put a 
sort of a remedial action in place.” 
(00007, Female, 62 years, Breast) 
“It made you think well actually if (Doctor) asks me how are things going, 
you’re very sort of generic, you know, mine would be always, yeah, you know, the 
worst of it is this but generally we’re doing okay. But that captured things that you 
probably wouldn’t talk about in detail with the doctor because they were sort of 
lower end in comparison to others.” 
(00072, Female, 33 years, Gynae) 
In addition, some patients also reported that they felt more comfortable disclosing potentially 
embarrassing symptoms as it was easier to write them down on a computer than to initiate a 
conversation with the clinician about it. 
“I think there was something to do with a bodily function, I can’t 
remember what it was now, and I thought, you know… I didn’t feel uncomfortable 
writing it down.” 
(00002, Female, 52 years, Breast) 
7.4.3.3.4 Influence on supportive care and treatment pathways 
Some patients reported that they were prescribed supportive medications for symptoms and 
side effects that were picked up by clinicians from the eRAPID symptom reports, and that 
these were symptoms which they otherwise might not have mentioned to the clinician. 
“I also have colitis and sometimes I get very, very bad gripey stomach 
pains. Now just because I get those anyway I might not have mentioned it other 
than somebody saying what are the symptoms you had? You know, because they 
are part of my existence I wouldn’t have thought oh well I must mention this. But 
because it’s asking for the symptoms I thought, yes, I can refer back to this, and in 
actual fact people picked up on that, the chemo nurses, and said we’ll give you 
some Buscopan and I found that very useful and very helpful.” 
(00007, Female, 62 years, Breast) 
“He changed the tablets, you know the sickness tablets, things like that 




have gone off after a time, and it hadn’t been, so he changed my tablets 
or gave me extra ones, so that I could try different ones” 
(00045, Female, 52 years, Gynae) 
Patients were also asked about any changes to their chemotherapy regimens (such as dose 
reductions) and whether or not they perceived that eRAPID had any influence on these 
changes. However, few patients were aware of having had any changes to their chemotherapy 
regimens and of those that did, they were unsure of whether or not eRAPID had any influence. 
7.4.3.4 Supporting coping with cancer treatment 
7.4.3.4.1 Reassurance and support 
Patients commonly used words like ‘reassuring’ to describe their experiences of using eRAPID. 
These words were not mentioned in the interview schedule, but emerged time and time again, 
particularly in relation to the symptom advice. As eRAPID was available to them 24 hours a 
day, they valued having access to information, advice and reassurance at any time, such as in 
the middle of the night. 
 “Reassurance when you're out there when you can't sleep on your 
steroids and it's 4 o'clock in the morning… you sometimes don't want to 
disturb everybody else and you're like well I'll just check this out actually 
I've been up for 2 hours and this is how I feel without…disturbing 
everybody can't you…. Almost like a chemo buddy in the night” 
(00006, Female, 51 years, Breast) 
Patients also found value in being able to identify that their symptoms were a common side 
effect of their treatment, and not necessarily anything that they needed to worry about. 
Patients found this reassuring and sometimes felt that the knowledge was enough, and didn’t 
always feel that they needed to take any further action. 
“It gave you options of additional, you know, ways to control 




normal symptom was often enough for me, so I did use it, yeah, as much for the 
reassurance as anything else.” 
(00072, Female, 33 years, Gynae) 
However, patients descriptions of the ‘reassuring’ and ‘comforting’ aspects of eRAPID went 
beyond the symptom advice and impact on self-management. Patients described how eRAPID 
became a very important part of their care, and felt it provided emotional and psychological 
support. Patients sometimes spoke about eRAPID being ‘there for them’ when they needed it. 
“It just felt like part of my normality, part of my routine. As much as it was 
from being put out of my world into my chemo world for 18 weeks to know that it 
was there for me with all this information and that it would guide me.” 
(00017, Female, 48 years, Breast) 
“It puts you back into your comfort zone, cos even if you are miles away 
from the hospital, it’s quite a while since you had your initial treatment, it’s like a 
comfort zone that someone is really there, listening to you.” 
(00044, Male, 70 years, Colorectal) 
7.4.3.4.2 Feeling connected to the hospital 
Patients sometimes felt that the periods in between routine hospital appointments, which 
could be several weeks at a time, were quite difficult as they sometimes felt isolated and 
alone. Some patients felt that eRAPID helped them to feel more supported and more 
connected to their clinical care teams during these times. One patient described it as the 
feeling that ‘you’re being looked after’. 
“It’s another way of having care, you know, cos I think they say, when you 
get to the end of your treatment it can be very hard cos you’re suddenly on your 
own whereas I think you’ve got that peace of mind that in between appointments 
you’ve got some contact with the hospital even though it’s not really contact so I 
suppose that was the enjoyment and I suppose the feeling that, you know, that 
you’re being looked after.” 




“I think it creates an empathy between patient and hospital and I 
think it is, in my case, it is knowing someone is there, without a form or 
appointment” 
(00044, Male, 70 years, Colorectal) 
7.4.3.4.3 Feeling like an active participant in care. 
Patients reported that eRAPID enabled them to provide accurate and valuable information to 
their healthcare teams. In addition to the perception that this enhanced their consultations 
with clinicians and improved communication, this also made them feel more involved in their 
own care and treatment decisions. One patient recalled a conversation she had with her 
partner about the impact that eRAPID had on their experience of care. The following quote 
eloquently depicts the potential for eRAPID to empower patients to be more active 
participants in their own care. 
“We talked about the eRAPID system being very much about your 
physical progression through the treatments and how they assist you with 
your symptoms, your side effects… but understanding your treatment and 
understanding your involvement in the consultation process and 
everything else would assist massively with your psychological process of 
managing cancer, you know? Because… Yeah, patient consultant 
involvement and the feeling involved, you know, but… it’s probably a 





7.5.1 Summary of findings 
The aim of this work was to use qualitative methods to explore barriers and motivators for 
patient engagement with eRAPID and the impact of eRAPID on patients’ experiences of 
chemotherapy. Findings supported the high levels of patient engagement with eRAPID found 
in the quantitative assessment. eRAPID was well accepted by patients, with many facilitators 
for engagement described and few barriers. 
Some findings were similar to those in the field usability study described in Chapter 4. 
Although some IT literacy was required for study eligibility, of those patients who did 
participate, the level of literacy was not a barrier to accessing eRAPID and even patients who 
described themselves as having limited IT skills reported being easily able to access and 
complete the symptom reports. The newly implemented reminder system was well received 
and seemed to keep eRAPID on the radar for patients during treatment. 
Health status during chemotherapy was again identified as a potential barrier to system use, 
and again this was bidirectional. Some patients reported that they were less likely to complete 
symptom reports when they felt very unwell. This is unsurprising with patients undergoing 
chemotherapy and again, a commonly reported barrier for engagement [159]. Although the 
majority of patients still managed to engage with weekly reporting, for some the practical 
challenges of completion outweighed any benefits they received in terms of self-management 
support or input from clinical staff. However, there were also a number of patients who did 
not engage with completing symptom reports when they were not experiencing symptoms. 
Following the same finding in the usability study, patient training was adapted to emphasise 
the importance of regular completions, even in the absence of symptoms, in order to provide a 
complete picture for clinicians. However, this still remained an issue for some patients, 




well, and may just want to live as normally as they can [161-163]. This may also be related to 
patient perception of staff engagement with symptom reports, as patients may not perceive 
much benefit if clinicians are not reviewing data. 
Patients desire to contribute to research was also identified as a facilitator for engagement, 
and this was independent of any personal benefit they perceived. This was not previously 
identified as a motivator in the usability testing, but altruistic and extrinsic motivations have 
been identified as common facilitators for engagement in other similar research [164]. 
Although extrinsic motivations such as these are not necessarily negative, one patient did 
describe feeling really bad when unable to complete the symptom report due to ill health and 
competing responsibilities. This illustrates an ethical need for more focused research on 
patient engagement, as engagement may not always be indicative of patients gaining personal 
benefit from the system. 
In terms of intrinsic motivations, and the benefits patients perceived from their interactions 
with eRAPID, the symptom advice was a strong motivator for engagement. Patients found it 
reassuring to have tailored and reliable guidance, particularly early on in their chemotherapy 
when they had less experience in managing problems and were most anxious. Patients 
reported a strong desire to self-manage where possible and appreciated clear guidance on 
when hospital contact was necessary. Patients reported feeling reassured and supported by 
symptom advice and talked about eRAPID being ‘like a chemo buddy’. Again, this supports 
previous findings both from the field usability testing of eRAPID and from other similar 
research [72, 165, 166]. However, patients did not always follow advice provided by eRAPID, 
particularly as they progressed though treatment and became more confident in making their 
own judgements. It may be that this aspect of eRAPID is much more useful to patients early on 
in their treatment to support them through those early uncertainties. 
Following findings from the usability study, patients were specifically asked about their use of 




over time. A number of patients reported that they used eRAPID as a tool for monitoring 
patterns in symptom fluctuation, and these patients tended to report that they remained 
engaged with completing regular symptom reports throughout the study period. 
While the majority of patients perceived eRAPID as enhancing their care and providing 
valuable additional information to their clinical team, a couple of patients did express some 
concerns about the potential for eRAPID to replace face to face or telephone care with 
clinicians. This belief about supportive technologies in healthcare settings has been discussed 
previously and identified as a potential barrier to implementation and engagement, 
highlighting a need to be clear with patients about the purpose of online systems [296]. 
One of the main themes which emerged from this analysis was the importance of clinician use 
of the data in routine consultations, supporting findings from the quantitative work. eRAPID 
was seen to be useful for facilitating communication, acting as a useful trigger to start a 
dialogue with clinicians about symptoms that might otherwise not have been picked up. Many 
patients reported that they did not know how they would remember to tell the clinician about 
side effects without the eRAPID prompt, and a number of patients talked about ‘chemo brain’, 
which impacted on memory. This is an issue commonly reported by cancer patients but rarely 
acknowledged by oncologists [20]. In addition, patients also felt that eRAPID made them feel 
more connected to the hospital and their healthcare team in between routine appointments 
and more like active participants in their own care. Patients seemed to feel empowered by 
contributing towards their care and symptom management, with one patient describing the 
psychological benefit of using eRAPID as ‘feeling involved’ in their own care. However, 
patients’ perceptions of clinician use of the data was varied. In some instances, patients 
reported that clinicians were very explicit about if and how they were using the symptom 
reports, which incentivised them to complete regularly. However, in other instances, patients 
were unsure of whether or not clinicians had even accessed their data, and subsequently did 




As outlined in Chapter 1, engaging clinicians to use PROMs data in consultations can be 
challenging [61-65]. Training clinicians has shown good promise in overcoming some of the 
barriers, but attitudes towards PROMs are still variable between clinicians and much more 
work is needed [61-64, 70]. 
Patients were also asked about their experiences and attitudes towards any changes to their 
treatment plans that had happened as a result of the symptom reports they completed for 
eRAPID. However, very few of the patients interviewed were aware of any changes to their 
treatment plan, and of those that were, they were unsure whether eRAPID data had any 
impact. 
7.5.2 Strengths and limitations 
The main strengths of this work were that it reported experiences of real patients using 
eRAPID over 18 weeks of treatment. This data has provided valuable insight and context to the 
quantitative findings discussed in the previous chapter. 
However, there were some limitations. The sample was relatively young with high levels of 
education, and a higher number of breast patients, in comparison to gynae and colorectal 
patients. In addition, few of the patients interviewed had experiences of eRAPID data 
impacting on their treatment plans, and few patients were admitted over the course of their 
treatment. End of study interviews were continued going forward into the main phase of the 
RCT. However, a stratification plan was put into place to ensure representation across age, 
gender and disease group. Patients were also stratified in terms of their experiences of 
treatment changes and admissions to further explore the impact of eRAPID. 
Although one of the aims was to inform the quantitative work described in the previous 
chapter, we did not explicitly ask patients about self-efficacy or activation. The interview 




The general approach to the interviews was quite pragmatic in order to meet the aims of the 
main trial. Much of the interview schedule consisted of close ended questions specifically 
aimed at informing future development and implementation of eRAPID. Using a more 
exploratory, patient-led approach with more open-ended questions may have given a more 
complex insight into patients’ experiences. However, an effort was made during the interviews 
to encourage patients to elaborate on their experiences, and to explore any unexpected 
themes raised. In fact, many patients did talk in detail about the more emotional impact that 
eRAPID had on their chemotherapy experience. This is something that will also be explored in 
more depth in the next round of interviews. 
In addition, I have been responsible for developing the interview schedule and the framework 
for analysis. This development was carried out with the support of my supervisory team, but 
will have been heavily influenced by my own experiences of spending many years working on 
the development and evaluation of the eRAPID system, and of working with cancer patients at 
different stages of diagnosis and treatment. Most members of the research team will have had 
similar experiences, and this may also have impacted how the interviews were carried out. 
Members of the research team also saw the patients at several stages throughout their time 
on study and as such, built a relationship with them. Although this was in many ways beneficial 
for the interviews, as researchers already had a good rapport with patients, there is also a 
danger that this relationship may have influenced patients’ responses. For example, patients 
may have had a greater motivation to be positive in their descriptions of eRAPID and may have 
over emphasised some of the benefits that eRAPID had on their chemotherapy experience. 
The setting of the interviews may also have influenced the direction of what was raised. 
Interviews generally took place in the same clinical area that patients attended throughout 
their treatment and time on study. Although this influence could have been diminished by 




patients, this would have been practically very difficult to arrange, and would have been much 
less convenient for patients. 
The timing of the interviews is also likely to have impacted on patients’ perceptions of their 
experiences at that time. Interviews took place at the end of study, which for the majority of 
patients, also coincided with the end of chemotherapy. Patients’ feelings at having finished 
this stage of treatment may have impacted on their interviews. In addition, not all patients 
would have been finished. Some patients may have been going on to have further 
chemotherapy, starting radiotherapy, or may have been scheduled for surgery. However, it 
was necessary to try and schedule interviews for this time point, in order to get a good 
reflection of patients’ experiences of using eRAPID as soon after their study completion as 
possible. 
7.5.3 Conclusion 
eRAPID was well received by patients, with few barriers to use reported. Patients reported that 
the symptom advice was a motivator for engagement, and found this reassuring. However, the 
advice became less useful to them over time as they became more confident in managing 
symptoms and side effects. One of the main motivators for sustained engagement throughout 
the study period was to provide information to clinicians for use in consultations. However, 
perceptions of clinician use of the data varied. Some patients reported that clinicians were 
explicit with them about their use of the data, while others were unsure of whether or not 
their data was being used. 




Chapter 8 Discussion 
8.1 Overview of aims and findings 
The overall aim of this thesis is to explore the patient perspective of using ePROM systems to 
report and manage symptoms and side effects during chemotherapy. The specific aims were to 
explore: 1) The main challenges patients face managing symptoms and side effects of 
chemotherapy in standard practice. 2) The potential for ePROM systems to support patients to 
overcome some of these challenges. 3) How patients engage with eRAPID over the course of 
chemotherapy treatment. 4) How eRAPID impacts on patient experience of chemotherapy. 
Aim 1 was addressed in Chapter 3, which highlighted some of the common challenges patients 
face in managing the side effects of chemotherapy, in particular, the lack of confidence 
patients feel in making decisions about when to self-manage and when they need to contact 
the hospital. Aims 2, 3 and 4 were addressed in the field usability study of eRAPID described in 
Chapter 4, which explored how eRAPID might support patients to overcome some of these 
issues. The main findings were that although eRAPID was generally acceptable to patients, 
patient engagement with the system was variable. End of study interviews indicated that 
patients found benefits from using eRAPID over and above improved symptom management, 
such as increased confidence to manage side effects of treatment and to cope with cancer and 
treatment. Aim 2 was addressed by the systematic review described in Chapter 5, which 
outlined available evidence on ePROM systems for patients undergoing cancer treatment. 
Robust evidence was scarce, with few RCTs identified. In addition, although a number of 
feasibility studies were identified, few explored the complex processes of engagement. 




management, and potential benefits of systems in terms of more psychosocial outcomes such 
as self-efficacy were not routinely assessed. 
Chapter 6 addressed aims 3 and 4. Quantitative analysis was used to explore the patient 
perspective of eRAPID. This analysis was informed by the findings of previous chapters. Patient 
engagement with eRAPID was explored in more depth, and validated measures were used to 
assess the impact of eRAPID on patient self-efficacy to manage side effects of treatment, self-
efficacy to cope with cancer and their levels of PA. In addition, the relationship between these 
outcomes and engagement with the system was explored. The main findings were that levels 
of engagement and adherence were generally high and eRAPID was well accepted by patients. 
A logistic regression model to predict engagement with eRAPID revealed that the only 
significant predictor was a measure of clinician use of patient data during routine 
consultations. There was a positive impact of the intervention on patient self-efficacy to 
manage side effects of treatment, but not on self-efficacy to cope with cancer or on PA. Within 
the intervention group, adherence to weekly completions was a significant predictor of 
improvement in self-efficacy for both managing symptoms and for coping with cancer, but not 
for PA. 
This was supported by qualitative analysis described in Chapter 7, aiming to further explore 
the patient perspective of eRAPID. Barrier and facilitators for engagement were explored, in 
addition to the impact eRAPID had on experience of chemotherapy. The findings indicated that 
eRAPID was well received by patients, with few barriers to use reported. Patients reported that 
the symptom advice was a motivator for engagement, and found this reassuring. However, the 
advice became less useful to them over time as they became more confident in managing 
symptoms and side effects. One of the main motivators for sustained engagement throughout 
the study period was to provide information to clinicians for use in consultations. However, 
perceptions of clinician use of the data was varied. Some patients reported that clinicians were 




their data was being used. Patients reported psychological benefits from their use of eRAPID, 
and felt it improved their care. 
8.2 Implications of findings 
The preliminary work highlighted the need for intervention to support patients to self-manage 
during chemotherapy and the potential for ePROM systems such as eRAPID to provide such 
support. The systematic review demonstrated that although there were many ePROM systems 
in development, there was little focus on how patients were engaging, or why. In addition, 
outcomes were focused on symptom management and few were exploring psychosocial 
benefits. This work was integral to inform the design of the evaluation of patient engagement 
and experience of using eRAPID during chemotherapy. 
Overall, the findings indicate that eRAPID was well received by patients. The quantitative 
analysis suggested levels of engagement with eRAPID were high, and this was generally 
supported by the qualitative data with few barriers to engagement reported. 
The regression analysis did not identify any socio-demographic variables such as age or IMD 
deprivation scores as predictive of engagement with eRAPID. Internet access was part of the 
eligibility criteria for participation in the study, but only 13% of patients considered for the 
study were ineligible for this reason, highlighting the growing use of the internet. In addition, 
of those patients who did participate in the study, previous computer usage did not seem to 
impact on engagement. This was supported by the interviews, with even older patients who 
described themselves as having limited computer literacy finding the system easy to use and 
access. There is a common perception that older patients will be less likely to engage in 
eHealth, but increasingly, this is no longer found, supporting the notion that the significance 
and magnitude of the ‘digital divide’ is decreasing [282, 297, 298]. In fact, some of the 




engaged with eRAPID. Interviews suggested this may be because differences in role and 
lifestyle, with patients with young families sometimes finding it difficult to manage with the 
burden of chemotherapy. However, the majority of patients found they were able to manage 
completions around other life commitments. This confirms previous findings about the 
importance of ensuring that systems are flexible and can adapt to patients’ needs [299]. 
Additionally, flexibility of eRAPID symptom reports and system access was an important 
facilitator for engagement when patients were feeling particularly ill or unwell during 
chemotherapy. The interviews suggested that while poor health status could be a barrier, they 
were able to work it around times when they felt well, again emphasising the need for 
flexibility and accessibility. 
Patients’ levels of activation (as measured by the PAM) did not predict usage of eRAPID. As 
discussed in Chapter 6, there was somewhat of a ceiling effect at baseline, which may have 
impacted the results. In addition, the suitability of this measure in cancer populations is 
unclear, with previous research limited to cross sectional studies with methodological 
limitations [262-264]. However, interviews also indicated that some patients had extrinsic 
motivations for engagement such as a desire to take part in research and help others, similar 
to findings in other studies [164]. Patients lower in activation tend to view successful self-
management as compliance, whereas those with higher levels view it as being in control [300]. 
In the case of eRAPID, it may be that patients lower in activation may complete the symptom 
report questionnaire weekly as requested, but they may not engage with other features of the 
system such as the self-management advice and subsequently may not perceive or experience 
much benefit from their participation. This highlights the value of qualitative research in this 
context to further understanding on the complexities of patient engagement. 
A measure of clinician use of the data was identified as being associated with patient use. 
There were some limitations to this measure (see Chapter 6 discussion), but the important role 




their main motivation for adhering to the weekly symptom reports, and patients valued being 
able to provide detailed and accurate information about their symptoms, which was easily 
accessible to clinicians for use in their consultations. The descriptive analysis outlined in 
Chapter 6 suggested that clinician engagement was generally good, but variable. The 
challenges of engaging clinicians to use PROMs data in routine consultations are well 
documented. Attitudes towards the usefulness of PROMs are variable and some clinicians have 
concerns about making consultations longer or interference with communication [61-65]. 
However, many of the patients interviewed in our sample found that the PROMs data 
improved communication, supporting other findings [46-48, 301]. 
Furthermore, when clinicians were clear and explicit with patients about their use of the data, 
patients were more engaged to continue completing symptom reports, but also felt their role 
was more valued, and felt like active participants in the consultation, again supporting other 
findings [301]. Logically we would expect that PA, which assesses patients’ engagement in their 
own healthcare, would assess these benefits. However, as described in Chapter 6, there was 
no impact of eRAPID on patients’ levels of activation over time, and no relationship with 
engagement. Again, this may have been due to the unsuitability of the measure for use in this 
population and ceiling levels at baseline. Other researchers have outlined the need for a more 
suitable measure to assess the construct of empowerment and activation in this population 
[302]. 
There was however, an impact for eRAPID on patients’ self-efficacy to manage symptoms and 
side effects. The qualitative data supported this, with many patients highly valuing symptom 
advice. Patients talked about eRAPID being ‘there’ for them when they needed it, and 
described it as ‘reassuring’ and ‘like a chemo buddy’. Reassurance has been identified as a 
benefit of ePROM systems in previous qualitative work [72, 165, 166], but as highlighted in 
Chapter 5, psychosocial outcomes such as self-efficacy are seldom included as an outcome for 




Although, it would seem logical to assume that this increase in self-efficacy would be largely 
related to the provision of symptom advice, many patients reported that this was much more 
important earlier on in their chemotherapy, and less important later on as they gained 
confidence in their own knowledge and skills. It would then seem logical to assume that most 
of this benefit in terms of self-efficacy may be derived early on in the patient’s chemotherapy 
experience, and that sustained engagement may not be necessary for patient benefit. 
However, increases in self-efficacy were highly correlated with patient engagement. Similarly, 
although there was no difference between patients using eRAPID and usual care on self-
efficacy to cope with cancer, sustained engagement was associated with improved scores. The 
true meaning of this relationship is unclear, as it is likely to be influenced by a number of other 
factors, but it does suggest that sustained engagement is important. Furthermore, the 
importance of sustained engagement is supported by other research [210]. As the interviews 
suggest that one of the main motivations for sustained engagement was clinician use of data, 
it may be that some of the improvements in self-efficacy scores are due to patients feeling that 
they are contributing towards their management and care by completing symptom reports. 
8.3 Strengths and limitations 
This work is contributing to an emerging field of research that is growing in importance. The 
nature of healthcare is changing and ePROM systems have potential to support self-
management [100, 303, 304]. However, patient engagement with systems is complex, and 
evidence is needed to inform future development, evaluation and implementation. 
As outlined in Chapter 2, much of the methodology in this thesis has been integrated into the 
development and evaluation of the work undertaken as part of the eRAPID development and 
programme grants. This has provided some unique opportunities, for example access to a large 




randomised controlled design with a large sample. In addition, the support of colleagues with 
data collection and analysis was invaluable. However, the integration also brought some 
limitations. The trial design, for example in terms of sample size, frequency of completion of 
outcome measures etc., were based on the primary outcomes for the trial, which needed to be 
prioritised. There was also a need to be conscious of patient burden for completion of 
outcome measures. For example, additional completion of measures, or additional patient 
interviews mid-way through patients’ chemotherapy cycle may have provided additional 
insight. However, overall the minor limitations of the thesis being integrated into the main trial 
were far outweighed by the benefits. 
The mixed methods approach used in this thesis worked well to address the research aims. The 
initial qualitative work, in combination with the results of the systematic review were highly 
informative for the design and development of the work described in Chapters 6 and 7. In 
addition, the combination of qualitative and quantitative methods used in these later chapters 
and the triangulation methods used to compare and contrast findings provided insights which 
would not have been possible using quantitative or qualitative methods alone. 
The methodological limitations of the individual studies are discussed in the relevant chapters. 
However, there were some more general limitations. As highlighted in the results of this thesis, 
the complexities of patient engagement are inherently related to clinician engagement and it is 
important to understand both and to explore how they interact. Some descriptive data on 
clinician engagement is reported in Chapter 6, but this has not been explored further. In 
addition, the different clinician roles have not been differentiated in our limited assessments. 
As described in Chapter 2, the clinicians involved in using eRAPID include senior oncologists, 
specialist registrars, clinical nurse specialists and other senior nurses qualified to carry out pre-
assessment consultations. In addition to differing levels of experience, these clinicians have 
different relationships with patients. In particular, the clinical nurse specialists seeing curative 




a very different relationship with patients than the oncologists who only tended to see them 
once during their treatment. Work is being undertaken as part of the main eRAPID trial to 
interview clinicians involved in the study to explore motivators and barriers for use and I will 
be involved in this analysis in the future, in addition to further analysis of the quantitative data 
available on clinical engagement. 
During this study, researchers had relatively frequent contact with patients over the duration 
of the study period, seeing them approximately four to five times over the eighteen week 
period. This may have influenced the levels of engagement for some patients and it remains to 
be seen whether the same levels of engagement would be maintained in standard practice. 
This further highlights the key role of engagement of clinicians for future implementation. 
The generalisability of the sample is somewhat limited. As described in Chapter 6, participants 
were predominately female, relatively young, well-educated with high performance status at 
baseline. Although research does support the utility of ePROMs with patient groups with more 
complex needs, additional support or alternative methods of PROMs reporting such as 
Interactive Voice Response (IVR) systems may be needed to ensure accessibility for all patient 
groups[77, 78, 165]. 
8.4 Recommendations and directions for future research 
As outlined in Chapter 6, it was necessary to begin analysis for the purpose of this thesis 
before completion of the eRAPID RCT. Data was extracted on 5th January 2018 at which point 
354 patients had completed the study. The full trial is scheduled to be completed in October 
2018, following a total of 508 patients being consented. In addition, further interviews have 
been undertaken with patients participating in the main phase of the trial, following on from 
the work described in Chapter 7. I plan to rerun all the quantitative analysis described in 




will be analysed using a similar framework to that described in Chapter 7. Following this, I plan 
to prepare the results for publication. 
The work described in this thesis will also have a direct impact on future evaluation and 
implementation of eRAPID. Chapter 6 described an analysis of the relationship between 
patient engagement with eRAPID and the evaluative outcomes and found a positive 
relationship. Based on these findings, an analysis of the relationship between patient 
engagement with eRAPID and the primary outcome measures for the trial (QoL measures of 
FACT-G, EQ-5D and QLQ-C30) will be undertaken. In addition, based on the finding that use of 
eRAPID improved patients’ self-efficacy over the 18 week study period, this assessment will 
also be integrated into any future evaluations of eRAPID in different clinical settings. 
Finally, and potentially, most importantly, this work provides evidence of the importance of 
clinicians being explicit about their use of patient-reported data during consultations. Based on 
the findings of the field usability study described in Chapter 4, this is something we already 
strongly encouraged clinicians to do, and is one of the main points of our online clinician 
training programme. However, the quantitative and qualitative evidence from this thesis can 
be incorporated into the training to further illustrate to clinicians just how important this is. 
There are also several recommendations and important directions for the future development, 
evaluation and implementation of ePROM systems that I would make based on the findings of 
this thesis. 
There is a need for researchers to be clear and transparent when describing ePROM systems in 
publications. The systematic review described in Chapter 5 highlighted the lack of detail 
generally provided on system features, which makes it difficult for researchers developing 
systems to learn from one another. The taxonomy of system features described in this chapter 
could provide a useful tool and checklist for researchers describing their interventions. 
In addition, the findings of this thesis support the benefit of providing a self-management 




on how to manage side effects. As highlighted in Chapter 3, patients are already being required 
to take a significant amount of personal responsibility for monitoring and managing health 
during chemotherapy and require support. The findings in Chapters 4 and 7 illustrate that 
ePROM systems have the potential to provide some of this support. Yet, less than half of the 
systems identified in the systematic review (Chapter 5) allowed patients to view their own 
data, and fewer still provided any self-management element. Our findings suggest that 
patients may not always follow advice provided. Nevertheless, if patients are being asked to 
routinely complete PROMs data from home, there is an ethical responsibility provide it [78, 
89]. 
There is also a need for researchers to report on patient engagement and to explore, and 
report on, the relationship between engagement and outcomes. Qualitative research should 
be undertaken where possible to inform quantitative assessments, and to provide insight into 
motivators and barriers. Theories on medication adherence (see section 1.1.5) have shown 
good utility in helping to understand, predict and ultimately try to improve patient adherence 
to medication. In a similar approach, as the evidence base on patient engagement with ePROM 
systems grows, researchers should aim to develop theory to help conceptualise and predict 
engagement. 
Clinician engagement is intertwined with patient engagement and will also require ongoing 
qualitative and quantitative assessment to inform future development and implementation of 
systems. Developing training to address clinician concerns and encourage explicit use of data 
with patients is necessary. 
This thesis also contributes to the evidence needed to support future implementation of 
ePROM systems by demonstrating their potential to improve patients’ self-efficacy to self-
manage during chemotherapy. Self-efficacy has been identified as a key indicator of improved 
self-management behaviours and is related to improved objective medical outcomes, in 




essential to drive the policy and investment needed to support future development, evaluation 
and implementation of systems. In addition to the main eRAPID trial described in this study, 
there are several other randomised trials currently underway which will assess the benefit of 
ePROM systems across a range of outcomes such as symptom burden, HRQoL, healthcare 
utilisation and cost effectiveness [94, 170, 215, 223]. However, this evidence will take time to 
be demonstrated, and one of the challenges with developing ePROM systems will be keeping 
up to date with current technology, and ensuring ongoing compatibility with smartphones, 
tablets and other home devices to ensure accessibility to all patients. 
In addition, ongoing investment is needed to link ePROM systems efficiently into primary and 
secondary care EPRs. Significant issues remain around implementing health informatics 
infrastructure relating to achieving integration without compromising the security of clinical 
databases, and the on-going discussions on ethical challenges of sharing personal health data, 
particularly with recent changes to policies and guidance on data protection [305]. 
Recent initiatives such as the NHS QoL metric are increasing the prevalence and profile of 
PROMs in broader settings [306]. In addition, ePROM systems have the potential to be applied 
to many different healthcare settings, and potentially could provide ongoing support after 
cancer treatment into survivorship. Using ePROMs for remote cancer surveillance is a natural 
extension to this work, supporting a more efficient and tailored healthcare system and better 
utilisation of limited resources [52, 157, 307]. In fact, this has recently been implanted into 
clinical practice in St James University Hospital with a group of testicular cancer patients at low 
risk of recurrence [308]. However, even the best designed systems are not a quick fix for 
changing behaviour or providing a solution to the national health crisis. Continuing evaluation 
and integration of the patient perspective should be central to inform the future research and 
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Appendix 1: Patient Information Sheet 
Version 1.4 28th September 2017 
 
eRAPID Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice: 
Randomised controlled trial in systemic cancer treatment 
We would like to invite you to take part in a research study that will assess a new online system 
for monitoring the symptoms and side effects cancer patients can experience when receiving 
treatment. 
Before you decide whether to take part, please read this information sheet to find out why the 
research is being done and what it involves. Please take time to read the information carefully. 
Talk to others about the study if you wish, and ask the researcher if you have any questions. 
Background 
eRAPID is an online system for patients to report symptoms and side effects during and after 
cancer treatment. Because the system is online, patients can complete questions about their 
symptoms from home or in clinic using the internet. This information is then immediately 
documented in individual patient’s electronic health record in the hospital. If patients report mild 
symptoms the system will provide advice on how to manage them. When serious symptoms 
are reported patients will be encouraged to contact the hospital team and an alert will be sent 
to their doctor or nurse via email. The eRAPID system also involves access to a patient website 
with information about coping during cancer treatment and managing related symptoms. 
We want to see how the system will work in practice in a large scale study – for example 
whether patients use the system and their experiences of using it to report their symptoms. We 
also want staff involved in patient care to test the system by viewing the results of the 
questionnaires in patient records and to tell us how useful the information is. We will be 





Version 1.4 28th September 2017 
The study is part of a 5 year research programme funded by the National Institute for Health 
Research (NIHR). The research is led by Professor Galina Velikova who is a consultant medical 
oncologist with Leeds Teaching Hospitals NHS Trust. 
Why have I been asked? 
We are inviting patients who are receiving treatment for breast, gynaecological or colorectal 
cancer at St James’s University Hospital. We aim to recruit a maximum of 588 patients. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. We are interested in understanding why 
people do not wish to take part in the study but you do not have to give us a reason for doing 
so. A decision not to take part will not affect the standard of care or treatment you receive in the 
future. 
What will happen if I take part in the study? 
You can take as much time as you need to decide if you want to take part in the study or not. If 
you decide to take part in the study, a member of the research team will answer any questions 
you have and ask you to sign a consent form. 
You will be then be asked to complete some initial paper questionnaires about you and your 
quality of life. This study is a randomised controlled trial (RCT). This means half the participants 
who agree to help with the study will be asked to use the eRAPID symptom reporting system 
and the eRAPID website during the study (in addition to Usual Care from the hospital and 
cancer team) and the other half will receive Usual Care alone. This way we can compare the 
two groups to see if the eRAPID system has any impact on patient care. Participant allocation 
to one of the groups is entirely by chance. 
If you are assigned to the group using the eRAPID system:  
• The researcher will explain how to complete the online eRAPID symptom questionnaire 
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 You will be given unique log-in details and a booklet to take home with you that explains 
how to use the system. You are welcome to ask a friend or family member to help you 
access the online system if this would be helpful though we would like you to answer 
the symptom questions yourself. 
 Whilst you are on treatment you will receive the usual care provided by the hospital and 
your cancer team but in addition you will be asked to log-in to the eRAPID system from 
home at least once a week to complete the symptom questionnaire. We will also 
encourage you to complete the questionnaire at any time when you feel unwell. The 
questionnaire takes around 15 minutes to complete. Your responses will be 
immediately documented in your electronic hospital records. 
 We will automatically send you a reminder each week to complete the questionnaire by 
your choice of email or text message. 
 There may also be the opportunity to complete the questionnaire in clinic before routine 
appointments. 
 We will also ask you at set time points (6, 12 and 18 weeks after you join the study) to 
complete some paper questionnaires about your quality of life and views of your health 
and treatment. We will also ask you to tell us about the number of contacts you have 
had with the hospital and GP while you are helping with the study (e.g. appointments 
and telephone calls). We are interested in understanding any extra financial costs you 
may have experienced as the result of receiving cancer treatment so the questionnaires 
will ask you about this too. 
 At the end of the study (at 18 weeks) you may be asked to take part in an interview or 
to find out what you thought about the research and the eRAPID system. 
 The eRAPID system is not a replacement for usual care, if you need advice on 
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If you are assigned to the Usual Care group:  
 You will receive the usual care provided by the hospital and your cancer team. 
 In addition the researchers will ask you at set time points (6, 12 and 18 weeks) after 
you join the study) to complete paper questionnaires about your quality of life and 
views of your health and treatment. We will also ask you to tell us about the number 
of contacts you have had with the hospital and GP (appointments and telephone calls) 
while you are helping with the study. We are interested in understanding any extra 
financial costs you may have experienced as the result of receiving cancer treatment 
so the questionnaires will ask you about this too. 
 At the end of the study (at 18 weeks) you may be asked to take part in an interview to 
tell us about your experience of managing any symptoms and side effects of your 
treatment and any contacts you had with the hospital during treatment. 
Will my taking part in this study be kept confidential? 
Yes. It is very important to us to respect your information (data) and keep it confidential. The 
answers you provide to the symptom and side effect questions, and additional questionnaires 
will only be seen by the research team and your clinical team. We will also ask for your 
permission to look at your medical records for information about the treatment you are receiving, 
disease condition, clinical care, hospital resource and management records 
All your data (questionnaires/interviews) will be stored on secure databases within either the 
University of Leeds or Leeds Teaching Hospitals NHS Trust and will only be accessible by the 
research and clinical teams. All data stored on the University of Leeds databases will be 
anonymised. Any analysis or publications of results from the study will not name or identify any 
individual patients. 
What are the disadvantages of taking part? 
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What are the possible benefits of taking part? 
We hope that the completion of the online eRAPID questionnaires will help patients and staff 
with monitoring and managing symptoms and side effects of cancer treatment. 
For participants in the Usual Care group, although there may be no personal benefits to your 
taking part in this study, we hope the information you provide will contribute to improving the 
support we can offer patients on cancer treatment in the future. 
What will happen if I don’t want to carry on with the study? 
If you agree to take part and then later decide you want to stop being in the study that is OK. 
You can withdraw from the study at any time. We will ask you if we may keep the information 
you have provided up until that point but this will be your decision. If you withdraw from the study 
we may ask you to complete a brief end of study feedback form to find out what you thought 
about the study and using the eRAPID system for reporting side effects. Again, it will be your 
decision whether you wish to provide this feedback. 
What if there is a problem? 
If you have any concerns about any aspect of the study please speak to the researchers 
who will do their best to answer your questions. Their contact details are at the end of this 
information sheet. If you remain unhappy you may wish to contact the Leeds Teaching 
Hospitals NHS Trust’s Patient Advice and Liaison Service (PALS)  
T: 0113 2066261 or 0113 2067168 
E: patient.relations@leedsth.nhs.uk  
Who has reviewed the study? 
The study has been reviewed by people who have experience of cancer themselves and 
independent experts in this area of research. All research in the NHS is also approved by a 
Research Ethics Committee, an independent group that works to protect your interests. This 
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What now? 
Please let the researcher know whether or not you would like to help with the study or if you 
have any further questions they will be happy to help answer them. If you need more time to 
think about taking part in the study just let the researcher know and they can speak to you at 
your next hospital appointment. 
Thank you for taking the time to read this information sheet 
If you would like to take part or have any questions please contact a member of the research 
team: 
Kate Absolom, Senior Research Fellow 
Andrea Gibson, Research Sister 
Marie Holmes, Research Assistant 
Beverly Clayton, Senior Research Nurse Zoe 
Rogers, Research Assistant 
Lorraine Warrington, Research Assistant 
To contact us please: 
Email: leedsth-tr.erapid@nhs.net 
Telephone: 0113 2067548 
Patient Reported Outcomes Group 
Level 3, Bexley Wing, St James' Institute of Oncology, Leeds, LS9 7TF 





Appendix 2: eRAPID end of study Questionnaire 





Day Month Year Participant 
ID 
Centre No Trial No 
                      
 
 
eRAPID: Electronic patient self-Reporting of Adverse-events: 
Patient Information and aDvice 
 
Systemic treatment RCT 
18 WEEK SYSTEM USABILITY QUESTIONNAIRE  

























We would be grateful if you could complete these questionnaires to tell us about your views of using the 
eRAPID system in the last few months. 
 
Most of the questions have a choice of answers. There are no right or wrong answers; you should choose a 
response that best reflects you or your situation. 
 
If after answering any of the questions you realise you have made a mistake (for example by ticking the wrong 
box) please cross out your answer clearly and then select the answer you meant to choose. 
 
If you have any questions please feel free to ask the researchers. Once you have completed the 
questionnaires, they can be handed back to a member of the research team. 
 
Thank you for your time and valuable contribution to the eRAPID study 
Patient Report Outcomes Group (POG) 
Level 6, Bexley Wing 
St James' Institute of Oncology 




eRAPID- System Usability Scale 
 
INSTRUCTIONS: Please think about how you found using the eRAPID system in the last few months 
to report the symptoms associated with your cancer and treatment. Rate how strongly you agree or 
disagree with each of the following statements by placing a check mark in the appropriate box. 
          
 
                 Strongly    Strongly  
                    disagree     agree 
 
1. I think that I would like to  
use this system frequently  
 
 




3. I thought the system was easy 
to use                        
 
4. I think that I would need the 
support of a technical person to 
be able to use this system  
 
 
5. I found the various functions in 
this system were well integrated 
 
 
6. I thought there was too much 
inconsistency in this system 
 
 
7. I would imagine that most people 
would learn to use this system 
very quickly    
 
8. I found the system very 
cumbersome to use 
 
 




10. I needed to learn a lot of things before I 
could get going with this system    
 
 




1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5
1 2 3 4 5




eRAPID End of study participant questionnaire 
 
The end of study questionnaires asks about your opinion of using eRAPID to monitor the symptoms and side 
effects of your cancer and treatment. 
 
Please answer all the following questions with the answer that best matches your experience. Please only 
provide one answer per question. 
1.  How easy or difficult was it to 
learn how to use the eRAPID 
system? 





2.  How easy or difficult did you 
find accessing the system? e.g. 
finding the website and logging 
in 





3.  How easy or difficult was it to 
answer the questions about 
your symptoms? 





4.  How did you feel about the 
amount of time it took to 
complete the symptom 
questions? 
 
Too long About right Too quick 
5.  How relevant were the 

















6.  What did you think about 
completing these 
questionnaires every week? 
Definitely 
too often 
A little bit 
too often 











7.  Were there any times when you 
missed a week of completing 
the symptom questionnaire? If 
so, why? 
 






8.  Did the doctors and nurses you 
saw during your treatment use 
your eRAPID symptoms 
information during 
consultations? 





9.  If yes, did you feel this 
improved your consultations 
with the staff? 
Yes, quite a bit No not at all Sometimes 
10.  To what extent do you feel that 
the symptom questionnaire was 
useful for the doctors and 
nurses you saw during your 
treatment? 
 
Very useful A little 
useful 
Unsure Not very 
useful 
Not at all 
useful 
11.  How useful did you find the 
information on the eRAPID 
website about the symptoms 
and side effects of cancer 
treatment?  
 
Very useful A little 
useful 
Unsure Not very 
useful 
Not at all 
useful 
12.  Would you recommend the 
eRAPID system to other cancer 
patients? 
No Not sure Yes 
























THANK YOU FOR COMPLETING THIS QUESTIONNAIRE
If you have any other comments about taking part in the eRAPID study please write them below. 
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